

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2012322018 B2**

(54) Title
Compositions and methods for treating and preventing coronary heart disease

(51) International Patent Classification(s)
C12Q 1/68 (2006.01) **G01N 33/53** (2006.01)
G01N 33/00 (2006.01)

(21) Application No: **2012322018** (22) Date of Filing: **2012.10.12**

(87) WIPO No: **WO13/056087**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	61/546,802		2011.10.13		US

(43) Publication Date: **2013.04.18**

(44) Accepted Journal Date: **2017.09.21**

(71) Applicant(s)
Boston Heart Diagnostics

(72) Inventor(s)
Schaefer, Ernst J.;Polisecki, Eliana

(74) Agent / Attorney
Spruson & Ferguson, L 35 St Martins Tower 31 Market St, Sydney, NSW, 2000, AU

(56) Related Art
AKAO HIRONOBU ET AL, "Genetic variation at theSLCO1B1gene locus and low density lipoprotein cholesterol lowering response to pravastatin in the elderly", ATHEROSCLEROSIS, (20110921), vol. 220, no. 2, pages 413 - 417



(43) International Publication Date
18 April 2013 (18.04.2013)

(10) International Publication Number
WO 2013/056087 A3

- (51) **International Patent Classification:**
G01N 33/53 (2006.01) *G01N 33/00* (2006.01)
- (21) **International Application Number:**
PCT/US2012/060014
- (22) **International Filing Date:**
12 October 2012 (12.10.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/546,802 13 October 2011 (13.10.2011) US
- (71) **Applicant:** **BOSTON HEART DIAGNOSTICS**
[US/US]; 175 Crossing Boulevard, Framingham, MA
01702 (US).
- (72) **Inventors; and**
- (71) **Applicants (for US only):** **SCHAEFER, Ernst, J.**
[US/US]; 71 Fieldstone Lane, Natick, MA 01760 (US).
POLISECKI, Eliana [US/US]; 175 Crossing Boulevard,
Framingham, MA 01702 (US).
- (74) **Agents:** **MEYERS, Thomas, C.** et al.; Brown Rudnick
LLP, One Financial Center, Boston, MA 02111 (US).
- (81) **Designated States** (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*

- (88) **Date of publication of the international search report:**
13 June 2013

(54) **Title:** COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE

(57) **Abstract:** The invention pertains to a method of determining a statin dosage for an individual in need of treatment with a statin, comprising determining a SLCO1B1 genotype from a nucleic acid sample of the individual, said genotype comprising the presence or absence of the SLCO1B1 -056 polymorphism, and determining an ApoE genotype or phenotype identifying an ApoE polymorphism selected from the group consisting of ApoE2, ApoE3, ApoE4, and any combination thereof, wherein the combination of a SLCO1B1 genotype identifying the presence of the SLCO1B1-056 C polymorphism and the ApoE genotype or phenotype identifying one of the ApoE3/4 or ApoE4/4 genotypes indicates the statin dosage.



WO 2013/056087 A3

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONARY HEART DISEASE

5 RELATED APPLICATION

The present application claims the benefit of and priority to U.S. provisional patent application serial number 61/546,802, filed October 13, 2011, the content of which is incorporated by reference herein in its entirety.

10 STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH

This work was supported by the following grant from the National Institutes of Health, Grant Number HL74753. The government has certain rights in the invention.

15 TECHNICAL FIELD

The present invention relates generally to compositions and methods for assessing the treatment of coronary heart disease (CHD) in individuals based on their individual genetic makeup. Specifically, the present invention pertains to methods for identifying genetic polymorphisms that affect uptake and metabolism of CHD specific therapeutics and assessing
20 treatment/prophylactic protocols to maximize efficiency of CHD treatment.

BACKGROUND OF THE INVENTION

Coronary heart disease (CHD), the leading cause of morbidity and mortality worldwide, is caused by atherosclerotic plaque deposition in the coronary arteries (*i.e.* atherosclerosis).
25 CHD is a multi-factorial disease, and independent risk factors include: age, gender, hypertension, smoking, diabetes, family history of premature CHD, elevated levels of low density lipoprotein cholesterol (LDL-C) (>160 mg/dl), and decreased levels of high density lipoprotein cholesterol (HDL-C) (<40 mg/dl for males and <50 mg/dl for females). However, these established CHD-risk factors account for only about half of the variability in CHD events in the U.S. population.
30 Accumulating data indicate that emerging risk factors, including lipoprotein sub-fractions, are better markers of CHD than many of the established CHD risk factors. Additionally, other

factors such as the genetic background of an individual may influence how much the major risk factors affect absolute risk.

A simple paradigm of atherosclerosis is that there is an antagonistic relationship between apolipoprotein-B (apo-B)-containing particles, such as low density lipoprotein (LDL) particles, and apoA-I-containing particles, such as high density lipoprotein (HDL) particles. For example, apo-B-containing particles promote atherosclerosis (*i.e.* they are atherogenic) because they are deposited on the arterial wall; however, apoA-I-containing particles counteract this effect (*i.e.* they are atheroprotective) because they remove excess cholesterol from the arterial wall.

The various HDL subpopulations differ in size and composition, which impart each of the varying HDL subpopulations with different functions and pathophysiological relevance. The many different functions of HDL are not distributed evenly among the various HDL subpopulations. The best illustration of this is the fact that cells have several different ways by which to remove excess cholesterol. Different HDL particles interact with the different pathways specifically depending on the cell type, the expressed receptor protein type on the surface of the cell, and the cellular cholesterol content. Moreover, the different HDL subpopulations participate differently in the anti-oxidation, anti-inflammation, and cell-signaling processes based on the particles' lipid and protein composition.

Most importantly, the HDL subpopulation profile can differentiate subjects with increased risk for CVD from subjects without such risk independently of HDL-C level. This is very important, as some subjects (or even an entire ethnic group) may have low HDL-C levels but present no history of elevated CVD risk. This is due to the fact that these subjects may have not only hyperactive HDL catabolism, but also hyperactive HDL function. However, some subjects with high HDL-C may experience a CVD event due to low HDL metabolism/catabolism or dysfunctional HDL.

Statins have emerged as an important class of therapeutic compounds for the treatment of CHD. Statins are drugs that inhibit HMG CoA reductase, the rate limiting enzyme in cholesterol biosynthesis, and thereby lower LDL cholesterol. By lowering cellular cholesterol synthesis, statins up-regulate the LDL receptor on the liver cell surface, resulting in enhanced LDL apolipoprotein B clearance. Lowering LDL cholesterol with statin therapy reduces the risk of CHD morbidity and mortality. It has been documented that the absolute reduction in statin

induced LDL cholesterol lowering clearly predicts reduction in CHD events. Moreover the absolute reduction in LDL cholesterol levels is greatest in subjects with elevated LDL cholesterol levels at baseline. Additionally, lathosterol is a direct precursor of cholesterol in the bloodstream, and serves as an excellent marker of cholesterol biosynthesis. Individuals with elevated plasma lathosterol/cholesterol ratios generally have significantly greater LDL cholesterol lowering in response to statin therapy than individuals with low plasma lathosterol/cholesterol ratios.

The SLCO1B1 gene encodes a liver-specific polypeptide member of the organic anion transporter family. The SLCO1B1 transporter is primarily responsible for the ability of statins to inhibit cholesterol synthesis. About 20% of the population is heterozygous for the rs4149056 allele, while about 3% is homozygous for the rs4149056 allele. The rs4149056 allele (625T>C) results in an amino acid substitution (V174A) in the SLCO1B1 protein that decreases the function of this transporter, thereby decreasing the efficacy of statin treatment in terms of LDL cholesterol lowering (Niemi M et al. (2006) "SLCO1B1 polymorphism and sex effect the pharmacokinetics of pravastatin but not fluvastatin." Clin Pharmacol Ther 80:356-66).

Niemi et al. (2006) reported that following a single oral dose of 40 mg of pravastatin in 32 subjects the areas under the curve of pravastatin blood levels were significantly greater for those subjects carrying the uncommon CC phenotype versus the wildtype TT SLCO1B1 genotype. In a study of 28 subjects, the SLCO1B1 haplotype significantly affected the degree of lathosterol (a marker of cholesterol synthesis) lowering induced by pravastatin (Gerloff T et al. (2006) "Influence of the SLCO1B1*1b and *5 haplotypes on pravastatin's cholesterol lowering capabilities and basal sterol serum levels." Naunyn Smiedebergs Arch Pharmacol 373:45-50). In another study of 16 healthy volunteers, Igel and colleagues reported that SLCO1B1 haplotype was associated with a doubling of plasma pravastatin levels as compared to other haplotypes (Igel M et al. (2006) "Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin." Clin Pharmacol Ther 79:419-26). In addition, it was also found that the SLCO1B1 genotype affected pravastatin metabolism and LDL-C lowering response in 20 children with familial hypercholesterolemia and 12 cardiac transplant recipients (Hedman M et al. (2006) "Pharmacokinetics and response to pravastatin in pediatric patients with familial hypercholesterolemia and in pediatric cardiac transplant recipients in

relation to polymorphisms of the SLCO1B1 and ABCB1 genes". Br J Clin Pharmacol 61:706-15).

The Apolipoprotein E (ApoE) genotype predicts LDL cholesterol lowering response to statins, including atorvastatin and pravastatin. The ApoE gene makes a protein that becomes a lipoprotein when combined with fat. The lipoprotein ApoE is a very low-density lipoprotein, which is responsible in part for removing cholesterol from the bloodstream. Genetic variations in ApoE affect cholesterol metabolism, and may alter an individual's chances of having heart disease, and in particular a heart attack or a stroke.

There are three relatively common variants of ApoE, known as ApoE2, ApoE3, and ApoE4. About 15% of the population carry the ApoE2 allele and are more responsive to statins in terms of LDL cholesterol lowering, while about 20% of the population carry the ApoE4 allele and are less responsive in terms of statin induced LDL cholesterol lowering.

Combinatorial analysis of an individual's genotype at multiple loci and their blood chemistry profile can be used to assess treatment and/or prophylaxis of the individual with respect to coronary heart disease (CHD).

SUMMARY OF THE INVENTION

The present invention provides compositions and methods for assessing and treating coronary heart disease; and in particular for managing elevated cholesterol. According to the invention, baseline cholesterol, and especially LDL cholesterol, in combination with certain genetic factors (as provided herein) are useful in combination for determining the amount and type of cholesterol-lowering treatment for patients on an individualized basis. For example, the identification of particular genetic polymorphisms in combination with baseline cholesterol determines whether a statin is indicated and, if so, at what dose. The invention recognizes the synergistic combination of baseline cholesterol levels and genetic polymorphisms in the diagnosis and treatment of coronary heart disease on a personalized basis.

In a particular application, the SLCO1B1 locus and the apolipoprotein E (ApoE) locus are analyzed to determine which polymorphisms are present. That information is then used in combination with baseline LDL cholesterol in order to determine whether a cholesterol synthesis inhibitor (e.g., a statin) is indicated and at what dose; or whether a statin is contraindicated and, instead, a cholesterol absorption inhibitor (e.g., ezetimibe) should be prescribed. In certain

disclosures, the diagnostic algorithm indicates that both a statin and ezetimibe should be prescribed.

The invention is implemented in any manner consistent with the teachings herein. Provided below are algorithms to guide the analysis of the synergistic effects described herein and their relation to treatment and dosage. In a preferred embodiment, an algorithm according to the invention weights cholesterol baseline and genetic polymorphisms in order to determine treatment and/or dose. An example of weighted approach is provided below. The baseline cholesterol component of the diagnostic algorithm can be total cholesterol, LDL cholesterol, HDL cholesterol, or some combination thereof. In addition cholesterol baseline can be expressed as a balance of different types of sterols; for example a ratio of plasma lathosterol to cholesterol in $\mu\text{mol}/\text{mmol}$.

The invention utilizes biomarkers that correlate with the efficacy of a cholesterol-reducing drug in view of baseline cholesterol in order to provide a proper treatment regimen and proper dose. Methods of the invention allow one to characterize the likelihood that a patient will respond to a drug treatment based on the patient's cholesterol levels and an array of polymorphisms associated with response to cholesterol-lowering drugs. The invention allows a patient to be characterized as hypo-responsive, hyper-responsive, or normally-responsive to statin treatment, which then allows proper prescribing and dosing.

Thus, herein disclosed is a method of determining a statin dosage for an individual in need of treatment with a statin. The method involves determining the genotype of the individual at the SLCO1B1 locus and the ApoE locus, and determining the presence or absence of the rs4149056 polymorphism at the SLCO1B1 locus, and the presence or absence of the ApoE2, ApoE3, and/or ApoE4 polymorphisms at the ApoE locus. According to the method, identifying the presence of the SLCO1B1 rs4149056 C polymorphism and the ApoE genotype or phenotype corresponding to either the ApoE3/ApoE4 or ApoE4/ApoE4 genotypes determines the statin dosage. The method may further involve identifying the plasma LDL cholesterol concentration (mg/dl) and/or the plasma lathosterol/cholesterol (LSC) ratio ($\mu\text{mol}/\text{mmol}$) for the individual, where a LDL concentration below about 100 mg/dl and a LSC ratio less than about 70 $\mu\text{mol}/\text{mmol}$ in men and less than about 85 $\mu\text{mol}/\text{mmol}$ in women indicates that statin treatment is contraindicated, or at least will not be effective, in lowering LDL-C unless the individual has an ApoE genotype or phenotype corresponding to ApoE2/ApoE2 or ApoE2/ApoE3. Alternatively, LDL concentration below about 100 mg/dl and a LSC ratio less than about 90 irrespective of gender indicates that statin treatment will not be effective in lowering LDL-C unless the individual has an ApoE genotype or phenotype corresponding to ApoE2/ApoE2 or ApoE2/ApoE3.

Also herein disclosed is a method of assessing statin dosage for an individual in need of treatment with a statin, the method involves determining the genotype of the individual at the SLCO1B1 locus and the ApoE locus, and determining the presence or absence of the rs4149056 polymorphism at the SLCO1B1 locus, and the presence or absence of the ApoE3 and/or ApoE4 polymorphisms at the ApoE locus. According to the method, determining that the SLCO1B1 genotype is homozygous rs4149056 C/C polymorphism and the ApoE genotype or phenotype is ApoE3/ApoE4 or ApoE4/ApoE4, indicates that the statin dosage needs to be in the range of about 40 mg to about 80 mg/day or the patient should receive ezetimibe therapy.

Also herein disclosed is a method of assessing statin dosage for an individual in need of treatment with a statin, the method involving determining the genotype of the individual at the SLCO1B1 locus and the ApoE locus, and determining the presence or absence of the rs4149056 polymorphism at the SLCO1B1 locus, and the presence or absence of the ApoE2, ApoE3, and/or ApoE4 polymorphisms at the ApoE locus. According to the method, determining that the SLCO1B1 genotype is heterozygous rs4149056 C/T or homozygous rs4149056 T/T and the ApoE genotype or phenotype is ApoE2/ApoE2, ApoE2/ApoE3, or ApoE3/ApoE3, indicates a statin dosage in the range of about 20 mg to about 40 mg/day. The method may further involve identifying a plasma LDL cholesterol concentration (mg/dl) and a plasma lathosterol/cholesterol (LSC) ratio ($\mu\text{mol}/\text{mmol}$) for the individual, where an LDL cholesterol concentration of about 100 mg/dL or greater and a LSC ratio about 90 $\mu\text{mol}/\text{mmol}$ or greater in both men and women indicates that statin treatment is indicated unless the individual has a SLCO1B1 rs4149056 genotype of C/C and an ApoE genotype or phenotype comprising ApoE4/ApoE4. When the latter variants are present the combination of low dose statin and ezetimibe should be used.

According to a first embodiment of the present invention, there is provided a method of determining a statin dosage, the method comprising the steps of: determining a level of cholesterol in a blood and/or plasma sample obtained from a patient; conducting an assay in the sample to identify the presence or absence of a SLCO1B1 biomarker and an Apolipoprotein E gene (ApoE) biomarker that are associated with statin efficacy; and determining a dosage of statin for said patient based upon said cholesterol level and said presence or absence of said SLCO1B1 and ApoE biomarkers, wherein the statin is selected from the group consisting of pravastatin, atorvastatin, and cerivastatin.

Also herein disclosed is a method of treating a patient to reduce serum LDL cholesterol by assessing the patient's ability to respond to statin treatment by obtaining a plasma LDL cholesterol level and a plasma lathosterol/cholesterol ratio, determining a SLCO1B1 genotype from a nucleic acid sample of the patient by identifying the presence or

absence of a SLCO1B1 rs4149056 polymorphism, and determining the patient's ApoE phenotype or genotype as either ApoE3/ApoE3 or ApoE4/ApoE4, where the combined characteristics of SLCO1B1 rs4149056 T/C or C/C genotype, ApoE3/ApoE4 or ApoE4/ApoE4, a plasma LDL cholesterol concentration of about 100 mg/dl and a LSC ratio of less than about 90 $\mu\text{mol}/\text{mmol}$ contraindicates statin treatment in the patient; and instead indicates treating the patient with ezetimibe and/or dietary modification to reduce the patient's cholesterol. The combined characteristics may include a plasma LDL cholesterol below about 160 mg/dl and a LSC ratio between about 90 - 160 $\mu\text{mol}/\text{mmol}$ in irrespective of gender indicate statin treatment in the patient. The ApoE3/ApoE3 or ApoE4/ApoE4 status may be determined by analyzing the nucleic acid of the patient. Alternatively, the ApoE3/ApoE3 or ApoE4/ApoE4 status may be determined by analyzing the protein of the patient.

Also herein disclosed is a method of treating a patient to reduce serum LDL cholesterol by assessing the patient's responsiveness to statin treatment by obtaining a plasma LDL cholesterol level and a plasma lathosterol/cholesterol ratio (LCR) and assigning weighted values (A) and (B), respectively, determining the patient's ApoE phenotype or genotype as one of ApoE3/ApoE3 or ApoE4/ApoE4 and assigning weighted value (C), and determining a SLCO1B1 genotype from a nucleic acid sample of the patient by identifying the presence or absence of a SLCO1B1 rs4149056 polymorphism and assigning weighted value (D). The weighted value is assigned to the plasma LDL cholesterol level (A) as follows: an LDL cholesterol concentration greater than about 160 mg/dl is assigned a weighted value of +2, an LDL cholesterol concentration between and including about 100 to about 160 mg/dl is assigned a weighted value of +1, and an LDL cholesterol concentration less than about 100 is assigned a weighted value of 0. The weighted value is assigned to the plasma LCR ratio (B) as follows: a plasma lathosterol/cholesterol ratio greater than about 160 $\mu\text{mol}/\text{mmol}$ in both men and women is assigned a weighted value of +4, a plasma lathosterol/cholesterol ratio between 90 - 160 $\mu\text{mol}/\text{mmol}$ in men and women is assigned a weighted value of 0, and a plasma lathosterol/cholesterol ratio < 90 $\mu\text{mol}/\text{mmol}$ in both men and women is assigned a weighted value of -4. The weighted value is assigned for ApoE type (C) as follows: an ApoE type of ApoE2/ApoE2 is assigned a weighted value of +2, an ApoE type of ApoE2/ApoE3 is assigned a weighted value of +1, an ApoE type of ApoE3/ApoE3 or ApoE2/ApoE4 is assigned a weighted value of 0, an ApoE type of ApoE3/ApoE4 is assigned a weighted value of -1, or an ApoE type of ApoE4/ApoE4 is assigned a weighted value of -2. The weighted value is assigned to the SLCO1B1 genotype (D) as follows: an SLCO1B1 genotype of T/T is assigned a weighted value of 0, an SLCO1B1 genotype of T/C is assigned a weighted value of -1, or an SLCO1B1 genotype of

rs4149056/ rs4149056 is assigned a weighted value of -2. The weighted values (A), (B), (C), (D) are combined. When the combined weighted value is in the range of +4 to +8, the patient may be characterized as hyper-responsive to statin treatment and requires a statin dosage in the range of about 10 - 20 mg/day. When the combined weighted value is in the range -3 to +3, the patient may be characterized as a normal responder and requires a statin dosage in the range of about 40 mg/day. When the combined weighted value is in the range -8 to -4, the patient may be characterized as hypo-responsive to statin treatment and requires treatment with maximal doses of statins at 40 - 80 mg/day and/or ezetimibe treatment. Once the patient is characterized as a particular type of responder, the method involves administering the required statin dosage to the patient, thereby treating the patient so as to reduce serum LDL cholesterol. The hypo-responsive patient may be treated with a non-statin drug. The non-statin drug may be ezetimibe.

According to another aspect of the present invention, there is provided a method for identifying a patient's likelihood of responding to statin treatment, the method comprising the steps of: determining a baseline level of cholesterol in a blood and/or plasma sample obtained from a patient; identifying a SLCO1B1 polymorphism and an Apolipoprotein E gene (ApoE) polymorphism in said sample that is indicative of statin efficacy; characterizing said patient's likelihood of responding to statin treatment based upon said level and the presence or absence of said SLCO1B1 and ApoE polymorphisms identified in said identifying step, wherein the statin treatment comprises a statin selected from the group consisting of pravastatin, atorvastatin, and cerivastatin.

Also herein disclosed is an in-vitro diagnostic kit for identifying an appropriate therapeutic regimen to enable an individual in need of treatment to obtain a target cholesterol level. The kit includes a first reagent for detecting the presence or absence of a polymorphism in the SLCO1B1 gene, and a second reagent for detecting ApoE3/ApoE3 or ApoE4/ApoE4 in a biological sample from the individual, where the first reagent includes an rs4149056 specific primer set, and the second reagent includes an rs7412 specific primer set and an rs429358 specific primer set, or an anti-ApoE antibody, and packaging therefore.

The present invention pertains to compositions and methods for assessing the treatment of CHD in individuals based on their genetic makeup (i.e. personal genome sequence) by identifying genetic polymorphisms at genetic loci that affect uptake and/or metabolism of CHD specific therapeutics, and assessing treatment/prophylactic protocols to maximize efficacy of CHD treatment. In a preferred embodiment, the invention provides compositions and methods for assessing the treatment of CHD in an individual based on their genotype at both the SLCO1B1 and ApoE loci.

Other and further aspects and features of the invention will be evident from the following detailed description and the accompanying drawings, which are intended to exemplify, not limit, the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows the wildtype ApoE nucleic acid molecule (NCBI Accession No. NM_000041.2) (SEQ ID No. 68).

Fig. 2 shows another exemplary wildtype ApoE nucleic acid molecule (NCBI Accession No. NG_007084.2) (SEQ ID No. 69)

Fig. 3 shows an exemplary ApoE polypeptide wildtype sequence (NCBI Accession No. NP_000032.1) (SEQ ID No. 70).

Fig. 4 shows an exemplary SLCO1B1 nucleic acid molecule (NCBI Accession No. NM_006446.4) (SEQ ID No. 71).

Fig. 5 shows an exemplary wildtype SLCO1B1 nucleic acid molecule (NCBI Accession No. NG_011745.1) (SEQ ID No. 72).

Fig. 6 shows an exemplary wildtype SLCO1B1 polypeptide sequence (NCBI Accession No. NP_006437.3) (SEQ ID No. 73).

DETAILED DESCRIPTION OF THE INVENTION

The invention features compositions and methods that are useful for assessing the treatment and/or prophylaxis of coronary heart disease (CHD) in individuals based on their individual genetic makeup.

The present invention provides methods of assessing the treatment and/or prophylaxis of coronary heart disease (CHD) by determining a subject's genotype and/or plasma LDL cholesterol level and/or plasma lathosterol/cholesterol ratio, and administering a therapeutically effective amount of a compound, such as, for example, a statin, to a subject (*e.g.*, a mammal such as a human). The present invention is based, at least in part, on the inventors' discovery that polymorphisms within genes that encode proteins involved in the uptake and metabolism/catabolism of therapeutic agents used to treat CHD modulate the efficacy of the therapeutic agent, and that this modulation is combinatorial (*i.e.* polymorphisms at different loci may interact with one another in either antagonistic or synergistic ways). A polymorphism or

variant is a polynucleotide or polypeptide sequence that differs from a wild-type or reference sequence by one or more nucleotides or one or more amino acids. A polymorphism may include single or multiple nucleotide insertions, deletions, and/or alterations of the genomic sequence of a specified locus.

5 Thus, one embodiment is a method of assessing treatment of a subject suffering from or susceptible to CHD, or a symptom thereof that is based, at least in part, on a knowledge of the combination of an individual's genotype at the solute carrier organic anion transporter family member 1B1 (SLCO1B1) locus and the apolipoprotein E (ApoE) locus. The method includes the steps of determining the subject's genotype at least at SLCO1B1 and ApoE, and
10 administering to the subject an assessed therapeutic amount of a statin dosage, or other suitable therapeutic compounds to treat CHD, or symptoms thereof, under conditions such that the disease is treated in a manner that has been assessed for the subject's own genomic sequence at the SLCO1B1 and ApoE loci. In one embodiment, knowledge of a subject's SLCO1B1 and ApoE genotype may be combined with knowledge of the subject's plasma LDL cholesterol level
15 and plasma lathosterol/cholesterol ratio, thereby further assessing treatment.

 The therapeutic methods of the invention (which include prophylactic treatment) in general comprise administration of a therapeutically effective amount of the compounds herein, such as a statin to a subject (*e.g.*, animal, human) in need thereof, including a mammal, particularly a human. Such treatment will be suitably administered to subjects, particularly
20 humans, suffering from, having, susceptible to, or at risk for heart disease, disorder, or symptom thereof, for example, CHD. Determination of those subjects "at risk" can be made by any objective or subjective determination by a diagnostic test or opinion of a subject or health care provider (*e.g.*, genetic test, enzyme or protein marker, marker (as defined herein), family history, as well as other medically accepted indicators).

25 In one embodiment, the invention provides a method of monitoring treatment progress. The method includes the step of determining a level of diagnostic marker (marker) (*e.g.*, any SLCO1B1 and/or ApoE polymorphism delineated herein) or diagnostic measurement (*e.g.*, screen, assay) in a subject suffering from or susceptible to a disorder or symptoms thereof associated with CHD, in which the subject has been administered a therapeutic amount of a
30 compound herein sufficient to treat the disease or symptoms thereof. The level of marker determined in the method can be compared to known levels of marker in either healthy normal

controls or in other afflicted patients to establish the subject's disease status. The controls or reference level can be established by determining the levels of markers in a subject that has not been diagnosed with a disease according to the invention, for example heart disease or CHD, and/or does not exhibit any detectable symptoms associated with this disease. In addition, controls or reference levels can be determined by levels of markers in a subject positively diagnosed with a disease according to the invention. In preferred embodiments, a second level of marker in the subject is determined at a time point later than the determination of the first level, and the two levels are compared to monitor the course of disease or the efficacy of the therapy. In certain preferred embodiments, a pre-treatment level of marker in the subject is determined prior to beginning treatment according to this invention; this pre-treatment level of marker can then be compared to the level of marker in the subject after the treatment commences, to determine the efficacy of the treatment.

Methods of the invention are used to assess treatment of heart disease. Heart disease includes but is not limited to coronary heart disease (CHD), cardiomyopathy, cardiovascular disease (CVD), ischemic heart disease, heart failure, hypertensive heart disease, inflammatory heart disease, and valvular heart disease. Heart disease is a systemic disease that can affect the heart, brain, most major organs, and the extremities. Coronary heart disease that causes the failure of coronary circulation to supply adequate circulation to the cardiac muscles and surrounding tissues. Cardiovascular disease is meant any of a number of specific diseases that affect the heart itself and/or the blood vessel system, especially the myocardial tissue, as well as veins and arteries leading to and from the heart. For example, CVD may include, but is not limited to, acute coronary syndromes, arrhythmia, atherosclerosis, heart failure, myocardial infarction, neointimal hyperplasia, pulmonary hypertension, stroke, and/or valvular disease. CVD may be diagnosed by any of a variety of methods known in the art. For example, such methods may include assessing a subject for dyspnea, orthopnea, paroxysmal nocturnal dyspnea, claudication, angina, chest pain, which may present as any of a number of symptoms known in the art, such as exercise intolerance, edema, palpitations, faintness, loss of consciousness, and/or cough.

Atherosclerosis is a heart disease in which an artery wall thickens as the result of a build-up of fatty materials such as cholesterol. It is a syndrome affecting arterial blood vessels, a

chronic inflammatory response in the walls of arteries, in large part due to the accumulation of macrophage white blood cells and promoted by low-density lipoproteins (plasma proteins that carry cholesterol and triglycerides) without adequate removal of fats and cholesterol from the macrophages by functional high density lipoproteins (HDL). It is commonly referred to as a hardening or furring of the arteries. It is caused by the formation of multiple plaques within the arteries.

In certain embodiments, methods of the invention are used to determine an appropriate treatment to lower low density lipoprotein (LDL) cholesterol (LDL-C), which is associated with increased heart risk. Typically, a low HDL-C blood concentration value is below 40 mg/dl in men and is below 50 mg/dl in women. In contrast to LDL, high density lipoprotein (HDL) cholesterol (HDL-C),” is the cholesterol level of “good particles” measured in plasma, after the removal of apo-B containing lipoproteins (very low density lipoprotein cholesterol and low density lipoprotein particles). High blood concentration values of HDL-C are above 60 mg/dl and protect against heart disease. A HDL-C blood concentration value between 40 and 60 mg/dl is considered borderline.

Methods of the invention can be used to determine a patient’s responsiveness to statin treatment to reduce LDL cholesterol and to determine a proper statin dosage for the patient. By Statin is class of drugs used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Statins may include but are not limited to Advicor® (niacin extended-release/lovastatin), Altoprev® (lovastatin extended-release), Caduet® (amlodipine and atorvastatin), Crestor® (rosuvastatin), Lescol® (fluvastatin), Lescol XL (fluvastatin extended-release), Lipitor® (atorvastatin), Livalo® (pitavastatin), Mevacor® (lovastatin), Pravachol® (pravastatin), Simcor® (niacin extended-release/simvastatin), Vytorin® (ezetimibe/simvastatin), Zocor® (simvastatin), or generic atorvastatin, lovastatin, pravastatin, or simvastatin. In certain embodiments, the proper statin dosage is the amount of a statin required to reduce LDL-C to target levels, relative to an untreated patient. The effective amount of statin(s) used to practice the present invention for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Additionally, statin dosage may vary depending upon which statin is being administered. For example, a typical statin dosage range for

atorvastatin, pravastatin, lovastatin, and simvastatin is from about 10 mg to about 80 mg. For these three statins, a “normal” statin dosage may range from about 10 mg to about 40 mg, while a “high” statin dosage may range from about 40 mg to about 80 mg.

Diagnostic Methods

5 The present invention provides a number of diagnostic assays that are useful for characterizing the genotype of a subject. The present invention can be employed to genotype a gene of interest in a subject, where the gene of interest has similar or variant isoform(s). In certain embodiments, genotyping is the characterization of two alleles in one or more genes of interest. Desirably, the methods of the invention discriminate between the genotype of a gene of
10 interest and the genotype of the similar isoform(s). Preferably, both or all alleles corresponding to a gene of interest are identified. Accordingly, the invention provides for genotyping useful in virtually any clinical setting where conventional methods of analysis are used.

 The genotype of an individual may be determined as heterozygous or homozygous for one or more variant alleles of interest. Heterozygous generally means that a chromosomal locus
15 has two different alleles. In one embodiment of the invention, heterozygous refers to a genotype in which one allele has a wild-type SLCO1B1 sequence (e.g., encoding a SLCO1B1 protein that has normal transporter activity) and the other allele has a sequence encoding a SLCO1B1 variant such as, for example, rs4149056 that does not have normal transporter activity (e.g., an alteration of Valine 174 to Alanine). Homozygous generally means a chromosomal locus has two identical
20 alleles. In one embodiment, homozygous refers to a genotype in which both alleles have a wild-type SLCO1B1 sequence (e.g., encoding a SLCO1B1 protein that has normal transporter activity). In some embodiments, homozygous can refer to a genotype in which both alleles have a sequence encoding a SLCO1B1 variant that does not have normal transporter activity such as, for example, rs4149056 that does not have normal transporter activity (e.g., an alteration of
25 Valine 174 to Alanine). In particular embodiments, the SLCO1B1 variant alleles with reduced or eliminated transporter activity are identical at one or more SNPs.

 In various aspects, the methods of the invention determine or detect the presence of both of SLCO1B1 and APOE genetic variants, whether at the nucleic acid or protein level. The present methods provide a genetic means for the analysis of biomarkers in SLCO1B1 and APOE
30 associated with drug metabolism, for example, statin metabolism. Results obtained from

SLCO1B1 and APOE genotyping assays may be used to select an appropriate therapy for a subject, monitor drug therapy in a subject, identify a subject as responsive to drug therapy, or identify a subject as sensitive to a drug. This level of genotyping will better enable individualized pharmacogenetic-based therapy.

5 An apolipoprotein E (ApoE) nucleic acid molecule is a polynucleotide encoding an ApoE protein that, when combined with fat, becomes a lipoprotein. An exemplary wildtype ApoE nucleic acid molecule is provided at NCBI Accession No. NM_000041.2 (SEQ ID No. 68) (see Fig. 1). Another exemplary wildtype ApoE nucleic acid molecule is provided at NCBI Accession No. NG_007084.2 (SEQ ID No. 69) (see Fig. 2). In certain embodiments, a ApoE polypeptide is a polypeptide or fragment thereof having at least about 85% amino acid identity to the exemplary wildtype sequence of NCBI Accession No. NP_000032.1 (SEQ ID No. 70) (see Fig. 3). In certain embodiments, an ApoE2 is an ApoE allele that encodes an ApoE protein that has a cysteine residue at amino acid positions 130 and 176 (sometimes listed as amino acid positions 112 and 158 in the early ApoE literature) in the receptor-binding region of ApoE. At the genotypic level, ApoE2 is defined by two SNPs: rs429358 (position 471 of the ApoE cDNA, position 7903 of the ApoE genomic DNA, and position 17680159 of the chromosome) and rs7412 (position 609 of the ApoE cDNA, position 8041 of the ApoE genomic DNA, and position 17680297 chromosome). The ApoE2 genotype is rs429358 (T) and rs7412 (T). In certain embodiments, ApoE3 is meant an ApoE allele that encodes an ApoE protein that has a cysteine at position 130 and an arginine at position 176. At the genotypic level, ApoE3 is defined by two SNPs—rs429358 and rs7412 (see above for nucleotide positions of these two SNPs). The ApoE3 genotype is rs429358 (T) and rs7412 (C). In certain embodiments, ApoE4 is meant an ApoE allele that encodes an ApoE protein that has an arginine at both positions 130 and 176. At the genotypic level, ApoE4 is defined by two SNPs—rs429358 and rs7412 (see above for nucleotide positions of these two SNPs). The ApoE4 genotype is rs429358 (C) and rs7412 (C).

Exemplary ApoE polymorphisms include rs7412, rs429358, rs769452, rs769455, rs11542029, rs11542031, rs11542038, rs28931576, rs28931578, rs28931579, rs111833428, rs121918392, rs121918393, rs121918394, rs121918395, rs121918396, rs121918397, rs121918398, and rs121918399. The most common ApoE polymorphism are commonly referred to as ApoE2, ApoE3, and ApoE4, respectively. These polymorphic forms differ from each other only by amino acid substitutions at positions 130 and 176 of the ApoE protein. These amino acid

changes are caused by SNPs at nucleotide positions 471 (rs429358) and 609 (rs7412) of the ApoE cDNA, respectively. The ApoE2 allele has a cysteine at amino acid positions 130 and 176 in the receptor-binding region of ApoE. The ApoE3 allele has a cysteine at amino acid position 130 and an arginine at amino acid position 176. The ApoE E4 allele has an arginine at both amino acid positions 130 and 130.

SLCO1B1 is the name for a solute carrier organic anion transporter family, member B1 nucleic acid molecule. In certain embodiments a SLCO1B1 is a polynucleotide encoding an SLCO1B1 polypeptide. SLCO1B1 is a gene that encodes a liver-specific member of the organic anion transporter family. The SLCO1B1 protein is a transmembrane receptor that mediates the sodium-independent uptake of numerous endogenous compounds including bilirubin, 17-beta-glucuronosyl estradiol and leukotriene C4. This protein is also involved in the removal of drug compounds such as statins, bromosulphophthalein and rifampin from the blood into the hepatocytes. An exemplary SLCO1B1 nucleic acid molecule is provided at NCBI Accession No. NM_006446.4 (SEQ ID No. 71) (Fig. 4). Another exemplary wildtype SLCO1B1 nucleic acid molecule is provided at NCBI Accession No. NG_011745.1 (SEQ ID No. 72) (Fig. 5). In certain embodiments, a SLCO1B1 polypeptide is a polypeptide or fragment thereof having transporter activity and at least about 85% amino acid identity to the exemplary wildtype sequence of NCBI Accession No. NP_006437.3 (SEQ ID No. 73) (Fig. 6). In certain embodiments, a SLCO1B1-056 polymorphism is the rs4149056 polymorphism, which results in a T to C nucleotide change at position 625 within the gene (sometimes referred to as position 521 in the early literature) that causes a missense mutation at position 174 in the SLCO1B1 protein from valine to alanine (V174A).

Exemplary SLCO1B1 polymorphisms include rs4149056, rs61176925, rs61760183, rs61760245, rs71581941, rs71581978, rs71581987, rs71581988, rs72559742, rs72559745, rs72559746, rs72559747, rs72559748, rs72661137, rs74064211, rs74064213, rs74700754, rs77468276, rs77871475, rs79109623, rs79135870, rs112560299, rs112909948, rs113495867, and rs113635866.

In particular embodiments, the invention provides for the detection of SLCO1B1 and APOE allelic variants and SNPs listed in Table 1 and Table 2, respectively. In preferred embodiments, the invention provides for the detection of the rs4149056 (corresponding to a T to C change at nucleotide position 625 of the SLCO1B1 cDNA, and a valine to alanine change at

position 174 of the SLCO1B1 protein) polymorphism in the SLCO1B1 gene, and the rs429358 (corresponding to a T to C change at nucleotide position 471 of the ApoE cDNA, and an arginine to cysteine change at position 130 of the ApoE protein) and rs7412 (corresponding to a C to T change at position 609 of the ApoE cDNA, and an arginine to cysteine change at position 176 of the ApoE protein) polymorphisms in the ApoE gene. Advantageously, the methods of the invention distinguish between homozygous and heterozygous alleles of SLCO1B1 and/or ApoE.

Table 1: SLCO1B1 Polymorphisms That Alter Amino Acid Identity

Polymorphism ID	Position on Chromosome 19	SEQ ID NO.	Sequence	Polymorphism: N in Sequence	Amino Acid Change
rs2291075	21331625(+)	1	GATTTNGCTAA	C/T	F
rs2306282	21329802(-)	2	CTCTANTGAGT	T/C	N/S
rs2306283	21329738(-)	3	TGAATNGATAT4 N	C/T	D
rs4149056	21331549(+)	4	ATATGNGTTCA	T/C	V to A
rs4149057	21331599(+)	5	TACCANTGGGG	T/C	L
rs4603354	21331636(+)	6	AGAAGNACATT	A/G	E,G
rs11045818	21329761(+)	7	ACATCNACCTT	G/A	S
rs11045819	21329813(+)	8	CATCANCTGAG	C/A	T,P
rs11045852	21349885(+)	9	GCACTNTCAGG	A/G	I,V
rs11045853	21349910(+)	10	TTCTCNATGGG	G/A	Q,R
rs11045854	21350034(+)	11	TCACTNTCTTT	G/A	L
rs11045859	21355537(+)	12	GCTGTNATGTC	G/A	V
rs11557087	21294536(+)	13	ATAAANCAGCA	A/G	T,A
rs34671512	21391976(+)	14	ATATTNATTTA	A/C	L,F
rs55737008	21392047(+)	15	GGATGNAGCAA	A/G	E,G

rs55901008	21353529(+)	16	CTATANTGGTG	C/T	T,I
rs56061388	21327529(+)	17	GATTGNATTTG	C/T	A,V
rs56101265	21325716(+)	18	GAAGCNTTGAA	C/T	L,F
rs56199088	21392011(+)	19	GAAAGNTATCA	A/T	D,V
rs56387224	21355583(+)	20	GTGAANACAAA	A/T	N,Y
rs57040246	21353557(+)	21	AAATANGTAGA	C/T	Y
rs59113707	21355489(+)	22	AAATTNAACT	C/G	F,L
rs59502379	21358933(+)	23	AGCAGNTTGCA	G/C	A/G
rs61176925	21355561(+)	24	CTATTNTATTT	A/C	L,F
rs61760183	21325669(+)	25	CTGGGNTAAAT	A/G	Q,R
rs61760245	21353483(+)	26	AGGGANGGGAA	A/G	I,V,Y
rs71581941	21375289(+)	27	TTATANGAGCA	C/T	RX
rs71581978	21327539(+)	28	GTGAGNTACTT	C/T	S
rs71581987	21370128(+)	29	AATGCNCAAGA	C/T	P,S
rs71581988	21370177(+)	30	AATACNAGTCT	A/T	Q,L
rs72559742	21349993(+)	31	TGCCGNAAAAT	-/A	K,Q
rs72559745	21329817(+)	32	ACCTGNGATAG	A/G	E,G
rs72559746	21331606(+)	33	GGGGCNTTCTT	G/T	R,L
rs72559747	21353478(+)	34	TAATCNCCTGT	C/G	P,R
rs72559748	21358855(+)	35	CTCAGNCTGCA	A/G	D,G
rs72661137	21370183(+)	36	AGTCTNGAATT	G/T	W,L
rs74064211	21358922(+)	37	TCACCNTGTCT	C/T	P
rs74064213	21358965(+)	38	AGCCTNTAGTG	A/G	I,V
rs74700754	21375275(+)	39	TTCCNCTCAA	A/T	H,L

rs77468276	21355535(+)	40	CTGCTNTGATG	G/C	L,V
rs77871475	21353471(+)	41	TCCTTNCTAAT	A/T	T,S
rs79109623	21353505(+)	42	TTTGANGTTGT	C/T	T,M
rs79135870	21331891(+)	43	CAATCNTTGGC	A/G	I,V
rs112560299	21391957(+)	44	ATCACNTGTTT	A/T	H,L
rs112909948	21370119(+)	45	ATTTGNGTGAA	A/G	S,G
rs113495867	21353483(+)	46	CCTGTNTATGTT	-/G	Y,V
rs113635866	21294538(+)	47	AAAACNGCAGA	A/G	T

Table 2: Polymorphisms That Alter Amino Acid Identity

SNP ID	CHROMOSOME 19 POSITION	SEQ ID NO.	SEQUENCE	Polymorphism: N in Sequence	Amino Acid Change
rs7412 (E2)	45412079(+)	48	AGAAGNGCCTG	C/T	R to C
rs429358 (E4)	45411941(+)	49	ACGTGNGCGGC	T/C	R to C
rs769452	45411110(+)	50	GGAACNGGCAC	T/C	P to L
rs769455	45412040(+)	51	AGCTGNGTAAG	C/T	R to C
rs11542029	45411121(+)	52	TGGGTNGCTTT	C/T	R to C
rs11542031	45411123(+)	53	GGTCGNTTTTG	C/T	R
rs11542038	45411153(+)	54	CAGACNCTGTC	A/G	T
rs28931576	45411151(+)	55	TGCAGNCACTG	A/G	T to A
rs28931578	45412008(+)	56	GCTGCNGGTGC	A/G	Q to R
rs28931579	45412493(+)	57	TGCCCNGCGAC	A/C	S to R
rs111833428	45411042(+)	58	CAAGCNGTGGA	A/G	A

rs121918392	45411034(+)	59	AGGTGNAGCAA	A/G	K to E
rs121918393	45412013(+)	60	GGGTGNGCCTC	A/C	S to R
rs121918394	45412043(+)	61	TGCGTNAGCGG	A/C/G	K to Q
rs121918395	45412289(+)	62	GCGACNGCCTG	C/T	R to C
rs121918396	45412236(+)	63	GGCCTNNGGCG	A/G	X to W
rs121918397	45412041(+)	64	GCTGCNTAAGC	A/C/G	H to R
rs121918398	45412428(+)	65	GCAGCNCCAGT	A/G	H to R
rs121918399	45411100(+)	66	GCCAGNGCTGG	C/T	H to R
rs7412	45412079(+)	67	AGAAGNGCCTG	C/T	R to C

Types of Biological Samples

The genotyping methods of the invention involve detecting or determining a genetic variant or biomarker of interest in a biological sample. In one embodiment, the biologic sample contains a cell having diploid DNA content. Human cells containing 46 chromosomes (e.g., human somatic cells) are diploid. In one embodiment, the biologic sample is a tissue sample that includes diploid cells of a tissue (epithelial cells) or organ (e.g., skin cells). Such tissue is obtained, for example, from a cheek swab or biopsy of a tissue or organ. In another embodiment, the biologic sample is a biologic fluid sample. Biological fluid samples containing diploid cells include saliva, blood, blood serum, plasma, urine, hair follicle, or any other biological fluid useful in the methods of the invention.

Genotyping of SLCO1B1 and APOE polymorphisms

A SLCO1B1 and/or ApoE isoform is amplified by long range PCR to determine the genotype of the polymorphism, e.g., the rs4149056 (corresponding to a T to C change at nucleotide position 625 of the SLCO1B1 cDNA, and a valine to alanine change at position 174 of the SLCO1B1 protein) polymorphism in the SLCO1B1 gene, and the rs429358 (corresponding to a T to C change at nucleotide position 471 of the ApoE cDNA, and an arginine to cysteine change at position 130 of the ApoE protein) and rs7412 (corresponding to a C to T

change at position 609 of the ApoE cDNA, and an arginine to cysteine change at position 176 of the ApoE protein) polymorphisms in the ApoE gene. The amplified nucleic acid corresponding to the SLCO1B1 and/or ApoE polymorphism may be analyzed using a variety of methods for detecting variant alleles to determine the genotype. For example, the presence or absence of one or more of the rs4149056 (corresponding to a T to C change at nucleotide position 625 of the SLCO1B1 cDNA, and a valine to alanine change at position 174 of the SLCO1B1 protein) polymorphism in the SLCO1B1 gene, and the rs429358 (corresponding to a T to C change at nucleotide position 471 of the ApoE cDNA, and an arginine to cysteine change at position 130 of the ApoE protein) and rs7412 (corresponding to a C to T change at position 609 of the ApoE cDNA, and an arginine to cysteine change at position 176 of the ApoE protein) polymorphisms in the ApoE gene may be evaluated using various techniques. For example, the SLCO1B1 gene is amplified by long range PCR and sequenced to determine the presence or absence of a single nucleotide polymorphism (SNP). In certain embodiments, real-time PCR may be used to detect a single nucleotide polymorphism of the amplified products. In other embodiments, a polymorphism in the amplified products may be detected using a technique including hybridization with a probe specific for a single nucleotide polymorphism, restriction endonuclease digestion, primer extension, microarray or gene chip analysis, mass spectrometry, or a DNase protection assay.

Long range Polymerase Chain Reaction (PCR)

Polymerase chain reaction (PCR) is widely known in the art. For example, U.S. Pat. Nos. 4,683,195, 4,683,202, and 4,800,159; K. Mullis, Cold Spring Harbor Symp. Quant. Biol., 51:263-273 (1986); and C. R. Newton & A. Graham, Introduction to Biotechniques: PCR, 2.sup.nd Ed., Springer-Verlag (New York: 1997), the disclosures of which are incorporated herein by reference, describe processes to amplify a nucleic acid sample target using PCR amplification extension primers which hybridize with the sample target. As the PCR amplification primers are extended, using a DNA polymerase (preferably thermostable), more sample target is made so that more primers can be used to repeat the process, thus amplifying the sample target sequence. Typically, the reaction conditions are cycled between those conducive to hybridization and nucleic acid polymerization, and those that result in the denaturation of duplex molecules.

Exemplary methods for performing long range PCR are disclosed, for example, in U.S. Pat. No. 5,436,149; Barnes, Proc. Natl. Acad. Sci. USA 91:2216-2220 (1994); Tellier et al., Methods in Molecular Biology, Vol. 226, PCR Protocols, 2nd Edition, pp. 173-177; and, Cheng et al., Proc. Natl. Acad. Sci. 91:5695-5699 (1994); the contents of which are incorporated herein
5 by reference. In various embodiments, long range PCR involves one DNA polymerase. In some embodiments, long range PCR may involve more than one DNA polymerase. When using a combination of polymerases in long range PCR, it is preferable to include one polymerase having 3'→5' exonuclease activity, which assures high fidelity generation of the PCR product from the DNA template. Typically, a non-proofreading polymerase, which is the main
10 polymerase is also used in conjunction with the proofreading polymerase in long range PCR reactions. Long range PCR can also be performed using commercially available kits, such as LA PCR kit available from Takara Bio Inc. Polymerase enzymes having 3'→5' exonuclease proofreading activity are known to those in the art. Examples of suitable proofreading enzymes include TaKaRa LA Taq (Takara Shuzo Co., Ltd.) and Pfu (Stratagene), Vent, Deep Vent (New
15 England Biolabs).

Sequencing

DNA sequencing may be used to evaluate a polymorphism of the present invention. One DNA sequencing method is the Sanger method, which is also referred to as dideoxy sequencing
20 or chain termination. The Sanger method is based on the use of dideoxynucleotides (ddNTP's) in addition to the normal nucleotides (NTP's) found in DNA.

Pyrosequencing is another method of DNA sequencing that may be used to evaluate a polymorphism of the present invention, for example as described in U.S. Pat. Publ. No. 2006008824; herein incorporated by reference). Pyrosequencing, which is also referred to as
25 sequencing by synthesis, involves taking a single strand of the DNA to be sequenced, synthesizing its complementary strand enzymatically one base pair at a time, and detecting by chemiluminescence the base that is added.

Pyrosequencing, optionally coupled with amplification of the nucleic acid target, can sequence large numbers of target molecules, usually employing automated sequencing apparatus,
30 including long sequences (e.g., 400 million bp/10 hr in a single run). Sequencing methods are well known to those of skill in the art.

Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary approach to determining the degree of identity, a BLAST program may be used, with a probability score between e^{-3} and e^{-100} indicating a closely related sequence.

Real-Time PCR (rtPCR)

The presence or absence of polymorphisms in SLCO1B1 and/or ApoE isoforms may be detected using real-time PCR. Real-time PCR typically utilizes fluorescent probes for the selective detection of the polymorphisms. Various real-time PCR testing platforms that may be used with the present invention include: 5' nuclease (TaqMan® probes), molecular beacons, and FRET hybridization probes. These detection methods rely on the transfer of light energy between two adjacent dye molecules, a process referred to as fluorescence resonance energy transfer (see, e.g., Espy et al (2006) Clin Microbiol Rev. 2006 January; 19(1): 165-256 for a review of various rtPCR approaches that may be used with the present invention).

5' Nuclease Probes

In certain embodiments, a 5' nuclease probe may be used to detect a polymorphism of the present invention. 5' nuclease probes are often referred to by the proprietary name, TaqMan® probes. A TaqMan® probe is a short oligonucleotide (DNA) that contains a 5' fluorescent dye and 3' quenching dye. Molecular beacons and FRET hybridization probes typically involve the measurement of fluorescence during the hybridization step.

Genotyping for the 12754T>del ("Asp260fs") or Gly143Glu (428G>A, "Gly143Glu") in the carboxylesterase-1 gene may be evaluated using the following (5' endonuclease probe) real-time PCR technique. Genotyping assays can be performed in duplicate and analyzed on a Bio-Rad iCycler Iq® Multicolor Real-time detection system (Bio-Rad Laboratories, Hercules, Calif.). Real-time polymerase chain reaction (PCR) allelic discrimination assays to detect the presence or

absence of specific single nucleotide polymorphisms in the SLCO1B1 and/or ApoE gene, may utilize fluorogenic TaqMan® Probes.

Real-time PCR amplifications may be carried out in a 10 µl reaction mix containing 5 ng genomic DNA, 900 Nm of each primer, 200 Nm of each probe and 5 µl of 2xTaqMan®

5 Universal PCR Master Mix (contains PCR buffer, passive reference dye ROX, deoxynucleotides, uridine, uracil-N-glycosylase and AmpliTaq Gold DNA polymerase; Perkin-Elmer, Applied Biosystems, Foster City, Calif.). Cycle parameters may be: 95° C for 10 min, followed by 50 cycles of 92° C. for 15 sec and 60C ° for 1 min. Real-time fluorescence detection can be performed during the 60° C. annealing/extension step of each cycle. The IQ software may be
10 used to plot and automatically call genotypes based on a two parameter plot using fluorescence intensities of FAM and VIC at 49 cycles.

FRET Hybridization Probes

FRET hybridization probes, also referred to as LightCycler® probes, may also be used to detect a polymorphism of the present invention. FRET hybridization probe technology permits
15 melting curve analysis of the amplification product. Like molecular beacons, FRET hybridization probes have the advantage of being recycled or conserved during PCR temperature cycling, and a fluorescent signal does not accumulate as PCR product accumulates after each PCR cycle.

Primer Extension

20 Primer extension is another technique which may be used according to the present invention. A primer and no more than three NTPs may be combined with a polymerase and the target sequence, which serves as a template for amplification. By using less than all four NTPs, it is possible to omit one or more of the polymorphic nucleotides needed for incorporation at the polymorphic site. It is important for the practice of the present invention that the amplification be
25 designed such that the omitted nucleotide(s) is(are) not required between the 3' end of the primer and the target polymorphism. The primer is then extended by a nucleic acid polymerase, in a preferred embodiment by Taq polymerase. If the omitted NTP is required at the polymorphic site, the primer is extended up to the polymorphic site, at which point the polymerization ceases. However, if the omitted NTP is not required at the polymorphic site, the primer will be extended
30 beyond the polymorphic site, creating a longer product. Detection of the extension products is based on, for example, separation by size/length which will thereby reveal which polymorphism

is present. For example, U.S. Ser. No. 10/407,846, which is hereby incorporated by reference, describes a form of primer extension.

RFLP

Restriction Fragment Length Polymorphism (RFLP) is a technique in which different DNA sequences may be differentiated by analysis of patterns derived from cleavage of that DNA. If two sequences differ in the distance between sites of cleavage of a particular restriction endonuclease, the length of the fragments produced will differ when the DNA is digested with a restriction enzyme. The similarity of the patterns generated can be used to differentiate species (and even strains) from one another.

Restriction endonucleases in turn are the enzymes that cleave DNA molecules at specific nucleotide sequences depending on the particular enzyme used. Enzyme recognition sites are usually 4 to 6 base pairs in length. Generally, the shorter the recognition sequence, the greater the number of fragments generated. If molecules differ in nucleotide sequence, fragments of different sizes may be generated. The fragments can be separated by gel electrophoresis.

Restriction enzymes are isolated from a wide variety of bacterial genera and are thought to be part of the cell's defenses against invading bacterial viruses. Use of RFLP and restriction endonucleases in SNP analysis requires that the SNP affect cleavage of at least one restriction enzyme site.

Mass Spectrometry

Mass spectrometry may also be used to detect a polymorphism of the present invention. By exploiting the intrinsic properties of mass and charge, mass spectrometry (MS) can resolved and confidently identified a wide variety of complex compounds. Traditional quantitative MS has used electrospray ionization (ESI) followed by tandem MS (MS/MS) (Chen et al., 2001; Zhong et al., 2001; Wu et al., 2000) while newer quantitative methods are being developed using matrix assisted laser desorption/ionization (MALDI) followed by time of flight (TOF) MS (Bucknall et al., 2002; Mirgorodskaya et al., 2000; Gobom et al., 2000). Methods of mass spectroscopy that may be used with the present invention include: ESI, ESI tandem mass spectroscopy (ESI/MS/MS), Secondary ion mass spectroscopy (SIMS), Laser desorption mass spectroscopy (LD-MS), Laser Desorption Laser Photoionization Mass Spectroscopy (LDLPMS), and MALDI-TOF-MS.

Hybridization

There are a variety of ways by which one can assess genetic profiles, and many of these rely on nucleic acid hybridization. Typically, a probe or primer of between 13 and 100 nucleotides, preferably between 17 and 100 nucleotides in length up to 1-2 kilobases or more in length will allow the formation of a duplex molecule that is both stable and selective. For applications requiring high selectivity, one will typically desire to employ relatively high stringency conditions to form the hybrids. For example, relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50° C to about 70° C. Such high stringency conditions tolerate little, if any, mismatch between the probe or primers and the template or target strand and would be particularly suitable for isolating specific genes or for detecting specific mRNA transcripts. Representative solid phase hybridization methods are disclosed in U.S. Pat. Nos. 5,843,663, 5,900,481 and 5,919,626. Other methods of hybridization that may be used in the practice of the present invention are disclosed in U.S. Pat. Nos. 5,849,481, 5,849,486 and 5,851,772. The relevant portions of these and other references identified in this section of the Specification are incorporated herein by reference.

Pharmacogenetics: Consequence for Drug Therapy

SLCO1B1 is important for the uptake and metabolism of many known compounds in humans and non-human animals such as, for example, bilirubin, 17-beta-glucuronosyl estradiol

and leukotriene C4, statins, bromosulfophthalein and rifampin. Thus, the presence or absence of one or more polymorphisms of the present invention may be used to "individualize" or modify a therapy for a subject or patient based on the sensitivity of the subject to a therapeutic due to the presence or absence of a polymorphism of the present invention.

5 A number of SLCO1B1 genetic variants alter the coding sequence of the SLCO1B1 protein, including rs4149056, rs61176925, rs61760183, rs61760245, rs71581941, rs71581978, rs71581987, rs71581988, rs72559742, rs72559745, rs72559746, rs72559747, rs72559748, rs72661137, rs74064211, rs74064213, rs74700754, rs77468276, rs77871475, rs79109623, rs79135870, rs112560299, rs112909948, rs113495867, and rs113635866 (see, e.g., Table 1).

10 The SLCO1B1 gene polymorphism rs4149056 (nt 625 T to C) results in Valine at position 174 being replaced with Alanine) is termed the SLCO1B1-056 mutation. It is further contemplated within the scope of the invention that any genetic polymorphism that encodes a V174A mutation is equivalent to rs4149056. This genetic variant, especially in the homozygous state, markedly impairs the catabolism of statins, resulting in significantly higher statin blood level relative to
15 statin blood level in an individual after administration an oral dose of statin. High statin blood levels also result in reduced efficacy in suppressing endogenous cholesterol synthesis and LDL-C lowering, and an estimated 50% chance of developing significant adverse effects especially myopathy on statin therapy in homozygotes. The 625T>C SNP due to the rs4149056 allele at SLCO1B1 resulting in the replacement of valine by alanine at residue 174 in the amino acid
20 sequence of the SLCO1B1 protein results in significantly less Pravastatin induced LDL-C lowering in a large elderly population with either established vascular risk or at risk of vascular disease.

In certain embodiments, evaluating the presence or absence of a polymorphism of the present invention may be used to individualize a therapy and/or determine the sensitivity of a
25 subject to a compound. The compound may be a prodrug, an illicit drug, an opioid, a dopaminergic or noradrenergic drug, an ACE Inhibitor, or an HMG-CoA reductase inhibitor or "statin".

Kits

30 The invention also provides kits for genotyping any one or more of a SLCO1B1 and/or ApoE polymorphism. Such kits are useful for the diagnosis of a sequence alteration in

SLCO1B1 and/or ApoE relative to wild-type SLCO1B1 and/or ApoE sequences in a biological sample obtained from a subject. Alternatively, the invention provides for selecting a drug treatment regimen for CHD, or adjusting a dosage of a CHD specific therapeutic, such as, for example, a statin. In various embodiments, the kit includes at least one primer pair that identifies a SLCO1B1 polymorphism and at least one primer pair that identifies a ApoE polymorphism (e.g., the rs4149056 (nt 625 T to C; aa 174 V to A) polymorphism in the SLCO1B1 gene, and the rs429358 (nt 130 T to C; aa 130 R to C) and rs7412 (nt 176 C to T; aa 176 R to C) polymorphisms in the ApoE gene), together with instructions for using the primers to genotype in a biological sample. In additional embodiments, the kit also includes instructions for selecting an appropriate therapy for a subject, monitoring drug therapy in a subject, identifying a subject as responsive to drug therapy, or identifying a subject as sensitive to a drug. Advantageously, such testing is carried out prior to drug administration or after an adverse event associated with drug administration. Preferably, the primers are provided in combination with a thermostable DNA polymerase capable of long-range PCR amplification (e.g., a high density array). In yet another embodiment, the kit further comprises a pair of primers capable of binding to and amplifying a reference sequence. The reference sequences serves as a basis for sequence comparison. By “single nucleotide polymorphism” or “SNP” is meant a DNA sequence variation occurring when a single nucleotide in the genome differs between members of a biological species or paired chromosomes in an individual. SNPs are used as genetic markers for variant alleles.

In various other embodiments, the kit includes reagents or components for genotyping SLCO1B1 and ApoE in combination with reagents or components for the detection of a single nucleotide polymorphism (SNP) or variant of a gene encoding an additional enzyme involved in drug. The kits which contain reagents and components for determining a SLCO1B1 and/or ApoE genotype and for detecting variants in additional enzyme and/or transporters involved in drug metabolism, are useful for guiding disease specific pharmacotherapies. For example, in the treatment of CHD, one or more drugs, including Angiotensin converting enzyme (ACE) inhibitors including Capoten® (captopril), Vasotec® (enalapril), Prinivil®, Zestril® (lisinopril), Lotensin® (benazepril), Monopril® (fosinopril), Altace® (ramipril), Accupril® (quinapril), Aceon® (perindopril), Mavik® (trandolapril), and Univasc® (moexipril)); Angiotensin II

receptor blockers (ARBs) including Cozaar® (losartan), Diovan® (valsartan), Avapro® (irbesartan), Atacand® (candesartan), and Micardis® (telmisartan); Antiarrhythmia drugs including Tambocor® (flecainide), Procanbid® (procainamide), Cordarone® (amiodarone), and Betapace® (sotalol); Antiplatelet drugs; Beta Blockers including Sectral® (acebutolol), Zebeta® (bisoprolol), Brevibloc® (esmolol), Inderal® (propranolol), Tenormin® (atenolol), Normodyne®, Trandate® (labetalol), Coreg® (carvedilol), Lopressor®, and Toprol-XL® (metoprolol); and Calcium Channel Blockers including Norvasc® (amlodipine), Plendil® (felodipine), Cardizem®, Cardizem CD®, Cardizem SR®, Dilacor XR®, Diltia XT®, Tiazac® (diltiazem), Calan®, Calan SR®, Covera-HS®, Isoptin®, Isoptin SR®, Verelan®, Verelan PM® (verapamil), Adalat®, Adalat CC®, Procardia®, Procardia XL® (nifedipine), Cardene®, Cardene SR® (nicardipine), Sular® (nisoldipine), Vascor® (bepridil); aspirin; digoxin; diuretic drugs; Heart Failure Drugs including Dobutrex® (dobutamine) and Primacor® (milrinone); Vasodilators such as Dilatrate-SR®, Iso-Bid®, Isonate®, Isorbid®, Isordil®, Isotrate®, Sorbitrate® (isosorbide dinitrate), IMDUR® (isorbide mononitrate), Apresoline® (hydralazine), and BiDil® (hydralazine with isosorbide dinitrate); warfarin; and surgery. In one preferred embodiment, an agent of the invention is administered in combination with a statin, such as Advicor® (niacin extended-release/lovastatin), Altoprev® (lovastatin extended-release), Caduet® (amlodipine and atorvastatin), Crestor® (rosuvastatin), Lescol® (fluvastatin), Lescol XL (fluvastatin extended-release), Lipitor® (atorvastatin), Livalo® (pitavastatin), Mevacor® (lovastatin), Pravachol® (pravastatin), Simcor® (niacin extended-release/simvastatin), Vytorin® (ezetimibe/simvastatin), and Zocor® (simvastatin) may be prescribed depending on their predicted efficacy in a patient. The patient is evaluated for SLCO1B1 and ApoE genotype and/or expression or catalytic activity to predict the responsiveness of the patient to an CHD-specific therapeutic whose metabolism is affected by SLCO1B1 and ApoE genotype. Such kits may contain one or more genomic tests of enzymes or drug transporters documented to have important SNPs. SNPs may be evaluated using a disease targeted panel of tests (e.g., a microarray). Such panels include commercially available microarrays for detecting one or more SNPs (e.g., AmpliChip® CYP450 Test; Roche). In other embodiments, the kit includes instructions for selecting one or more treatments based on the results of genotyping SLCO1B1 and ApoE and detecting one or more genetic variants in an enzyme involved in drug metabolism

or drug transporter. Thus, testing performed on a patient using the kits of the invention may guide treatment selection specifically tailored to the individual.

The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the assay, screening, and therapeutic methods of the invention, and are not intended to limit the scope of what the inventors regard as their invention.

EXAMPLES

Example 1

Determination of Sample Population Baselines for Key Risk Factors

As summarized in Table 3, the participating subjects were elderly, with a median age of 75 ± 3 years at baseline. Mean LDL-C levels were in the moderate-risk category (130-160 mg/dl), as defined by the United States National Cholesterol Education Program (Expert Panel. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97). Also, approximately 50% of the men and about one third of the women reported a history of all types of vascular disease. Data on ApoE phenotype distribution in this population are also shown in Table 3. Genotype frequencies for all SNPs examined conformed to Hardy–Weinberg equilibrium ($p > 0.05$, data not shown).

Table 3. Study Subjects (n=5,418)

Study Characteristics	Men (n=2,621)	Women (n=2,797)
Mean (SD) ^a		
Age (years)	74.99 (3.3)	75.64 (3.4) ^b
BMI (kg/m ²)	26.56 (3.6)	27.12 (4.7) ^b
History diabetes mellitus, n (%)	324 (12.4)	251 (9.0) ^b
History hypertension, n (%)	1333 (50.9)	2026 (72.5) ^b
History vascular disease, n (%)	1371 (52.3)	1033 (37.0) ^b
History of MI, n (%)	508 (19.4)	222 (7.9) ^b
Current smoking, n (%)	847 (32.3)	586 (21.0) ^b
Alcohol consumption, n(%)	1851 (70.6)	1165 (41.7) ^b
Total cholesterol (mg/dl)	207.0 (30.7)	231.9 (34.5) ^b

LDL-cholesterol (mg/dl)	138.5 (27.8)	154.9 (35.3) ^b
HDL-cholesterol (mg/dl)	45.6 (12.2)	53.0 (13.4) ^b
Triglyceride (mg/dl)	132.4 (64.3)	140.6 (59.4) ^b
apoA-I (mg/dl)	124.4 (22.2)	139.9 (24.1) ^b
apoB (mg/dl)	110.6 (21.3)	119.1 (22.6) ^b
apoE 2/2+2/3 (%)	13.1	11.3
apoE 3/3 (%)	63.1	65.7
apoE 3/4+4/4 (%)	23.8	23.0
SLCO1B1_625T>C-rs4149056	MAF C:0.16	
SLCO1B1_388A>G-rs2306283	MAF G:0.38	
LXRA_-115G>A-rs12221497	MAF A:0.14	

BMI: body mass index. MAF: minor allele frequency.

^a Means (S.D.) unless otherwise specified; differences between men and women were assessed using a t-test for continuous traits and χ^2 test for binary traits.

^b $p < 0.001$, apoE 2/4 carriers were excluded (see Materials and Methods section)

5

a) Sample Population Baseline TC or LDL-C Levels Are Not Genotype Dependent

Genetic analysis of the sample population revealed no association of baseline TC or LDL-C levels with any SLCO1B1 or LXRA genotype as stratified by gender (see Table 4).

10 Table 4. **Adjusted Baseline Lipid Levels (mean $\pm$ SD, mg/dl) by Gender and Genotype**

Gene	SNP	Genotype	n	TC	LDL-C		<i>p</i> ^a	Men	Women	<i>p</i> ^a
			Men	Women	Men	Women				
SLCO1B1	625T>C	TT	1871	1997	207.2±30.9	232.3±34.8	0.880	138.6±28.0	155.2±31.8	0.850
		TC	674	721	207.2±30.3	231.7±33.4		138.8±27.6	154.6±30.3	
		CC	73	75	207.1±29.1	232.1±37.6		139.7±26.5	153.9±30.7	
SLCO1B1	388A>G	AA	1010	1125	208.3±29.5	232.7±33.9	0.161	139.3±27.9	155.1±31.0	0.330
		AG	674	1280	206.6±30.9	231.3±34.8		138.2±27.9	154.6±31.5	
		GG	395	388	206.4±29.9	232.5±35.6		138.3±27.2	155.6±32.6	
LXRA	-115G>A	GG	1924	2076	206.8±30.6	232.6±34.9	0.936	138.2±27.9	155.3±32.0	0.729
		GA	647	661	208.5±31.0	230.5±33.8		140.1±27.9	154.3±30.2	
		AA	46	53	206.8±28.3	231.6±29.9		135.9±24.7	155.3±26.5	

^a p values using the three genotypes, men and women combined; adjusted for gender, body mass index, age, alcohol, smoking, diabetes, ApoE phenotype, and country.

b) *SLCO1B1* SNP is Associated with Lowered LDL-C Response to Pravastatin

The effect of SNPs at nucleotide positions 388 (*e.g.* A>G) and 625 (*e.g.* T>C) of the *SLCO1B1* gene and also at nucleotide position -115 (*e.g.* G>A) of the *LXRA* gene on responsiveness to Pravastatin in subjects of various genotypes was assessed by analyzing the correlation of different SNP genotypes with the 6 month and 12 month changes in TC and LDL-C levels in treated subjects, as shown below in Table 5. Neither the presence of the *LXRA* SNP at nucleotide position -115 nor the *SLCO1B1* SNP at nucleotide position 388 were associated with lipid lowering. However, subjects carrying the *SLCO1B1* SNP at nucleotide position 625 (*e.g.* T>C) had significantly less LDL-C lowering in response to Pravastatin. For example, subjects who were wildtype (T/T) for the SNP at position 625 represented about 71.5% of the sample population and displayed -37.0% LDL-C lowering, subjects who were heterozygous (T/C) for the SNP at position 625 represented about 25.8% of the sample population and showed -36.0% LDL-C lowering, and subjects who were homozygous (C/C) for the SNP at position 625 represented about 2.7% of the population and showed -31.8% LDL-C lowering ($p=0.003$ at 6 months, and $p=0.022$ at 12 months). The percentage reductions in LDL-C given are for the 6 month time point (Table 5).

Table 5. **Percent LDL-C Response to Pravastatin by Genotype**

Gene	SNP	Adjusted mean percent LDL-cholesterol reduction ^a					
		n	6months	p^b	n	12months	p^b
<i>SLCO1B1</i>	625T>C						
	TT	1345	-37.0±10.8		1331	-35.9±11.8	
	TC	509	-36.0±10.4	0.003	504	-34.6±12.5	0.022
	CC	47	-31.8±12.8		45	-31.8±11.7	
<i>SLCO1B1</i>	388A>G						
	AA	772	-36.7±10.5		758	-35.9±11.2	
	AG	859	-36.6±10.7	0.775	861	-35.3±12.3	0.157
	GG	269	-36.2±11.6		260	-34.3±12.8	
<i>LXRA</i>	- 115G>A						

GG	1412	-36.6±10.7		1403	-35.5±12.1	
GA	463	-36.4±10.7	0.822	150	-35.1±11.6	0.871
AA	27	-37.4±10.9		29	-35.3±11.2	

^aValues are provided as mean±S.D, ^b*p* values for data combining men and women, adjusted for gender, body mass index, age, alcohol, smoking, diabetes, ApoE phenotype, and country.

c) SLCO1B1/LXRA SNPs Are Not Associated with History and Incidence of CVD

5 Genetic analysis of the sample population revealed no association of any of the SLCO1B1 or LXRA SNPs with either vascular disease at baseline or fatal or non-fatal CHD events on trial in either the placebo or statin groups (see, *e.g.*, Table 6).

Table 6. Analysis of Incidence of Coronary Heart Disease (CHD) Death or Nonfatal

10 Myocardial Infarction (MI) on Trial by SNP Carrier Status

SNP	Genotype	Number of new case/ Total subjects (%)	Adjusted ^a		Number of new case/ Total subjects (%)	Placebo ^b		Number of new case/ Total subjects (%)	Pravastatin ^b	
			HR ^c	<i>p</i>		HR ^c	<i>p</i>		HR ^c	<i>p</i>
625T>C	TT	427/3868 (11.0)	1		232/1956 (11.9)	1		195/1912 (10.2)	1	
	TC	155/1395 (11.1)	1.01 (0.84-1.21)	0.996	83/693 (12.0)	1.03 (0.80-1.33)	0.738	72/702(10.3)	0.99 (0.76-1.30)	0.659
	CC	16/148 (10.6)	0.99 (0.60-1.64)		12/81 (14.8)	1.24 (0.69-2.22)		4/67(6.0)	0.64 (0.24-1.73)	
388A>G	AA	224/2135 (10.5)	1		122/1051 (11.6)	1		102/1084 (9.4)	1	
	AG	279/2489 (11.2)	1.08 (0.90-1.29)	0.426	150/1275 (11.8)	1.04 (0.82-1.32)	0.577	129/1214 (10.6)	1.13 (0.87-1.47)	0.629
	GG	94/783 (12.0)	1.17 (0.92-1.49)		54/404 (11.4)	1.17 (0.85-1.61)		40/379 (10.6)	1.12 (0.78-1.62)	

^a*p* values for men and women combined; adjusted for gender , body mass index, age, alcohol, smoking, diabetes, hypertension, ApoE phenotype, randomized treatment, and country. No significant differences were noted when men and women were separated.

^b*p* values for men and women combined; adjusted for gender, body mass index, age, alcohol, smoking, diabetes, hypertension, ApoE phenotype, and country. No significant differences were noted when men and women were separated.

^cHazards ratio (95% confidence intervals).

The SNPs 625T>C and 388A>G are within *SLCO1B1*

d) *SLCO1B1* SNP is not Associated with Myositis and/or Myalgia

In this randomized study with 5,804 subjects, 2,913 subjects received placebo and 2,891
5 received Pravastatin (three of whom refused medication). Of the 2,888 subjects started on
Pravastatin, 724 discontinued their medication (5 withdrew consent, 219 died, 346 refused to
participate or did not attend follow up examinations, and 107 had non-fatal adverse events). This
adverse event rate was very similar to the placebo group where 116 subjects discontinued
medication because of non-fatal adverse events. There were no reported cases of rhabdomyolysis
10 in PROSPER, and there were 36 reported cases of myalgia in the Pravastatin group versus 32
cases of myalgia in the placebo group. At the 3 month visit there no subjects that had creatine
kinase levels > 10 the upper limits of normal. There was no association of the *SLCO1B1*
rs4149056 SNP with myalgia in the Pravastatin group.

Example 2

Assessing Statin Dosage Using Combined *SLCO1B1* and ApoE Genotyping

Elevated levels of plasma or serum low density lipoprotein (LDL) cholesterol are a major
risk factor for coronary heart heard disease, a leading cause of death and disability in our society
(1,2). Lowering LDL cholesterol with statin drugs has clearly been shown to inhibit cholesterol
20 biosynthesis, and decrease the risk of CHD. Moreover the degree of risk reduction is dependent
on the amount of LDL cholesterol lowering. Four factors that are clearly and significantly related
to LDL cholesterol lowering response to statins were identified:

- 1) the plasma level of LDL cholesterol,
- 2) the ratio of lathosterol/cholesterol in plasma,
- 25 3) apolipoprotein (apo) E genotype, and
- 4) solute carrier organic anion transporter (*SLCO1B1* rs4149056) genotype.

According to the invention, a novel point system was developed to predict statin induced LDL
cholesterol lowering response, as shown below. This model provides an excellent fit ($p < 0.0001$)
to actual data with regard to LDL cholesterol lowering generated on over 3,000 subjects studied
30 at baseline and then placed on pravastatin 40 mg/day for 6 months. Moreover this model predicts

more than 75% of the marked variability in statin response that is observed. Those with +4 to +8 points are hyper-responders to statins, and are ideal candidate for statin treatment. Those with -4 to +4 points are normal responders and are candidates for statin therapy. Those with -8 to -4 points are hypo-responder to statins (emphasize dietary modification and consider use of ezetimibe and/or anion exchange resins).

Prediction of LDL Cholesterol Lowering Point System

1. Plasma LDL Cholesterol (mg/dl):

>160:	+2
100–160:	+1
<100:	0

LDL Cholesterol Points = _____

2. Plasma Lathosterol/Cholesterol Ratio umol/mmol cholesterol:

>160:	+4
90 – 160:	0
< 90 :	-4

Lathosterol Points: _____

3. ApoE Genotype:

ApoE2/2:	+2
ApoE2/3:	+1
ApoE3/3:	0
ApoE3/4:	-1
ApoE4/4:	-2

ApoE Genotype Points: _____

4. Statin Uptake Transporter (SLCO1B1) Genotype:

T/T:	0
T/C:	-1
C/C:	-2

Statin Uptake Genotype Points: _____

5. Total Points:

+4 to +8 Points = Hyper-responder (ideal candidate for statins)

-3 to +3 Points = Normal Responder (candidate for statin)

-8 to -4 Points = Hypo-responder to statins (emphasize dietary modification and consider use of ezetimibe and/or anion exchange resins)

5

According to one embodiment, the determination of whether an individual having high LDL cholesterol and in need of statin treatment to reduce the level of LDL cholesterol is a hyper-responder, a normal-responder, or a hypo-responder with respect to the ability of the individual to metabolize a statin can be made by solving the equation $X=A+B+C+D$, where A is the number of points associated with the individual's plasma LDL cholesterol level, B is the number of points associated with the individual's plasma lathosterol/cholesterol ratio, C is the number of points associated with the individual's ApoE genotype, and C is the number of points associated with the individual's SLCO1B1 genotype. The resulting value of X is then used to determine the class of responder to which the individual belongs.

10

15

Methods and Materials

Study Subjects: The results and the methodology used in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) study have been previously described (see *e.g.*, Shepherd J et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet (2002) 360:1623-30 and Shepherd J et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol (1999) 84:1192-97).

20

25

30

In the present study 2,804 men and 3,000 women between the ages of 70 and 82 with pre-existing vascular disease (n=2,404) or at least one of three major vascular risk factors (diabetes n=575, smoking n=1,433, or hypertension n=3,360) were randomized to Pravastatin 40mg/day (n=2,891) or placebo (n= 2,913) and followed up on for 3.2 years, on average. Over this 3.2 year period of time, the mean LDL-C reduction in the active treatment group was 32%, and the risk of developing CHD was decreased by 19%, which was statistically significant (Shepherd J et al. (2002) Lancet 360:1623-30). This effect translates into an estimated 30% risk reduction in CHD events over 5 years, which is consistent with other statin trials. Additionally, analysis of the treatment group found that HDL-C was increased by 5% and triglycerides were decreased by

12% versus baseline in those subjects placed on Pravastatin. For subjects that were judged to have good compliance (i.e. taking medication more than 75% of the time), these alterations on the lipid levels were even greater: -34% (risk reduction for CHD), +5% (increased HDL-C), and -13% (decreased triglycerides), respectively. No significant lipid changes were noted in the placebo group. Lipid levels were similar at onset of the study in subjects randomized to Pravastatin or placebo.

Biochemical and DNA analysis: Total cholesterol (TC), HDL-C, and triglycerides were assessed in subjects after an overnight fast at 6 months, and at 12 months, and LDL-C was calculated by the Friedewald formula, as previously described (Shepherd J et al. (2002) Lancet 360:1623-30). Apolipoprotein B (apoB) was measured only at baseline as described. DNA was isolated from cells from this cohort, and DNA from 5,783 subjects participating in this study was also available. ApoE phenotype was determined on plasma samples by Western blotting, using the method of Havekes et al. in the central laboratory of the Royal Infirmary in Glasgow, Scotland (Havekes LM et al. A rapid micro method for apolipoprotein E phenotyping directly in serum. J Lipid Res (1987) 28:455-63). Subjects were classified according to the presence of apoE2, apoE3, or apoE4 bands on gel blotting (Havekes LM et al. (1987) J Lipid Res 28:455-63). This gel phenotyping method has been shown to have 99% concordance with genotyping (Lahoz C et al. Frequency of phenotype-genotype discrepancies at the apolipoprotein E locus in a large population study. Clin Chem (1996) 42:1817-23).

DNA analysis was conducted by genotyping two single nucleotide polymorphisms (SNPs) of the SLCO1B1 gene—388A>G (rs2306283) and 511T>C (rs4149056)—using standard methods (e.g. Taq Man® SNPs genotyping assays by Applied Biosystems, Foster City, CA). The custom assay identification numbers for these analyses were C_1901697_20 and C_30633906_10, respectively. Additionally, DNA analysis was also conducted by genotyping one SNP of the LXRA gene, rs12221497, and the custom assay identification number for this analysis was C_30887860_10. The end points were ascertained after PCR amplification was performed using standard methods (e.g. an Applied Biosystems 7900 HT Sequence Detection System). Genotypes with quality scores below the 95% threshold were repeated and 5% blinded replicates for genotype determinations were performed. In addition, a total of 119 subjects

(~2.2% of the sample size) who had the apoE4/2 phenotype were excluded from these analyses, as well as 246 subjects who had missing apoE phenotype. These subjects were excluded because apoE phenotype or genotype can affect statin-induced LDL-C lowering response, as well as CHD risk, in an allele dependent manner. For example, subjects carrying the apoE4 allele having the greatest response in terms of LDL-C lowering and the highest CHD risk, however, apoE2 and apoE4 phenotype have opposite effects in this regard. The subject characteristics for these individuals representing the 5,418 subjects are shown in Table3.

Statistical analysis: Observed genotype frequencies were compared with those expected under Hardy-Weinberg equilibrium using a χ^2 test. For data analysis, multivariable analysis of covariance (ANCOVA) was performed to detect associations between the lipoprotein levels at baseline as well as changes in response to the treatment with Pravastatin at 6 months and with SLCO1B1 genotypes adjusted for gender, body mass index, age, alcohol, smoking, diabetes, apoE phenotype, and country of origin, since subjects participating in PROSPER were either from Scotland, Ireland, or the Netherlands. Prevalence at baseline of myocardial infarction (MI) and all types of vascular disease (history of angina, claudication, MI, stroke, transient ischemic attack, peripheral arterial disease surgery, or amputation for vascular disease more than 6 months before study entry) at baseline, as well as incidence of primary endpoints (CHD death or nonfatal MI or fatal non-fatal stroke), and all cardiovascular events (primary endpoints and coronary artery bypass grafting, coronary angioplasty, and peripheral artery surgery or angioplasty), were compared between carriers of different SLCO1B1 SNP genotypes using multivariable logistic regression analysis in all subjects and stratified by gender and treatment. All analyses were fully adjusted for age, gender, country, history of vascular disease, body mass index, history of diabetes, as well as history of hypertension, alcohol use, current smoking, and apoE phenotype. To evaluate the modifying effects of genotypes and gender on the response to treatment, gene-treatment and gene-gender interaction terms were added to the regression models. Lewontin's D value was calculated to assess the linkage disequilibrium (LD) between the two SNPs of interest (Lewontin RC. The interaction of selection and linkage. II. Optimum models. Genetics 1964;50:757-82). There was no interaction between these SNPs and also no interaction between these SNPs and apoE genotype. All analyses were performed using SAS/STAT and

SAS/Genetics [including proc haplotype procedure] (SAS Version 9.1, SAS Institute Inc., Cary, NC). A two-sided $p < 0.05$ was considered statistically significant.

Other Embodiments

5 From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

Incorporation by Reference

10 All citations to sequences, patents and publications in this specification are herein incorporated by reference to the same extent as if each independent patent and publication was specifically and individually indicated to be incorporated by reference.

Claims:

1. A method of determining a statin dosage, the method comprising the steps of:
determining a level of cholesterol in a blood and/or plasma sample obtained from a patient;
conducting an assay in the sample to identify the presence or absence of a SLCO1B1 biomarker and an Apolipoprotein E gene (ApoE) biomarker that are associated with statin efficacy; and
determining a dosage of statin for said patient based upon said cholesterol level and said presence or absence of said SLCO1B1 and ApoE biomarkers, wherein the statin is selected from the group consisting of pravastatin, atorvastatin, and cerivastatin.
2. The method of claim 1, wherein said cholesterol is LDL-cholesterol.
3. The method of claim 1, the biomarker is a genetic polymorphism.
4. The method of claim 3, wherein the polymorphism is an rs4149056 C polymorphism at a SLCO1B1 locus.
5. The method of claim 1, wherein the biomarkers are genetic polymorphisms, and the polymorphisms are an rs4149056 C polymorphism at a SLCO1B1 locus and selected from the group consisting of an ApoE2 polymorphism, an ApoE3 polymorphism, and an ApoE4 polymorphism at an ApoE locus.
6. The method of claim 1, wherein said polymorphism is C/T or a T/T genotype at SLCO1B1-056 and an ApoE genotype selected from the group consisting of ApoE2/E2, ApoE2/E3, and ApoE3/E3.
7. The method of claim 6, wherein said statin dosage is between about 20 and about 40 milligrams.
8. The method of claim 1, further comprising the step of measuring an amount of said biomarker.
9. The method of claim 8, wherein said level and said amount are weighted.

10. A method for identifying a patient's likelihood of responding to statin treatment, the method comprising the steps of:

determining a baseline level of cholesterol in a blood and/or plasma sample obtained from a patient;

identifying a SLCO1B1 polymorphism and an Apolipoprotein E gene (ApoE) polymorphism in said sample that is indicative of statin efficacy;

characterizing said patient's likelihood of responding to statin treatment based upon said level and the presence or absence of said SLCO1B1 and ApoE polymorphisms identified in said identifying step, wherein the statin treatment comprises a statin selected from the group consisting of pravastatin, atorvastatin, and cerivastatin.

11. The method of claim 10, further comprising categorizing said patient as a normal responder or a hypo-responder.

12. The method of claim 10, further comprising the step of obtaining a plasma lathosterol/cholesterol ratio in said sample and wherein said characterizing step further comprises said ratio.

13. The method of claim 12, wherein said baseline level of cholesterol, said ratio, and said polymorphisms contraindicate statin treatment.

14. The method of claim 13, wherein said cholesterol is LDL cholesterol.

15. The method of claim 14, wherein said baseline level of cholesterol is about 160 mg/dl or less and said ratio is less than about 215.

Boston Heart Diagnostics

Patent Attorneys for the Applicant/Nominated Person

SPRUSON & FERGUSON

Fig. 1. ApoE nucleic acid sequence (NCBI Accession No. NM_000041.2) (SEQ ID No. 68)

GGGATCCTTGAGTCCTACTCAGCCCCAGCGAGGTGAAGGACGTCC'TCCCCAGGAGCCGACTGGCCAAT
CACAGGCAGGAAGATGAAGGT'TCTGTGGGCTGCGTTGCTGGTCACATTCC'TGGCAGGATGCCAGGCCAAG
GTGGAGCAAGCGGTGGAGACAGAGCCGGAGCCCGAGCTGCGCCAGCAGACCGAGTGGCAGAGCGGCCAGC
GCTGGGAACTGGCACTGGGTTCGCTTTTGGGATTACCTGCGCTGGGTGCAGACACTG'TCTGAGCAGGTGCA
GGAGGAGCTGCTCAGCTCCCAGGTACCCAGGAAC'TAGGGGCGCTGATGGACGAGACCATGAAGGAGTTG
AAGGCCTACAAATCGGAAC'TGGAGGAACAAC'TGACCCCGGTGGCGGAGGAGACGCGGGCACGGCTGTCCA
AGGAGCTGCAGGCGGCGCAGGCCCGGCTGGGCGCGOACA'TGGAGGACG'TGTGCGGCCGCTGGTGCAGTA
CCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCCTCGCCTCCACCTG
CGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGCGCCTGGCAGTGTACCAGGCCG
GGGCCCCGAGGGCGCCGAGCGCGGCTCAGCGCCATCCGCGAGCGCCTGGGGCCCCCTGGTGGAAACAGGG
CCGCGTGCGGGCCGCCACTGTGGGCTCCCTGGCCCGCCAGCCGCTACAGGAGCGGGCCAGGCCCTGGGGC
GAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCAGCCGGACCCGCGACCGCCTGGACGAGGTGAAGGAGC
AGGTGGCGGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCAGCAGATACGCCCTGCAGGCCGAGGCCCTCCA
GGCCCGCTCAAGAGCTGGTTCGAGCCCTGGTGGAAAGACATGCAGCGCCAGTGGGCCGGGCTGGTGGAG
AAGGTGCAGGCTGCCGTGGGCACCAGCGCCGCCCCCTGTGCCAGCGACAATCACTGAACGCCGAAGCCTG
CAGCCATGCGACCCACGCCACCCCGTGCTCCTGCCTCCGCGCAGCCTGCAGCGGGAGACCCTGTCCCC
GCCCCAGCCGTCTCCTGGGGTGGACCCTAGTTTAATAAAGATTACCAAGTTTCACGCAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Fig. 2 Wildtype ApoE nucleic acid sequence (NCBI Accession No. NG_007084.2) (SEQ ID No. 69)

TGGAGAGCTGGTCTACCAACGGCGGCCTGGAGAGGAGGGCACTGTCATGTCCTCTAGCTGGGAAATACACA
TGTGAGCCTGGCGCCTGGGTCCGAGGGTGGAGGGGCTGGGCCCCTGGACTCCTCCTGGGTCTGAGGGAGG
ACGGGCTAGGGCCCTGGACACTCAGGTCTGAGGGAGGAGGCCTGGGTCCCAGATGCCCAAATCCCCCTTG
GTAATGAGACCCCGCTCCACCCCACTCTCTGACAGTGAACAACGGTTGGCAACGGTAACGTTGGGCCA
GGCGGGCATGCACGCAACATACTACCACAAAGCCAGTGACCAGGTGAGTGGGTGCAGGCACTAGCTGGTG
CTGCCAGGGGCTGCTGGGCCCTGGAAGTCCAGGTGGGGCCACTTGCTAATTCTCATGTGTGTCTCCGGCCC
CTCCAGCTGCAGGTGGGTGTGGAGTTTGAGGCCAGCACAAGGATGCAGGACACCAGCGTCTCCTTCGGGT
ACCAGCTGGACCTGCCCCAAGGCCAACCTCCTCTTCAAAGGTAAAGGTCCTCGTTCCCTACCGGGGAAAC
AGGCAGGAGGTGACTCAACTCTGAGTGGATGTGTGGGCCACCACAGGTGCTGGAGGACAGTGTGCTGCCA
CCCTGTGGGCCTCCACATTTACCAGGGAACACTTGTAAAAGGTAGGTGGGGCCGGGTGCGGTGGCTCACG
CCTGTAATCCCAGCACTTTGGGAGGCCAAGGCGGGCCGAGGTAAGGAGATTGAGACCATCCTGGCTAACA
CGGTGAACTCCGCTCTCTACTAAAAATACAAAAACAAATTAGCCGGGTGTGGTTGCGGGTGCCATAGT
CCCAACTACTGAGGCTGAGGCGGGAAATGGTATGAACCCAGGAGGCGGAGCTTGCGGTGAGCCGAGATC
GTGCCACCGCACTCCAGCCTGGGTGACAGAGCAAGACTCCATCTCAAAAAAAAAAAGTAGGTGGACAAC
CCTCTACTATGTTTTATGCTTGGAAAAAAAAAGTAGGTAGAGCAGCCAGGCGTGGTGACTCACGCCTGTA
ATCCAGCATTTTGGGAGGCCAAGCCAGGTAGAATACTTGAGGCCAGGAGTTGGAGACCAGCCTGGCCAA
CGTGGTGAAATCCCCTCTCTACTAAAAGTACAAAAATTAGCCAGGTGTGGTAGCGTGCTGCAACTGTAGT
CCCCGCTACTTAGGAGGCTGAGGCACAAGAATCACTTGAACCTGGGAGGCGGAGGTTGCAGGGAGTTGAG
ACTGCACCACTGCACCTCCAGCCTGGGTGACAGAGTGAGACTCCATCTCAAAAAAAAAATAAATGAAATAA
ATAAATAAATGTTAAAAAAATCTGGTGGAGCATCTGATGGGTGTTTGGGCCAAGCTGGAGCTTTGTCCA
TCCCCCTCTATTTTTCTGCACCTGACTCTCTATTTTTCTGAGACTGGTCTCCCTCTGTGCGCCAGGCTA
GAGTGCAGCAGTGCAACTGCGGCTCACTGCAGCCTCCACCTCCCGGCTCAAGCAGCCTTCCACCTCAG
CCTCCTGAGTAGCTAGGACCACAGGTGTATGCCACCAAGGCCAGCTAATTTTTTTGATAGTTTGGGAGA
CATGGGGGTTTTACCATTGTGCCCAGGCTGGTCTCGAATCTGGACTCAAGCCTTGGCCTCCCAAGTG
CTGGGATTATAGGTGTGAGCCACCACCCAGCCAGGGTAGAAGGCACCTTGGAAAGCTCGAGCCTGCCC
CATTCTCTTACGTTAGTGGAACTGAGGCTTCCAGAGGTTTCAAGGTACAACTAAATCCAGAACCTCA
TCTCAGGCACACTGGTCGTAGTCCCAATGTCCAGTCTTAAGTCTTCTTGGATATCTGTGGCTCACAGATT
TTGGGTGTTTGGCCTCCTGCTGAGCACTGCTGGGGCCACAGCGGTGACCAGCCCTGTCTTCACGGGACT
CAGTGAGAGGAACAGATTCTCCGAGAGTGGGCAGGACTAGGTTGGGGGAACCCAGGGGTCTAGAGGGC
TTTTTCAGAGGGCAGGGGTCACTGAGCGGAGAGCAGAGGAGGAGTGAGCCATTTGCTCCAGCGTGAAGTTG
TTGGTGTGATGGGGTTTTCAGGGTGGCAGAGCAGTGTGGTTAAAGGTCTGGAAGCTGTGCGCATGTGGCT
GGTATCCAAGGTGGCCAGGAACCTGTCATGGATATGGTGGGAAGCTGGCACGCCCTCACCTCAGCTCTT
CCCTGCAGGCTCTGTGGATAGCAACTGGATCGTGGGTGCCACGCTGGAGAAGAAGCTCCACCCCTGCCC
CTGACACTGGCCCTTGGGGCTTCCCTGAATCACCGCAAGAACAAGTTTCAGTGTGGCTTGGCCTCACCA
TCGGCTGAGCCCTCCTGGCCCCCGCTTCCAGCCCTTCCGATTCCACCTCCACCTCCACCTCCCCCTGC
CACAGAGGGGAGACCTGAGCCCCCTCCCTTCCCTCCCCCTTGGGGGTTCGGGGGGGAGCTGGGAGAGGTT
GGGACCCCGCCACCCAGCAGCTGAGGAGGGGATTCTGGAACCTGAATGGCGCTTCGGGATTCTGAGTAGC
AGGGGCAGCATGCCAGTGGGCTGGGGTCCCGGAGGGATTCCGGAATTGAGGGGCACGCAGGATTCTG
AGCACAGGGGCAGAGGCGGCCAGACAACCTCAGGGAGGAGTGTCTGGCGTCCCCATCCTCCAAAGGGC
CTGGGCCCCCGAGGGGGCAGCGAGAGGAGCTTCCCCATCCCGGTGAGTCCACCTGCCCCGTCCAC
TTTCCCCTCTCCTCGGTATAAATCATGTTTATAAGTTATGGAAGAACCAGGACATTTTACAGAAAAAAA
CAAAAAACAACAAAAATATACGTGGGAAAAAAAACGATGGGAGGCCCTCCGTTTTCTCAAGTGTGTCTGG
CCTGTTTTGAGCATTTTCATCCGAGTCTGGCCGCCCTGACCTTCCCCAGCCGCTGCAGGGGGCGCCAG
AGGGCCGGAGCACGGAAGCAGCGGATCCTTGATGCTGCCTTAAGTCCGGCTCAGAGGGGCGCAGCGTGG
CCTGGGGTCTGCTATCTTCCATCCGGAACATCTGCCCTGCTGGGGGACACTACGGGCTTCCCTTGCCCTG
AGGGTAGGGTCTCAAGGTCACTTGGCCCCAGCTTGACCTGGCCGGAGTGGCTATAGAGGACTTTGTCCCT
GCAGATGCAGCAGCAGAGATGACACTGTCTCTGAGTGACAGATGGGGGCAGGGAGCTGGGAGAGGTT
CAAGCTACTGGAACAGCTTCAAGAACACTAGGGTACTAGGAACCTGCTGTGTCAGGGAGAAGGGGCTCAAG
GACTCGCAGGCTGGGAGGAGGGGCTAGGCCAGCCATGGGAGTTGGGTACCTGTGTCTGAGGACTTGG
TGCTGTCTGGATTTTGCCAACCTAGGGCTGGGGTCACTGATGCCACCACGACTCCCGAGCCTCCAGGA
ACTGAAACCTGTCTGCCCCAGGGTCTGGGGAAGGAGGCTGCTGAGTAGAACCACCCAGGTTACCAA
CCCCACCTCAGCCACCCCTTGCCAGCCAAAGCAACAGGCCCGGCCCGGCACTGGGGGTTCCTTCTCGAA
CCAGGAGTTCAGCCTCCCCTGACCCGCAAGATCTTCTGATCCACCCGCTCCAGGAGCCAGGAATGAGTC

3/37

CCTTCTCCCCGCCTCCCACTGTGCGACACCCTCCCGCCCTCTCGGCCGCGAGGGCGCTGATGGACGAGACC
ATGAAGGAGTTGAAGGCCTACAAATCGGAACTGGAGGAACAACCTGACCCCGGTGGCGGAGGAGACGCGGG
CACGGCTGTCCAAGGAGCTGCAGGCGGCGCAGGCCCGCTGGGCGCGGACATGGAGGACGTGTGCGGCCG
CCTGGTGCAGTACCGCGGCGAGGTGCAGGCCATGCTCGGCCAGAGCACCGAGGAGCTGCGGGTGCGCCCTC
GCCTCCCACTGCGCAAGCTGCGTAAGCGGCTCCTCCGCGATGCCGATGACCTGCAGAAGCGCTGGCAG
TGTACCAGGCCGGGGCCCGCGAGGGCGCCGAGCGCGGCCCTCAGCGCCATCCGCGAGCGCTGGGGCCCCCT
GGTGGAAACAGGGCCCGCTGCGGGCCGCCACTGTGGGCTCCTGGCCGGCCAGCCGCTACAGGAGCGGGCC
CAGGCCTGGGGCGAGCGGCTGCGCGCGCGGATGGAGGAGATGGGCGAGCCGACCCGCGACCGCTGGACG
AGGTGAAGGAGCAGGTGGCGGAGGTGCGCGCCAAGCTGGAGGAGCAGGCCCAGCAGATACGCTGCAGGC
CGAGGCCTTCAGGCCCGCCTCAAGAGCTGGTTCGAGCCCCCTGGTGGAAAGACATGCAGCGCCAGTGGGCC
GGGCTGGTGGAGAAGGTGCAGGCTGCCGTGGGCACCCAGCGCCGCCCTGTGCCAGCGACAATCACTGAA
CGCCGAAGCCTGCAGCCATGCGACCCACGCCACCCCGTGCCTCCTGCCCTCCGCGCAGCCTGCAGCGGGA
GACCCCTGTCCCCGCCCGAGCCGTCTCCTGGGGTGGACCCCTAGTTTAAATAAAGATTACCAAGTTTCACG
CATCTGCTGGCCTCCCGCTGTGATTTCCTTAAGCCCCAGCCCTCAGTTTCTCTTCTGCCCCACATACTGG
CCACACAATTCTCAGCCCCCTCCTCTCCATCTGTGTCTGTGTATCTTTCTCTCTGCCCTTTTTTTTTT
TTTTAGACGGAGTCTGGCTCTGTACCCAGGCTAGAGTGCAGTGGCACGATCTTGGCTCACTGCAACCTC
TGCTCTTGGGTTCAAGCGATTCTGCTGCCCTCAGTAGCTGGGATTACAGGCTCACACCACCACACCCGGC
TAATTTTTGTATTTTTTAGTAGAGACGAGCTTTCACCATGTTGGCCAGGCAGGTCTCAAACCTCTGACCAA
GTGATCCACCCGCGGCCCTCCCAAAGTGCTGAGATTACAGGCCTGAGCCACCATGCCCGGCTCTGCCCC
TCTTTCTTTTTTAGGGGGCAGGGAAAGGTCTCACCCCTGTACCCGCCATCACAGCTCACTGCAGCCTCCA
CCTCCTGGACTCAAGTGATAAGTGATCCTCCCGCTCAGCCTTTCAGTAGCTGAGACTACAGCGCATA
CCACTAGGATTAATTTGGGGGGGGGGTGGTGTGTGTGGAGATGGGGTCTGGCTTTGTTGGCCAGGCTGA
TGTGGAATTCCTGGGCTCAAGCGATACCCCACCTTGGCCTCCTGAGTAGCTGAGACTACTGGCTAGCAC
CACCACACCCAGCTTTTTATTATTATTGTAGAGACAAGGTCTCAATATGTTGCCCAGGCTAGTCTCAA
CCCCGGGCTGCCCACTTAATAATACTTGTTCCCTCAGAGTTGCAACTCCAAATGACCTGAGATTGGTGCCT
TTATTCTAAGCTATTTTCATTTTTTTCTGCTGTCTATTATTCTCCCCCTTCTCTCCTCCAGTCTTATCTG
ATATCTGCCTCCTTCCACCCACCCCTGCACCCCATCCACCCCTCTGTCTCTCCCTGTTCTCCTCAGGAG
ACTCTGGCTTCCTGTTTTCTCCACTTCTATCTTTTATCTCTCCTCCTACGGTTTCTTTCTTTCTCCC
CGGCCTGCTTGTCTTCTCCCCAACCCCTTCATCTGGATTTCTTCTTCTGCCATTCACTTTGGTTTGAGC
TCTCTGCTTCTCCGTTCCCTCTGAGCTAGCTGTCCCTTCACCCACTGTGAACCTGGGTTTCCCTGCCCAA
CCCTCATTCTCTTTCTTTCTTTCTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGAGACAGAGTCTTGCT
CTGTTGCCCAGCCTGGAGTGCAGTGGTGCATCTTGGTTCACTGCAACCTCCACTTCCAGATTCAAGCA
ATTCTCCTGCCTCAGCCTCCAGAGTAGCTGGGATTACAGGCGTGTCCACCACACCCGACTAATTTTGT
ATTTTTGGTAGAGACAAGGCTTCGGCATTTGTTGGCCAGGCAGGTCTCGAATCCTGACCTCAAGTAATCT
GCCTGCCTCACCCCTCCAAAGTGCTGGGATTACAGGCATGAGCCACCTCACCCGACCATCCCTCATTCT
CCATCCTTTCCCTCCAGTTGTGATGTCTACCCCTCATGTTTCCCAACAAGCCTACTGGGTGCTGAATCCAG
GCTGGGAAGAGAAGGGAGCGGCTCTTCTGTGCGAGTCTGCACCAGGCCCATGCTGAGACGAGAGCTGGCG
CTCAGAGAGGGGAAGCTTGGATGGAAGCCAGGAGCCGCCGCACTCTCTTCTCTCCACCCCTCAGT
TCTCAGAGACGGGGAGGAGGTTCCCAACCGGGGACAGGCTGAGACTTGAGCTTGTATCTCCTGGGC
CAGCTGCAACATCTGCTTGTCCCTCTGCCCATCTGGCTCCTGCACACCCTGAACCTGGTGTCTTCCCTG
GCACTGCTCTGATACCCACGTGGAGGCAGACCCCTCCCCCT

Fig. 3 ApoE polypeptide wildtype sequence (NCBI Accession No. NP_000032.1)(SEQ ID No. 70)

MKVLWAALLVTFLAGCQAKVEQAVETEPPEPELRQQTETWQSGQRWELALGRFWDYLRWVQTLSEQVQEELL
SSQVTQELRALMDETMKELKAYKSELEEQLTPVAEBETRARLSKELQAAQARLGADMEDVCGRLVQYRGEV
QAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRA
ATVGSLAGQPLQERAQAWGERLRARMEEMGSRTDRDLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLK
SWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH

Fig. 4 SLC01B1 nucleic acid sequence (NCBI Accession No. NM_006446.4) (SEQ ID No. 71)

AAAGGGTGGACTTGTTCAGTTGCTGTAGGATTCTAAATCCAGGTGATTGTTTCAAACCTGAGCATCAACA
ACAAAAACATTTGTATGATATCTATATTTCAATCATGGACCAAAATCAACATTTGAATAAAAAACAGCAGAG
GCACAACCTTCAGAGAATAAGAAAACAAGATACTGCAATGGATTGAAGATGTTCTTGGCAGCTCTGTAC
TCAGCTTTATTGCTAAGACACTAGGTGCAATTATTATGAAAAGTTCCATCATTCATATAGAACGGAGATT
TGAGATATCCTCTTCTCTTGTGGTTTTATTGACGGAAGCTTTGAAATTGGAAATTTGCTTGTGATTGTA
TTTGTGAGTTACTTTGGATCCAACTACATAGACCAAAGTTAATTGGAATCGGTTGTTTCATTATGGGAA
TTGGAGGTGTTTTGACTGCTTTGCCACATTTCTTCATGGGATATTACAGGTATTCTAAAGAAAATAATAT
CAATTCATCAGAAAATTCACATCGACCTTATCCACTTGTTTAATTAATCAAATTTTATCACTCAATAGA
GCATCACCTGAGATAGTGGGAAAAGGTTGTTTAAAGGAATCTGGGTCATACATGTGGATATATGTGTTCA
TGGGTAATATGCTTCGTGGAAATAGGGGAGACTCCCATAGTACCATTGGGGCTTTCTTACATTGATGATTT
CGCTAAAGAAGGACATTCCTCTTTGTATTTAGGTATATTGAATGCAATAGCAATGATTTGGTCCAATCATT
GGCTTTACCCTGGGATCTCTGTTTTCTAAATGTACGTGGATATTGGATATGTAGATCTAAGCACTATCA
GGATAACTCCTACTGATTCTCGATGGGTGGAGCTTGGTGGCTTAATTTCTTGTGTCTGGACTATTCTC
CATTATTTCTTCATACCATTCTTTTTCTTGCCCCAACTCCAAATAAACACAAAAAGAAAGAAAGCT
TCACTGTCTTTGCATGTGCTGGAACAAATGATGAAAAGGATCAAACAGCTAATTTGACCAATCAAGGAA
AAAATATTACCAAAATGTGACTGGTTTTTTCCAGTCTTTTAAAGCATCCTTACTAATCCCCTGTATGT
TATGTTTGTGCTTTTGACGTTGTTACAAGTAAGCAGCTATATTGGTGCCTTTACTTATGTCTTCAAATAC
GTAGAGCAACAGTATGGTCAGCCTTCATCTAAGGCTAACATCTTATTGGGAGTCATAACCATACCTATTT
TTGCAAGTGGAATGTTTTTAGGAGGATATATCATTAAAAAATTCAAACTGAACACCGTTGGAATTGCCAA
ATTCTCATGTTTTACTGCTGTGATGTCATTGTCTTTTACCTATTATATTTTTTCATACTCTGTGAAAAC
AAATCAGTTGCCGGACTAACCATGACCTATGATGGAATAATCCAGTGACATCTCATAGAGATGTACCAC
TTTCTTATTGCAACTCAGACTGCAATTTGTGATGAAAGTCAATGGGAACCACTGTGTGAAACAAATGGAAT
AACTTACATCTCACCTGTCTAGCAGGTTGCAAACTCTCAAGTGGCAATAAAAAGCCTATAGTGTTTTAC
AACTGCAGTTGTTTGAAGTAACGGTCTCCAGAACAGAAATTACTCAGCCCATTTGGGTGAATGCCAA
GAGATGATGCTTGTACAAGGAAATTTTACTTTTTTGTGCAATACAAGTCTTGAATTTATTTTTCTCTGC
ACTTGGAGGCACCTCACATGTCTGATGATTGTTAAAATTGTTCAACCTGAATTGAAATCACTTGCCTG
GGTTTCCACTCAATGGTTATACGAGCACTAGGAGGAATTCTAGCTCCAATATATTTTGGGGCTCTGATTG
ATACAACGTGTATAAAGTGGTCCACCAACAACTGTGGCACACGTGGGTCACTGTAGGACATATAATTCAC
ATCATTTTCAAGGGTCTACTTGGGCTTGTCTTCAATGTTAAGAGTCTCATCACTTGTTTTATATATTATA
TTAATTTATGCCATGAAGAAAAATATCAAGAGAAAGATATCAATGCATCAGAAAAATGGAAGTGTATGG
ATGAAGCAAACCTAGAATCCTTAATAAAAAATAACATTTTGTCCCTTCTGCTGGGGCAGATAGTGAAC
ACATTGTTAAGGGGAGAAAAAAGCCACTTCTGCTTCTGTGTTTCAAACAGCATTGCAATGATTGATTGAGTA
AGATGTTATTTTTTGAGGAGTTCCCTGGTCCCTTCACTAAGAAATTTCCACATCTTTTATGGTGGAAAGTATAA
ATAAGCCTATGAACCTTATAATAAAACAACTGTAGGTAGAAAAATGAGAGTACTCATTGTTACATTATA
GCTACATATTTGTGGTTAAGGTTAGACTATATGATCCATACAAATTAAGTGAGAGACATGGTTACTGTG
TAATAAAAGAAAAAATACTTGTTCAGGTAATCTAATCTTAATAAAACAAATGAGTATCATACAGGTAG
AGGTTAAAAAGGAGGAGCTAGATTCTATCCTAAGTAAAGAGAAATGCCTAGTGTCTATTTTATTAACA
AACAAACACAGAGTTTGAACATAATACTAAGGCCTGAAGTCTAGCTTGGATATATGCTACAATAATATC
TGTTACTCACATAAAATTATATATTTACAGACTTTATCAATGTATAATTAACAATTTATCTTGTTTAAGT
AAATTTAGAATACATTTAAGTATTTGTGGAAGAAATAAAGACATTCCAATATTTGCAAAAAAAAAAAAAA

Fig. 5 Wildtype SLC01B1 nucleic acid molecule (NCBI Accession No. NG_011745.1) (SEQ ID No. 72)

GATTCTCTGCAGTGTAACTTCATGGTTTTTGAGGCCAAAGGAAGGCTGGCAGTAAACAAAATATGTGAGT
AAAATTTATAGTATGATGGTGAGAGAAATAAAATTTGAGTGTCAAAGGGAGTAATATTTAAAAAATGTTAG
AGAAGACTTCGCTGGGAAAGTGTCTTTGTTTGGGTACTAGAATATGGTGAGGGAGTAAGTTATGCAGCT
ATAGGGAAAGAACATTCCAGACAGAAAGAAAAATAGGAACAAAGATTCTCAGTAGAGGATCTATAACTTA
TAAGGCCTTAAAGCTGTTCTTTGGATTTTTGAGTGATATGTGAAGCCAATGGGGGATTTGAGCAGAGCTA
TGACATGGTATGACCTCACTTATATGTTAAGATTTACACAGGGGAAGGAGGTTGGGGAAGAGGGGCTGT
GAGTGGTCAGGAGGAAAGCTGAGATACAAAGTATGAGGGTATTGCAATAATTCAGGACCAGCCTGAAAGTT
GTGGAGGAGGTAAGAAATCATCAGATTCTGGGTATATTTGGAAATTAGAGCCTAATGTGAGTGTGAGAAA
TAGAGAAGAATGATTCTAATATTTGTATGTGGCTGTGCATGTGCACGCATGTGTGCAACTGGAATGACAGA
ATTACAATGTATGGGGATTATTGTCTTCCCTGGACAATAATCCCTGGAAATGGGGATTATTACAAGAGGA
GAGGTTGGGGAAGGAAAGACAAAGATACCATGTTAGAAAATATTAAGTGTAAAGATGCCATTAGAGATAT
ATAGGAAGATGGTGAGAAGTCAATGGATAAATCTAGAGTTTCATGAGTAACCTGGCTAGAGAAAAATTTT
GGAATTATCAACGTATGGATAAGATTTAAGACATGAGAATAGATGAGGTACACAAACACACAGTAAGG
TTATTGTCTGACATGCTTCAATTTAGAAGACAAAGATAAAGAATTTAGAGTAAATGAAGTGTAAATAAGT
AAGTCAGTGAGTTAGAAGGCAAACCAAGGGTAGTGTCTGCAAAGTTTGTGCTTAGGGAGGGAATTCT
CAGTTCTGAAAAATGCTGCTAATAGTTCAAGTCAGATGAGGACTATTAGATGTAGCATTTAGGTAATTTA
TGACTTAGGAGAGAGTAGTTTTCAGTGGAAATTTGGGGGCAAAGCCTGATAAGAGTGTGCTCAAGAGAGAA
TGTAGAGAGAGAGATTGAAAGCAATAATTAGACAAGCTATTCTCTGTAAAAATAGCAGAGAAATAGGGC
AATATTAGGAAAAATGGGATCAAAAGAGAGATTTTTGGAAGATGAAAAGTGACAGCATTTCTTACATGC
TGATGGAAACATTTAAAAAGAGGATAGTGCTATCCTTAAAAACACAAGGGGAGGAGTCAATGTCTATATGC
AAGTGGAGATTGGCCTTAGCTTAACTTGGGTAGTTCACTAAGGCAGACCATGTGGTGGTACTGGGGCTT
TACATAGATAAATGTGGTCAAGGGAGCTTTTGAAGTTTCTTCTTTATTTATTTATTTTTCAGTAAATA
ATTCATCAGCTGAAGGTGGGGAAGGGATGTATTAGAATTTCAAAAAAAGATGAAGGCACAA
AATGCTCAGAGTGCAAATGGCGTGAATGATTTCTTGGCAAATGAAAGGTCCATTTGGGCTTCCTAATC
ATACGTTTAAAGTCAGCATGGTTGAGAGATTTTCTCAGTTACATTTAGCTTCATAAGGGAAATGTGCAG
AGTTATTTGAGAGTTAAATTTAATCAAGATTGTGGCTTTGACATGCAATTAATAATGCAAAACAGTCA
AAATTATATGAAGTTATATAGAAGAGAGTGATTACCGTGACCATTAAATTAACCCAGATGTATAGATAAG
GAACACCGAAATCTCTGGCAAATCAAATGTAGGTTATACATCCTGGTCAGTGGAAGCATGTGGATCTA
GGGTGTTACTGAGTGTAGTGCCAGAGCTTTGATCAATAGAGTGGTGCTCCAATCTTTGATATTGGAGAGATTA
CAGTGGTGTGAAAAGCATAGGATATGCCATAGCAGTAGGTAGAAGCCAAGATCATTAGGGAGAGGCTA
AAAAATAAAAAAGAAAATAAAAAAGAAAACAGAGAATTAATAAGATTCTCTTCATGGTCAATACCATCATGA
ATAATTAATAATAGTAGTAGCATTTTGAGAGAATGGCTTTGGATCGAGAGCTAAATTTGTCATGAAATGAG
TGGGAGTGACTGAGCGTTGATAGATGATTTCAACAAGAGGAATAAGTGATAGAGTCTTTCAATATGAGAT
CCAAACTATGGATTATGAGTGTAAAGGTGGGGAAATGTAAAGAACTAGCAAAGTGAGGCACATTGGA
AACCAGCCCATCTGGTTTGCAGCAATATGGGGGATAAGGCAACCCCTATGTATCACTGCTGCAGGAGAGG
GAGTGTCTCAGGGAAGACCAATTTTAAAGTTCAAGGCAGAAGTGAAGCAGAATAAATCAGAGAAGAGGTA
AAGGTAAGGGGAGTTTCAGTCATGACTAGTGATGGGTTCCAGAAAACCTCAAGAGAAGAATTCAGTCCAG
GATTGGGAGAAAGAGAGAAGATGGGGGCAACATAGGAATGTGCAGAGCCCTGTGGGGATTAGAGAAGAG
GTGATGAGTCAATCAGGGAATCCCTACCTTCTTATGGTGGTCACTACCATAAGAGCGATAAATGCCATGGT
AATATTAGTCTTGATGTATGCCAGAGCTTTGATCATTGGTGGGTATAGAAACATGTTTGGAGAATAATATG
TAGAATAGGAGTTCTTTCCAGGAGAGTGTAGCTTTCTGGAGCTGTCTCTTAATCAGCACCAACAGAAGTG
AAATGTTCCGGTAAGGGCGGATCTGCTTGGAGCCTGACGTTCCCTCTTGAGGTGTGCCGTGGTACACA
CCTGAGAACTCTGGGGCTAAACCTATTGGACATAGGTTTTACAGATCTACAGGATACAGATCTCAGAGA
TTTTATTTGTATTCAATTAATATAAATTAAGTCTCTAAAATTTATAATATGCAATATCATACAATTA
TCTAATTAGGTGTTGAATCTATAATGTGCCAGGCATTATGTAAGGCACCTTACATACACTAAATCTTTAT
TCCAAATATAGACTTCTTACTTTATAGATGAGTGCACTGATGCTCAGAAAATGGTAAATAACCTACTGATG
TTTATACTGCTGGCAGGTAGCAGAGACATATCGGCATTTAAGTCTTTTCAGACTTCAAGGCCATGATATT
TCATCAGAGCTGTGATAGCCGTTCCGAAAAAATATCAGCTGATTCTTTAAATCAATTTTGTCTATCTA
ACTGATGCGTGGCTGTTAGCATAATATTGATCTTGAAAGATGTTTTGCAACATCTTTCCCTGGTGTACT
CTTGTGTTTCCATGATCCCAAAAATGAGCAGTCTAATTATTACACAATTAGGAAGAGAAAAGGGGCAC
AGAGAATGCTCTTTGACCTCTGAAAATATTGGAGAATTTTCAACTGGCACCTTTAGCTCAGGATATATA
AGGTTGTTAGTTAGTTTGTACTGTTTTATCTTCATTGTATATAATATATATATTAGTCTCCAACATGTT
GATGTGTTTTCAATGAAATGGATGTCTGAGGAGAAAACCATTAGCCTGAGAAAACCCAACTGTATCCCC

ATTGTGAATAAAAAGGAAGTCCATAAAAATGATGGAAAATGTTCTGCATTCCCTGTTATGATATCAAAATCT
GGCAGTACATGAAAATTTTTCAAAGTGCTTATTTAACAGGCATAATCTTTGGTCTCCTGAGCCAGAATCT
GCTGGGTATGGGACTGGATTGCTATTTTGACAACTCGCCAGTAGATTCTTACTCAGCAGAGTATTTGGAA
GCCTTACTCTAATATTTTGGCCTTGGGTCTACATTTCTCAGTTCTGCACAGTCATTCTTCCCTCTACAC
TACTCTTTAGTTTGTCTCATGATTCCAATACTCTCAATAATTAACCAAGAATAGAACTAATCAATCAGAT
AACTGTGGCACAGACATCAAATACATTTTGTGCAACCATATCAACAAATGTCCCATGAATGATAAGGGG
TAACCATATTCTCATATATGCATCCTCACATTACCACATATATATATGTGCATATGTGTATACAGGTAAA
AGTGTGTATATATGTATACATGTATGTTTGTGTATATACATACATATATCTTCACACTTTTCTGAAAT
ATATATATTTATGTGAGAGAAGGGTCTGTACTTTATTTTCAAGAGAGCTTAATGTCCAAGGTATAATTG
AGAGTCTAAAATGTTTGTGATTATTGAATTAATFAAACTTCATCTCTACTCAAGAAAACCTTTAACTGAGT
TAAGCTCTTCTCTCCACAAGTCAAGTCAATAAAAGGAACTGTGATATTAATAATCTTTCCTGTTT
TGATGTAAAGAATCTATCGCATAAAGCAGTCTTAATTTTCATCATTCAAGAAAATGGTCTTGCAGTTAAT
TGGGACTCTCTTATTCAGGTGGTATCTCCAGTCTCCATACATACCACGTTAGAACCATACTATTATGTACC
AAGCAAAGAGGGTATATTTTAATTTTTTAAATGCCAATGTAACCTGTAGGCATATTTTATTTGTCTTAA
ATTATTTCTTATTTGGAAGTTTTTAAATACCTGGAATAATTTATTGTACTCATATTTTTTAAAGAAAAAAT
CTTATGCCACCAACTTAATTGAATAAACAGTAAAAGCCATTCCCAAAGTAAGGTTTACTTGTTAAGAT
TAACAAAAAATAATGTGAGAATTCTGAGAAATATAATCTTTAAATATTTGGCAACTGGAGTGAACCTTAA
AACTAACTAGGTTTTATATGTTTGTAGTAGCAATGACATAATAAGGTGGTTAATCATCACTGGACTTGT
TTTCAAAAAGCCAACCTACTTTAAGAGGAATAAAGGGTGGACTTGTTCAGTTGCTGTAGGATCTAAATC
CAGGTAAGAACCATTGAGATTCTCTAATTTTACATATATTTTATGTAAGAAATTTTCACGGAAGAGAT
TTTGATGGTCTTGA AAAATATTACGAATTTTATGCTCTGTGTCTTCCACACGCTTACATTCTGAGCCCTT
AAAACATAGTAAATATTCTTCTGGGAGTAGAAGAGCCTCAGGTTTATATACGTTTAAAAATAAAGTAGA
GAAAATAATACCTTTATATATTTAAATATAAAGTTTCAAATCTTGGTCTTATTAAATTTCCAAACAAATAA
AAATCAAGTCTCAAAAATGAAGCTCTAGTTACCTCTTTAAATATGCTACAGGATAATTATTTTGTCAA
CTACATTGACTGATCACACTAGACTCCTTATTTCTTTGATGTCTTCTTAACCTGGATGAAGGCAGCCAAGG
GTGGGAGTAGAGGGAAGAGTTAATTGGCAAACATAAAAAACAGGTGTCTCAAAGTCAACATAACCACCTCA
GTTTCTTGTTCCTCAACTCAAGTTTGATACAGGGTGAAGGGAAATATATTTTCTAGATAATTTATCTCCAA
TTAAATAAGCAAAAAGTCTTCTCAGTACAGTTTTTTTTCTTTTTTATTTCATTATTATTATACTTTAAGT
TTTAGGGTACATGTGCACAACATGCAGTTTGTACATATGTATACATGTGCCATGTTGGTGTGCTGCAC
CCATTAACCTCATCTTTAACATTGGGCATATCTCCTAATGCTATCCCTCCCTCTCCCCACCCACAAC
AGTCCCCGGTGTGTGATGTTCCCTTCTCTGTGTCATGTGTTCTCATTGTTCAAGTTCCCACCTATGAGTG
AGAACATGCGGTGTTTGGTTTTTGTCTTGGCATAGTTTGTGAGAAATGATGGTTTCCAGTTTCATCCA
TGTCCCTACAAAGGACATAAACTCATCATTTTATGGCTGCATAGTATCCATGGTGTATGTGTGCCACA
TTTTCTTAATCCACTCTATCGTTGTGGACATTTAGGTTGGTTCGAAGTCTTTGCTACTGTGAATAGTGC
CGCTATAAACATACGTGTGCATGTGCTTTATAGCAGCATGATTTATAATCCCTGGGTATATATCCACT
TATGGGATGGCTGGGTCAAATGGTATTTCCAGTTCTAGATCCCTGAGGAATCGCCACACTGCTCTTCCACA
ATGGTTGAAGTAGTTTACAGTCCCACCAACAGTGTAAGAGTGTTCCTATTTCTCCACATCCTCTCCAGCA
CCTGTTGTTTCTGACTTTTTAATGATCGCTATTCTAACTGGTGTGAGATAGTATCTCATTGTGGTTTTG
ATTTGCATTTCTCTGATGGCCAGTGATGATGAGCATTTTTTACAGTGTTTTTTGGCTGCATAAATGTCTT
CTGTTGAGAAGTGTCTGTTTCATGTCTTCCACCCACTTCTTGATGGGGTCTGTTTGTCTTTGTAAATTTGT
TTGAGTTTCAATTGTAGATTTTGGGTATTAGCCTTTTGTGAGATGAGTAGGTTGCAAAAATTTTCTCCCAT
CTGTAGGTTGCTGTTCACTCTGATGGTAGTTTCTTTTGTGCTGTGCAGAAAGCTCTTTAGTTTAATTATATC
TCATTTGTCTATTTTGGCTTTTTGTTGCCATTGCTTTTGGTGTTTTAGACATGAAGTCCCTTGGCCATGCCT
ATGTCCTGAATGGTATTGCCCTAGGTTTTCTTCTAGGGTTTTATGGTTTTAGGTCTAACATTTAAGTCTT
TAATCCATCTTGAATTAATTTTTGTGTAAAGTGTAAAGGAAGGGATCCAGTTTCACTTTCTACATATGGC
TTGCCAGTTTTTCCAGCATCATTTATTAATAGGGAATCCTTTCCCATTTGCTTGTTTTTCTCAGGTTTG
TCAAAGATCAGATAGTTGTAGATATGCGGCCTATTTCTGAGGGCTCTGTTCTGTTCCATTGGTCTATAT
CTCTGTTTTTGGTACCAGTACCATGCTGTTTTTGGTTACTGTAGCCTTGTAGTATAGTTTGAAGTCAGGTAG
GGTGATGCCTCCAGCTTTGTTCTTTTCGCTTAGGATTGACTGGTATGCGGGCTCTTTTTTGGTTCCATA
TGAACCTTTAAAGTAGTTTTTTCCAATCTGTGAAGAAAGTCATTGGTAGCTTGATGGGGATGGCATTGAA
TCTATAAATTACCTTGGACAGTATGGCCATTTTCATGATATTGATTCTTCTGCCCATGAGCATGGAATG
TTCTTCTATTTGTTTCGTATCCTCTTTTATTTCAATGAGCAGTGGTTTTGTAGTTCTCTTGAAGAGGTCTT
TCACATCCCTTGAAGTTGGATTCCCTAGGTATTTTATTCTCTTTGAAGCAATTTGTGAATGGGAGTTCACT
CATGATTTGGCTCTCTGTTTGTCTGTTTATGGTGTATAAGAATGCTTGTGATTTTTATACATTGATTTTG
TATTCTGAGACTTTGCTGAAGTTGCTTATCAACTTGAGGAAATTTTGGGCTGAGATGATGGGGTTTTCTA
GATATACAATCATGTGATCTGCAAACAGGGACAATTTGACTTCTCTTTTTCTAATTGAATACCCTTTAT
TTTTCTCTCTGCTGATTGCCCTGGCCAGAACTTCCAACATTATGTTGAATAGGAGCAGTGAGAGAGGG

CATCCCTGTCCTTGTGCCCCGTTTTCAAAGGGAATGCTTCCAGTTTTTGCCCAATTCAGTATCATATTGGCTG
CAGGTTTGTCTAGATAGCTCTTATTATTTTGAGATACATCCCATCAATACCTAATTTATTGAGAGTTTT
TAGCATGAAGGGTTGTTGAATTTTGTCAAAGGCCCTTCTGCATCTATTGAGATGATCATGTAGTTTTTG
TCTTTGGTTCTGTTTATATGCTGGATTACATTTATTGATTTGCGTATGTTGAACCAGCCCTGCATCCCAG
GGATGAATCCCACTTGGTCATGTTGGATAAGCTTTTTGATGTGCTGTTGGATTGGTTTTGCCAGTATTTT
ATTGAGGATTTTTGCATCAATGTTTCATCAAGGATAATTGGTCTAAAATTCTCTTTTTTTGTTGTTTCTCTG
CCAGGCTTTGGTATCAGGATGATGCTGGCCTCATAAAATGAGTTAGGGAGGATTCCCTCTTTTTCTATTTG
ATTGGAATAGTTTCAGAAGTATTGGTACCAGTTCCCTCTGTACCTCTGGTAGAATTCGGCTGTGAATCC
ATCTGGTCCCTGGACTTTTTTTTTGTTGGTAAGCTATTGAGTATTGCCTCAATTCAGAGCCTGTTATTGGT
CTATTTCAGAGATGCAACTTCTTCCCTGGTTTAGTCTTGGGAGGATGTATGTGTCAAGGAATTTATCCATTT
CTGCTAGATTTTCTAGTTTATTTGCCTAGAGGTGTTTATAGTATTCTCTGATGGTAGTTTGTATTCTGT
GGGATCGGTGGTTATATCCTCTTTATCATTTTTTATTGCATCTATTTGATTCTTCTCTGTTTTCTTCTTT
ATFAGTCTTGTAGTGGTCTATCAATTTTGTGATGCTTCAAAGAACAGCTCCTGGATTTCATTAATTT
TTGAAGGGTTTTTTGTGTCTCTATTTCCCTTCAGTTCTGCTCTGATGGTAGTTATTTCTTGCCTTCTGCT
AGCTTTTGAATGTGTTTGTCTTGTGCTTTCTAGTTCTTTTAATTGTGATGTTGGGGTGTCAAATTTTGGAT
CTTTCTGCTTTTCTTGTGGGCATTTAGTGTCTATAAATTTCCCTCTACACACTGCTTTAAATGTGCTCC
AGAGATTCTCGTATGTTGTGTGTTTGTCTCATTTGGTTTCAAAGAACATCTTTATTTATGCTTTCATTT
ATTATGTACCCAGTAGTCATTTCAGTAGCAGATTGTTTCAGTTTCCATGCAGTTGAGCAGTTTGTAGTGAGT
TTCTTAATCCTGAGTTCTAGTTTGTGATTGCGCTGTGGTCTGAGAAACAGTTTGTATAATTTCTGTTCTTT
TCCATTTGCTGAGGAGAGCTTTACTTCCAACATATGTTGGTCAATTTTCAGAGTAGGTGTGGTGTGGTCTGA
AAAGAATGTATATTCTGTTGATTGTTGGGGTGGAGAGTTCTGTAGATGTCTATTAGGTCCGCTTGGTGAGA
GCTGAGTTCAATTCCTGGGTATCCTTGTAACTTTCTGTCTCATTTGATCTGTCTAATGTTGACAGTGGGG
TGTTAAAGTCTCCCATTTATTATTGAGTGGAAATCTAAGTCTCTTTGTAGGTCACTAAGGACTTGCCTTAT
GAATCTGGGTGCTCCTGATTGTTGGTGCATATATATTAGGATAGTTAGCGCTTCTTGTGAATTTGATCCC
TTTACCATTAGGTAATGGCCTTCTTTGTCTCTTTTGTATCTTTGTTGGTATAAAGTCTGTTTTATCAGAGA
CTAGGATTGCAACCCCTGCTTTTTTTTTGTTTTTCCATTTGCTTGGTAGATCTTCCCTCCATCCCTTTATTTT
GAGCCTATGTGTGTCTCTGCATGTGAGATGGATTTCCTGACTACAGTGCAGTGAATGGTCTTGTACTCTTT
ATCCAATTTGCCAGTCTGTGTCTTTTAATTGCAGCATTTAGCCCATTTACATTTAAAGTTAATATTGTTA
TGTGTGAATTTGATCCTGTCTATTGTGATGTTAGCTGGTTATTTTGCTCATTAGTTGATGCAGTTTCTTCC
TAGCCTTGATGGTCTTTACAATTTGGCATGTTTTTGCAGTGGCTGGTACCAGTTGTTCCTTTCCATGTTT
AGTGCTTCCCTTCAGGAGCTCTTTTAGGGCAGGCCGTGGTGGTGACAAATCAGCATTGCTTGTCTGTGAA
GGATTTTGTCTTCTCCTTCACTTATGAAGCTTCGTTTGGCTGGATATGAAATTCCTGGGTTGAAAATCTTTT
TCTTTAAGAATGTTGAATATTGGTCCCACCTCTCTTCTGGCTTGTAGAGTTTCTGCCGAGAGATCAGCTG
TTAGTCTGATGGGCTTCCCTTTGTGGGTAAACCAACCTTTCTCTCTGGCTGCCCTTAATATTTTTTCTCT
CATTTCAACTTTGGTGAATCTGACAATTATGTGTCTTGGAGTTGCTCTTCTCGAGGAGTATCTTTGTGGC
GTACTCTGATTTTCTGAATCTGAACGTTGGCCTGCTCTGCTAGATTGGGGAAGTTCTCTCGGATTAAT
CCTGCAGAGTGTTTTTCAACTTGGTTCCCTTCTCCCATCACTTTTCAGGTACACCAATCAGAGCTAGATT
TGGTCTTTTACATAGTCCCATATTTCTTGGAGGCTTTGTTGCTTTCTTTTTATTTCTTTTTCTCTAAAC
TTCTCTTCTCACTTCATTTTATTTCATTTCTGCTTCCATCACTGATAACCTTTCTTCCAGTTGATCCTATC
AGCTACTGAGGCTTCTGCATTTGTCTATGTGGCTCTCTGCTTGGTTTTTCAGCTCCATCAAGTCTTTAA
GAACTTCTCTGCATTGGTTATTCTAGTTATCCATTTGTCTGATTTTTTTTTCAAAGCTTTTAACTTCTTTG
CCATTGGTTTTGAATTTCCACCTGTAGCTCAGAGTAGTTTGATCATCTGAAGCCTTCTTCTCTCAACTGT
CAAAGTCATTCTCCATCCAGCTTTGTTCCGTTGCTGGTGAGGAGCTGCATTCTTTGGAGGAGGAGAGGC
GCTCTGATCTTTAGAGTTTCCAGTTTTTCTGCTCTGTTTTTTCTCATCTTTGTGGTTTCATCTATCTTT
GGTCTTTGATGATGGTGACGTACAGATGGGTTTTTGGTGGGATGTCCTTTCTGTTTGTATTCTTCTT
CTAACAGACAGGACCCTCAGCTGCAGGCTGTTTAGAGTTTGTAGAGGTCCACTGCAGACCCTGTTTGGC
TGGGTTTACGCCCTCAGTGGCTGTAGAAGAGCGGATATTGGTGAACCACAAATGCTGCTGCCTGATCGTT
CTCTGGAAGTTTTTGTCTCAGAGGAGTACCCGACCGTGTGAGGTGTGAGTCCGCCCCCTACTGGGGGGTGGC
TCCCAGTTAGGCTACTCGGGGGTCAAGGACCCTTGGAGGAGGAGTCTGCCGTGTTCTCAGATCTCAAGC
TGCGTGCTGGGAGAACCCTGCTCTCTTCAAAGCTGTGAGAGGGACATTTAAGTCTGCAGAGGTTACT
GCTGTCTTTTTGTTTGTCTGTGCCCTGCCCCAGAGATGGAGCCTACAGAGGAGGAGGAGGCTCTTGG
CTGTGGTGGGCTCCACCCAGTTTCAGGCTTCCAGCCGCTTTGTTTACCTAATCAAACAACCTAAGTCA
ATGGTGGCCGCCCCCTCCCCAGCCTCGCTGCCACCTTGCAGTTTGTATCTTGGATGGCTGTGCTTGCATG
AGCGAGACTCTGTGGGCATAGGACCCTCCAAGCCAGGTGCAGGATATAATCTCCTGGTGTGCTGTTTTTT
AAGCCGGTTTGGAAAAGCACAGTATTAGGGTGGGAGTGACCAATTTTCCAGGTGCCGTCTGTACCCCC
TCTCTGACTAGGAAAGGGAATCCCTGACCCCTTGTGCTTCCCGGGTGGGCAATGCCCTCGCCCTGCTTT
GGCTTGGCACGGTGCCTTCAACCACTGTCTGCACCTACTGTCTGGCACTCCCCAGTGAGATGAACCC

GGTACCTCAGTTGGAAATGCAGAAATCACCAGTCTTCTGTGTTGCTCATGCTGGGAGCTGTAGACCAGAG
CTGTTTCCATATTTGGCCATCTTGGCTCCCTCCCTCAGCACAGTTTTTATGATGAACTAAGGCTCAATAAA
TATTAGTTCCCTTCTCCAATTCAGAAAGTTGTCTGCCTTGATAAGACAATTGTTTTTATTGTGAAAAGTGA
GGTGGAGATGGGGGATTGTCTCTCCTATAAAAGGTCTAAGAAGTTAGCAAATGCTGTTTTTCCCTTTTTCG
TCCTCAGTTGCATAAGTACATGGTAGAAATGGGTCACTTTGCCTAAACCGTTTTCTATAACCTATTAA
GTATTAAAAGCTTGACACAGATAAGTAGAGGCTGATAAGATTCTGTCTGCACCCCACTCTATCAAATT
TGGGAAGAACTGACCTCTTCCGGGAAGAAATGCAATGCTAAATCCAAATGCCTATGGTTCATCTTATAAA
CAAATGGTGTCTCAAAATTCATTTATGTAAATCATTTGAAATTTAAGAAAAAATATGTTTCAGAGAAAA
ATATGTTAAATGTCAAGGTGAATTAGAAAGTGTGGCATTAGTCAAGCATAAATTAATATTCCAACCTTC
TAGTTACTTTGTAGTAACCTATTTTAACATTTTGGTGAAATGAGGAACAAAGTGTCCACCTTTTTTCTCTG
AATATTTTATCTGAAGATCTAGGAGAGAGATGTGAAATAGTATTTTCTGGGGAAGTAGGGGAAATACAA
AGAAAAGTAATGACTTCAGGTATATTCTCCACTGCTACAGCAGGATGGGAGATATTATCAACAGGTGGTA
AGTATAAAAAATATTGAAGAGGTACAATTTGGATCAGCATTACAACCAAGAATGGAGAATGCATTCAGGA
TTGAAAGAAACATACAAGAGGGCAGAAAGCTTTCTTCTGGGACTGTGGTTTCATGTCTCTGCAGGTGCT
ATGGGTATATTGAGAATGGTTCTAAAAACAGGGGCTTGGTTTAGGTTGTGAAGACCATCAAATAGAACT
GTGAATTTTATTTTGTGTCTGTTAAAGGGATCTTTGAAAGATTCTTAGGATAAATATGATATGCATAGGAT
AGAAAGAAAGGTGGGAGACAGGACAAACAGAACTTAATCAATTGAAATAAACAGGTTTGGAGTGGTGGG
ACAATAGCCTTCAAGACATCAAGAATATTTGTAGTAGAAAGAAAATCGAAGCCTAAAACATAAGGAAGA
CTATCCACCTTGCAAGTCATACAGAGATATTGCTATTATATAATTTTTTTAAAAAAGATTTCCTAATA
TTTAAATTATGAAGAAAGAGATAGAAACAGATATTCATGGAAAAAATGGGGTGAATTTAATCAAAGGGCA
GCTTATTACCTTGAGACTAAACAGCCATTGACTTTTTCTTACCTCACTGAACCCAGAAACCCGACATAT
CTAGGTACAGGCATGCATAAAACATGTACACACACAAAATGTAATAATTGGAGTTTCACTTAGAGGTACAC
ATGTATGGGTTTTCTGTATTCAACCATATGTTGATATATCTACATATATGTAAGTGATAATATCTGTGT
TGTTACTTCCACATTTATGCACATATCCCTTAAATATGTATTATATATATTTATATTATTCAGAAATCCATC
AGCCCTTGTGTAATAAATTAGTGAATAAAATATAGAGTCGAGTCTCATTATTCACAGATTCTATATAAGA
AAATTTGTCTATTCACTAAAATTCCTTTGTAACACCAAAATCAATACTGCTGGACTTTTCATGGGCATTCA
CATGCATGTGCAAAGTGGTGAAAAATTTGAGCTGCCATGTTCCCAACTAAGGTTGAACAAAATGAAGCTC
TGTCTTCTTGTCTTCTGCTCACATATGATAAGAAATATCCTTTTCACTGTATTTATGCCCACATTTTT
GGCATTTTTGTGTTTTGTGTTTTCTGAGTTGAATGTTTCGAATGGGCCCCAAAGATAGTGTGAAGTGCTC
TCCGGTGCACAAGAGTATCTGAGGGAAAAGATACATATGCTGTATAAGCTTCTCCAGGCCCTGAACATACA
GTGTTGTTGACAACATAATTCAATGTTAATGAATCAATAGTATGTATTAAATAAAGTGTCTTTAAACAAAA
CATACATAAAACACAGTTCTATATTGAACAAATTTACCAAAATATTGTGACCAGAGGCAGACAGGCATATA
ACTAACCCACATCTCTCCAAGGAACAATGGTTCAATATTTGCTAATTCAGTGTTCACAGCACTTTATA
AAACATAACTACTGCAACAAGTATCAACTGTACATATAATATATATTAGACATATTGTATAATTACTGCC
CTATTAAAAATCATGTATCTATGCTGTCTGCTTATATAGATATCTTAGATACATAAAATGTATGTGTT
TACATACATAGGAGCAAGAATGTATTTCTAAAACTCCATGAAGAACACATTATTTCTATATAAAAGAGT
CAGTTGAAGTAAAAGTTAACTCATTTTACTAGTCTTTAAAGTAGGACTTTAATGACTCTCAAAATAACA
ATTTCTCTCATACATTGACTCCAAACCTTAGTGTGTTGAATTTATTTCTGCAGATATGGCCACATAAAACC
AAAATGGCATATGATATATTAAAGAACATCTTTAATATGAAATGATTAGATACAACCTAAAAGCTGATGAA
TATAGAACCAGTTGCATATATTATGGACAACTTAATACCCTGCTACCATAAGAAAAATGAGAAAGACTTA
TTAAGATTAAGTATATAGAGAAGATAAAAAGGTAGAGAATGATGTTTAAAGGTATGCTACCATTGTCATTG
AAAAGGAAAATATTATGTACTTAATGAAAAATCCATATTATATTTCTGGATAATGGGACAAAGAGTTAGAG
GAAGAATCTTTGTTTTATTTTTTTAATTTGCATTTTCACTATATGCATTTTCTCTTGGAAAAAGAAATGA
ACAAAATCAAAATAAAGTAACATCATGATGGTGGTAAGGTCAAGCAATACCAGAGTTGCTCTGAGAAGTA
CTTGGAGTACACTTTGCTCTTTTTAACAAATCCAAATCTGTTTGCTTTTTGAGCCTGATTCCAGTGGT
TCTCCTTTATAAACTGAGGCCATTCTAATTTAATTTCTTTATATTATTTTTGTATCTGTTTTGAATATCT
ACTCTGTGCAAGGGCTAATAGGCACATTTTAAAACTAGAAGGATAAAGAAAACATATATTTGCTTTTAT
AAATTTTACAATATAGGTGTGTAGAAAAGATAAATAATTTAAATTTCTATAATTTAAAATGTTTCATGTAAT
CTGGTGTGTGATTCTATATTACTTACTTGTTCAAATTTCTCTCCACAAATTTATTTTTCTATTAATTTG
TAATCTCCTTAGGCTAGAATTTGTGTCTGTCTTTCTACTTTTGTTCAGCATTGACCTAGCAGAGTGG
TAACGACATAGTAGACCCTGAGTGAATGTTAGTGAATGGTTGATTGATTGATGATGATCTTGTGGCTTTT
CTTATTTCTAAATTATATATTGTAAAAATAAAATAAACTATACTTTTTCTTCTTAAATAGGTGATTGTTT
CAAACCTGAGCATCAACAACAAAAACATTTGTATGATATCTATATTCAATCATGGACCAAAATCAACATT
TGAATAAAACAGGAGGACAAACCTTCAGAGAATAAGAAAACAAGATACTGCAATGGATTGAAGGTAGA
ATAAGTTTTATCTTTTTGAGCTAAAATAAGTAAATAGGGAACCTTAATGTATAGAAAAGCAAGTTGTTAA
AAAGAACATTATGTTTTCAAATTATAATTTTCAATTTGAAGCATATATTGAAATATTAACATAATGATTTCAT
ACCTTGATTTAAACCAGTCTTTTAAATCTGATTAAAGTATTTCTTTGGCGAAATTTTTGATGCTTAATAGTT

TATCAATGTAGAAAATTTAGAAAATATTTTGATAGCTTCTCTTTGGTTTTGGATTGATCACGACATATTTA
GGAATGTGATTAAAAATAAAAAATGCATAATGAATAATATTTTAAAAATCTTAGAATTGACTTATAAACTT
AGAATATTAATGTCTTGAGACTCACCTTGTGATACTGACTTATTTAAAAATCTTTTAAAAAAAACACA
AAAAACAGGATTTAAAAAAGTTCTGATAAGTAATTTAGGCTCATGGAACGGAGGTCTATGATAGTCAAAA
ACTTGGCCAAAAGACCTGTTTTGACGATTTAGAAAAGCCATTTAATGTTTTTCATTTGCCAGCTGGTAAAAG
TAATAATCTGCTTTTTGCTTTTGGCACAACTGTATTAAATGATACAGTTGAGGTATTAAAGTGATGCTG
GCATTTTTTATAAACAGGAATGAGTACTCCTAAGCACAAATGCTAAATGAGAAGCCAAGACTCAGAAAAGTT
AAGAAATTTTCTGAAGTCATCTACATTTGTGAATTGAAAACCTTGAACCCAAGACAAAGCCTTTAAATC
CCCATATGGAAGTCTTGAGGAAATCAAGAAATAAGGGTCACCTTTTATCAATGTTTTAACTTTTTTATTT
AGTCAAATTTGTAGTCTTATACAGCTGAATAAAGGCCACCAAGATTGGAGTCAATTACAATAATGTTATA
AAAGGTTCCTTTTAGCTCCTTCCAGGGAACATAAAAATTTGTTTTGTTTTCTGAGATTACTGATAAAGCCTT
CTCTGATGAAATATTTGAGTAACATTTAGGCCAAGTGGCAGTCATAAGGAAAAAGTATTGGTTAATGCAA
GTGAATTATGTTCTATATCTAAGGATAATATAATGTACTGAATTGTTTTTATTTTTAAATACTGAGTGT
TACAGTAATTTCACTGACATGTGCATAGCAAAATGGCAGCAAACTGCCGTAAGCAATAAAAATTTCCAGAG
TGATCCCCTTATAGCATATCTGGAGAAGCTGGGAGTTAGGGAATTAGCAGTGTGTGGAAGGACATTAACT
GCAGCCCAATAAAGAAGACTAGAGCTAGAGGAAGATACTGGGATAAGACTGGCATCCCTAATGCTGGTAT
TTCAGAAACATCGCTAAATTTGGTTAATCATGTCTACAAGTGATATTTAAAAATAATATTTTCACTCACTTA
AATTGTTAACATTGATATGTTGTTGATAAAGAATATTAACTCAACAATCATTTTACAATAATTTCTGTAA
AGACTTGCCTGCTGTAGTTGAGGTTGTTGCATTTCTGAGCTTACTTTTTTATTCATGAGAAATGAAAAC
ATAATGGGAGAAAATTTTTTAAATAAAGGGTATTTTAAATTTTTTATGAAGTTTGGGACTTCAAAGTATTA
ACAAAAGTTGCTGAAAATATATTTGACTTTTACTTTTCATTAAATTACATTTTATCATCTAATTTCTTAATT
TTCTGTATTTGAAATATTATGATTTAGAGATATCTCTGTAGATAGAAAGATAATGAAAACAATAGTAAAA
CAAATGTAATTCAGGAGCATAAAAAAGATGAGAGAAACCTTAATAATAGTAGCTAACATTTATCAAGCA
TTTACTATATGCCAGACATTTGATTTAGTGTTTTACTTTTGCTAACAGATTTTTTCCCTTACCATAATTCTA
TCAACTGGATGGTATTATCTCCCCTTTTTCCAGATGAAAAAACCTAGATATAGACAGGGCAAATGTCTTCTC
CTAGGCTCTCAAAGTTGGTAATTGGTACACTGAAGGTCTGAACCTCAGGCAATCTGATTTCCAAATCCTATGC
TCTCAACTGTATTTCCATATTGCTAAAAATAAATGTGGATTTTTGTAAATATTAGTACCCCTCAAGATGTTATG
GCAAGCAGGCTTTTTATAAGTGGTGTCTTTAATAACTTTTCTCATTTCCATACTTCTAAAAAATTATCTTAA
GGTTAAATTTATTGAGTGTCAAGCAACTGTGGATTCTAACACTTGCTAACATGCATGCACACACCCAAATA
TACATGTTGTTACTGACTTACATATACAGACACAGCAGGTGGCAATATATAAGTGCAAATTGATAATATA
TCCGTGGAAATACAAACAAAACCTTTGAGAAATCAAATACTTGAATTTCTTTTCTACCCCTTCTCCTCAATT
TTTGTACTGAACTAACATACATAGAACCTGCTAGTATATGTTTCATCATTACACTTGTCTATTTCTT
CTCTTCAAATTTAAACCAACAAGATACAGGGGAAGATTTAAATGCAATCCAAAGAAAACAGGAAAACAA
TTCAAGAGTTTAAAGATGACATAGTCAATTTTAAAGAAAGAACCAAAATTAACCTTCTGAAATTTAAATATTTT
ACTACAGGAATTTTATAATACAATTTATAGTAATTAACAACAAAATAGACCAAGCTTAAAGAAAGAATCTCA
GAGTTTGAAGATTACCCCTTTTGAATCAACACAAGCAGACAAAATTAAGGAAAAATATTAAATGAAAAAA
CCTCTGAGAAATATGGGATTATGTAAAGAGACCAAGCCTGTGACTCATTTGGCATTCTGAAAGAGGAGAA
AGAGTAAGCAACTTGGAAAAATGCTTTGAGGATAAAGTCCATGAAAAATTTCCCAAGTCTTCTGATGAGAGG
TGGATATGCAAGTTCAAATAATTTCAAAGAATCCCTTCAAGATACTATACAAGATGGTTCATCCACAAGACA
CATAATCATCAGATTCTCCAAGGTAACAAGAAAGAAAAAACCTTAAAGGCAGCTAGAGAGAAGGGGCA
GGTCACTTACAAAAGGAGCCCCATCAGTCTAACAATAGATCTTTCAGCAGAAAGCTTACAAGCTAGAAGA
GATTGGGGACCTATTTTACCATCCTTAAAGAAAAGAAATTGCAACTAAGAATTTTATATTTCTGCCAAAC
TAAGCTTCATAAGTAAAGAAAAAATATTATTTTCGGTCAAGCAAATGCTAACAGAAATTTGTTACCATTAG
ACCTGCCTTACCAGAGATGCTTAAGGGAGTCTTAAACATGGAAATGAAAGAAATGATACCTGTCAACCACAA
AAATAGACTTAACTACAGAGCCACAGACATTATAAAGCAATTATGCAATCAAGCCAACATAATAACCAG
CTAACAACTATGACAGAATCAAATCCTCAGATATCAGTATTAATCTTGAATGTAAATGGGTTAAATGC
CTACACTTAAAGGCATAGAAATAGCAAGTTGGATAAAGAAGCAAGACCAACCGTTTTGTTGTCTTCATG
ACTCATGTATCATGACATCCATAAGATAGAAAATGAATAAATTTGAAATAATATTTATCTCAGAGTTGTCA
GGATATTTATAAGGTGCTTAGCACAGTGTACATAGAAACTCAATAAATTTGGAAAGTTTCCAACATAGTAG
CATTATAGTTGCTGCACTTTTTTTTGAGACAGGGCCTCTGTCAACCAGGCTGGAGTGCAGTGGCATAATCT
TGGCTCACTGCAAACTCCACCTCCCAGGCTCAAGTGATTCTCCACCTCCTGAGTAGCTGGAACACAGG
CACATGCCACTTCAACCAGCATTTTTTTTCAATTTTTTTTTTTTTTTTTTTTTTTTTTTTAGTAGAGATGAGGT
CTTACCTTGTGGCAGGCTGGTCTTAAATTCCTAGGCTCAAGCAATCAGCCCGCCTTGGCCTCCFAAGT
GCTGGAATTACAGGTATGAGCCATCACATCTGGAAGCTGTTTCTTTTTTAAAGTGACTACATTAATTTACT
TGATCACGAGTAATACATAAATGAAAAATTTGAGAATACATTCACTCCAATATTTGGAATTTATGTGACTTC
TAGATTTTTGCAATTTAAGTAGGCATAAAATGGTACTTTGTTTTAGTATTTGTCTGTGCTCCTTGATTCT
TATAAATATTATATTTTGTGAAATCCATTGCTGAATGCAAGTGGTGTGTTACATTTGCCTATTTCCAA

GT TTTAGTACATTTATTTTGAATATATTTTATCAGTTTAAAGGACTTACTTGTAATATCTTTGTGTGGT
CTTGGTATTTAGGTTAAATGTTGGCTCAATAAATGAGATAGGAAGTATTTTCTGCTTCTAACCTCTGA
AAAAAAGTGTAGAGAATTGATATAAATAATTCTTAGGTATTTGGTAGAATTCAACAGTGAAACCATGTA
GGCCTGTTTCTTTCTGTTTGGAAAAGTTATTAATAATCAGTTCATTTCTTAAACAGAAATAGTCCTTTTA
ATATTGTCTATTTATTTCTGTACAAAATTGGGTAGATCGTGTCTTTCAATATATTGGTCTATTTTATATA
GGTTATCATAGTTGTAGGCAGAGTGTGCTTATAGTATTTCTTTATTTATCCTTTTCATGTATATTGGATC
TG TAGTTATGTCCCCGCTTTATTTCTGTTATTAGTAATTTGTGCTTCCCTCATCTTCTTAGGTAACCT
GGCTGGGTCAATTTTATTAATCTTTCTAAAGAATTAACCTGTGGTTTTGTCAATTTCCCTCTATTGATTTT
CTGTTTATGATTTAATTGATTTTCAGGTCCAATTTTTATTCTATTTTCTTGTGCTTACTTAAAATTTAA
TTTGCTTTTCTTTTGTATTTTCCCAAGGTGGAACTTAGATATTGATTTTAGCATTTTCTTGTTTTCTAA
CATATGCATTCAGTGCAATAAATCTCTAAGTCTTGATTTTGTACCTTTTCAAAAATTTTGATCACTTGTA
TGTTTAAATTTTATTTTCTCAAGATGTTTTAAATTTTCTTTCAGATTTCTTTTGAATCATAAAGTTACTT
AAAAGTGTGCTAGTTAATCTCCACATATTTTGGTATTTTCCAGTTATCTTTCTGTTATATTCTAGCTTA
ATTTTCATTGTCTCTCAAGAGAAGACATTATTAGTTTAAATGTGTTAAGGTGTGTTTATGGCTTAGGCTG
TGGTATATATTGGTGAATATTCCATGTAAGCTTAAGAAGAATGTGTATTCTGTTGTTGTTGGATGAAATA
ACATATAGATGTTTATTATATCCAGTTAATTGATGATGTTGTTAAGGTCAATCATGTTCTTCTGTTTTT
ACCTGCTGGATCTTTCCATTTCTAGAGAGATGTAGAGTCTCCAAATACCATAGTGATTCATTTATTTCT
CCTTGTATTTCTACTGGCTTTTACTTTCAGATAGTTTGCAGCTCTGTTGTTTGGTGCCTCTATGTTAAGAA
GTGTTATGTTTTCTTAAAGATTTGACCCCTTTAAACATTTTGTAAATGCCCGTTTACCTCTGTTAATTTT
CTTGCTTTAGAGTCTGCTGTGTCAAAATTAATTTAGATTGCTTGTCTTGTGTTTGGTTATTGTTACCAT
GGAATGTTTTTCTCCACTTCTTTACTTTTTTAAAAAATTACACTTTAAGTTCTGCGGATACATGTGCAGAA
TGTGCACATTTGTTACATAGGTAAACACATGCCATGGTGGTTTGTGTCACCCATCAACCCGTCTATCTACA
TTAGGAATTTCTCCTAATGCTACTCCCTAGCCCCCAACCCCAACAGGTGCTGGTGTGTAATGTTCCCC
TCCCTGTGTCATGTGTTCTCATTTCAACTCCCACTTATGAGTGGGAACATGCAGTGTGTTGGATTTCT
GCTCCTATGTTAGTTTTACTGAGAATGATGTTTCCAGCTTCATCCATGTTCCCTGCAAGGACATAAACTC
ATTTCTTTCTTTTGGCTGCATAGTATTCCATGGTGTATATGTGCCACATTTTATTTATCCATTCAATTATT
GATGGGCATTTGGGTTGGTTTCCAAGTCTTTGCTATTGTGAATAGTGTGCTGCAATAAACATACATGTGCATG
TGTCTTTATAGTAGAATGATTTATAATCCTATGGATACATTCAACAATGGTTGAATTAATTTACTCTCC
ACCAACAGGGTAAAAGCATTCCTATTTCTCCACATCTCTCCAGCATCTGTTGTTTCTGACTTTTTAAT
GATCGCTTCCAACCTGGCTGAGATAGTATCTCATTGTCAGTTTGTGATTGTCATTCTCTAATGACCAGTGAT
GATGAGCTTTTTTAAATATGTTTGTGTCACATAAATGTCTTATTTTGAAGAGTGTCTGTTTCATATCCTT
GGCCCACTTTTGTATGGCATTGTTTGTCTTTCTTGTAAATTTGTTTAAAGTTCTTGTAGATTCTGGAT
ATTAGCTCTTTGTGTCAGATGGATAGATTGTAAAAATTTTCTCCCATCTCTGTAGGTTGCTGTTCACTCTGA
TGATAGTTTCTTTTGTATGTCAGGAGCTTTTGTAGTTAATTAGATCCCATTTGTCAATCTGGGTTTTGT
TGCCATTGCTTTTTGTGTTTTAGTTCATGAAGTATTTGTCCATGCCATGTCCTGAATGGTATTGCTTAGG
TTTTGTTCTAGGGTTTTTTATGGTGTAGGTCTTACATTTAAGTCTTTAATCCATCTTGAGTTAATTTTTG
AATAAGGTGTAAGAAAGGGTCCAGTTTCAATTTCTGCATATGGCTAGCCAGTTTTCCCAACATCATAT
ATATTAAGAAGGGAATCCTTTTTTCCATTGCTTTTTTGGTTCAGACTTGTCAAAGATCGGATGGTTGTAGA
TATGTGGCATTATTTCTGAGGTCTCTGTTCTGTTCCATTGGTCTATATATCTGTTTTGGTAAAAGTACCA
TGCTGTGTTGGTTACTGGAGGCTTGTAGTATCATTTAAAGTCAGGAAGCATGATGCCCTCCAGCTTTGTTC
TTTTTGCTTAGGATTGCTTTGGCTATATGGGCTTTTTTTTTTTTTTTTTTTTTTTGGTTCCATATGAAATTTA
AAGTAGTTTTTTCCAAATCTGTGATGAAAGTCAATGGTAGCTTGATGGGGATAGCATTTGAATCTATAAAT
TACTTTGGGCAGTATGGCCATTTTACAAATATTGATTTCTTCCATCCATGAGCATAGAATGTTTTTCCAT
TTATTGTGTCTCTCTTATTTTCAATTGAGCAGTGGTTTGTAGTTCTCGTTGAAGAGGTCCCTCACACCCC
TTGTAAGTTGTATTCCTAGGTATTTTATTCTCATTTGTAGCAATTGTGAATGGAAGTTCACTCATGATTTG
GCTCTCTGTTTGTCTATTATTGGTGTATAGGAATGCTTGTGATTTTACACATTGATTTTGTATCCTGAG
ACTTATCATCTGCAACAAAGACAAATTTGACTTCTCTCTTCTTATTTGAGTATCTTTTATTTATTTCTC
TTGCTGTATTTGCCCTGGCCAGAACTTCCAATACTATGTTGAATAGGAGTGGTGAGAGAGGGCATCCTTGT
CTTGTGCCGGTTTTCAAAGGGAATGCTTCCAGCTTTTACCCTTTCAGTATGATATTGGCTGTGGGTTTGT
TATAGATAGCTCTTATTATTTTGAATATATTCCATCAATACCTAGTTTATTGAGAGATTTTAGCACAGC
TCCAGTGTGCAGCTCCCAAAAAGATCAACGCAGAAAGGTGGGTGATTTCTGCATTTCCAACCTGAGGTACCC
AGCTCATCTCTTTGAGACTGGTTAGACAGTGGGTGCAGCCAACAGGGGGCAAGCCGAAGCAGGGTAGGGT
GTCACCTAACCTGGGAAGTGCAAGTTGTGTCAGGAACTTCTCTCCCTAGCCAAAGGGAAGCCAGAGGGACT
GTGCCCTGAGGAAAAGTGCAATCTGGTCCAGATACTATGCTTTTCCAGTCTTTGCCACTGGCAGACCAG
GAGATTTCCCTCGGGTGCTTACACCACAGGGCCCTGGGTGCAAGCACAAAAGTGGGTGGCTGTTTGGGC
AGACACTGAGATAGCTGCAGGATTTTCTTTTAAACCCAGTGGTGCCTGGGACACCAGCAAGACAGAAC

CCTTCACTCCCCTGGAAAAGGGGCTGAAGCTAGGGAACCAAGTGGTCTAGCTCAGTGGATCCCACCCCCA
TAGAGCCCAGCAAGCTGAGATCCACTGGCTTGAAATTCTCCTTGCCAGCCGAGCAGTCTGAAGTCAACCC
GGGATGCTCGAGCTTGGTAGGGGAGGGGTGTCTGCCATTACTGAGGCTTGAGTAGGTGCTTTTCCCTCA
CAATGCAAAACAAAGCCACTAGGAACTGGGTGGAGCCACCCGAGCTCCACAAAGCCCCGTGATGCCAGACT
GCCTCTCTAGATTCCCTCCTCTCTGGGCAGGGCATCTCTTAAAGAAAGGCAGCAGCCCCAGTCACGGGCTT
ATATATAAAATTCCCTCTATCTGGGACAGAGCACCTGGGAGAAGGGGCAGCTGTGGGCGCAGCTTCAGCA
GACTTAAACTATCCTGCCCTGCTGGCTCTGAAGAGGGCAGTGGATCTCCTAGCACCATTCTCAAGCTCTGC
TAAGGGACAGACTGCCCTCCTTAAGTGGGTCCCTGACTCCCGTGCCTCCTGACTGGGAGACACCTCACAGC
AGGGTTCAACAGACACCTCATGCGAGAGAGTTCTGGCTGGCATCTGGTGGGTGCCCCCTCTGGAATGAAGC
TTCCAGAGGAAGGAACAGGCCGCAATCTCTGCTGTTCTGCGAGCCACTGCTGGTGATACCTAGGCAACAG
GGTCTGGAGTGGACC'TCCAGCAAACCTCCAGCAGACCTGCAGCTGAGGGGCGCTGACTGTTAGAAGAAAAAC
CTACAAACAGAAAGGAATAGCATCAACATCAACAAAAAGGATGTCCACACAAAAACCCCATCTGAAAGGC
ACCAACATCAAAGACCAAAGGTAGATAAATCCACGAAGATGAGGAAAAACAAGTGCAAAAAAGGCTGAAAA
TTCCAAAACCCAGAATGCCCTCATCTCTCCAAAGGATCATGTTTACTTTTAATCTATATGTGTTTATATA
TTTAAAGTGGGTTTTCATGTAGACAACATATAGTTGGTTCTTGTGTACTTGATCTACTGTCAAGTTTCAAT
CTTTTAATTAATACATTTAGATCATTTGCGTTAAAAGTGATTACTGATATATAGTCATGTGTCAATTTAAC
AACAGGAATGCATTATGAGAAATGCATTGTTAGATAATTTTGTCAATGTGCAACATCTTAGCGTGTACA
TACATAAACCTAGATATTATAGCCTACTACACACCTAAGCTTATGGTATAGGCTATTACTTTGATGCTAC
CAAAACCTGTACATTATTGTAGTTTACTAAATACTAATTACAACACAGTGATATTGGTGTATCTAAACAT
ATCTGAGCACAGAAAAGATAAAGTAAAAATATGGTATTATAATCTTATGGGACCATCATTTGTATATGCTC
TCCAACATTGACTTAAATGTCAATTATGACATGTGTGACTGTAGTTAGATTAGTATCTACCATAGCGGTTG
GGTTGCCTGGGTGTTTGCAGATAAATTTACAAATAATTCAAGTCCACTTTCACGTGACGTCATACCACT
TCATGGGTAGTATGAGTACCTGATAATAGCAAATTATTTATAATACTTTCCTTCCATTTCTTGTATCATT
ATTGTCAATTCATTTCAATTTTGTGTGTCAGCATACATAATCAAATACATTATAGATATTATTTTAAAAACAG
TTATGTCTTAGATTAAAGAATAAGAAAAGTAATAATTTATATTTTATGCTCACTTATTTCTCTCCCAATGT
TTTCCTTGCTTTAAGTAGATCTGAGTTTCTGATTTATATTATTTTATCTTTCTGTAAAGAACTCCTTTTA
ACACCTTGCAAGGCTGATCTAAAGGCAAAACATTTCTTTTCAGTTTCATTTCTCAGAGGAAGTTTTATTTT
TCCTTCATGTTAGATGGATAAATACACAGGGTATGGGGAAGGTATTTTCTCTGTATTCTTTTGGGAT
TTTTTTCTTTGTCTGTGATTCTTCTATAGTTTAAATGACATGACTAGGTGTAACTTTGGGCATTTA
TACAACCTGTTATTCTATGGACTTCCAGGATCTGTGGTTTGTGTCTGATACTAATTTGGGGAATTTCTC
GGTTGTTATTGTTTCAAATATTTCTTTAGTCTCTATTTCTCCTTCTAGTGATTCCATPATGTATATGCTA
TACCTTTTTTAGTTGGCCACAGTTTTTGATACTTTGTTCTGATTTTTTTGTCTTTGTATTTTTATTT
GCTTTTTTAGTTTTGCAGATTTTAATTCATATATCCTGAATCTCAGATATCCTGTTTTCAGTCTTGTGCAG
TATACTGATGTGTTTACCAAAGGCATTTCTTCATTTCTGCTACGATGTTGTGACATTATAATTTTTTAAT
GAAATTTTTATCTGCTGCTTACATTGCTCTGTTCTTGTGTGCTTCTTTATTTTACCCTAGAACACTTA
GCATATTAATCACAGTTGTTTTAAATCTCAGTCCAATAAATCCAACATCCTTTCTGTATCTGAGTTTGG
TTCTGATTCTTGCTCTGCTCTCTTCAAATATATATATTTTTTTCTTTTAGATGACTGGTAATATATTTC
TGGATATCCAGACATAATGTATTGAGTTTGTGTAAGGCTGCTATACATAGGCCTTCAATAATTGTTGCTA
AGGTGTGGGAGAGGAGAGGCTTTTTTTTTTTTTTTTTTGCCTCTGGACTGTAACCTTCACAAGTGTTTTT
TTAGTATTTTTTTTCTTCTTGGTCAGAAATGGGTTTGGTAGAGTGAGATGGATTTTGGTATTTTCTTCT
GTCACATGGAAGACTAGAATTGGCTGGAGCTGGGTATTTCTTTTCCCTTCGGTCAGTTAGGCTCTAATAA
CACACCATCTTATGAGGCTCTGATAAACTAGTCTGCTTAAGGGCAAGCATAAAAGTCTTATTAATAAAC
AGAGGGCTCTAGTCTATTTCAAAAATGAGTCTTGTCTCCTCATGCTACTGAAAGAACAGATAATTTTTTC
TCCAACATTTACTATAAGAACCTGGTCAAGCTCCTGGAGGGAAAACCTCAAAATGTGGAGGTCACCGACTG
GGTTCCTTGGAGTGTTTAGTGCTCAGACTTAACCACACTGAGTGAGACTCTAGCAGTTTATCAATTATA
GTGAAGGTATTTCTACCTTGTCACTGGTTCTGTGTCAGTTTCTGTTTCATGAGTCTCTACTGCTATAAGCT
GTGACACTTTGTAATCACCTATTTGTCTCTCCAATCTTGAAGGCAGTCGATTGCCATTGGTCTCACCCTC
TTTTACAGATCCAGAAAGAGTTGCTGCAATTTAAATGGTTTCAGTGTTTTTTCTTGTGTTTACTATATAAAT
GGCAAGCTCCAAGCTCCTTGAAGGTTTCCAGAGCCTAGAAACCAGAAATACCAGCATATATTTTTTATTG
TATTTTCTTATCTCATGTC'TTACAGTTCTACATTTTACTTAAGAATTCATTGTGATTGCTTGATTAATAT
ACAAGTTATTTTTAAATAACATTTTCTTCAAATATTTGGAGATTTTTCGTAATAAATTTTTTGGCAGTAA
TATTTGTCAATAATTGCATTGTGGAAGCTATGACAACATAATTTTTGAAATTAGTTGAGACTTCTCTATGTC
CTAGTACATCATTGATGTTTGTAAAGTCTCCCTGATGTACTTAATAAAAATGCATATTTCCATATCTTTCA
ATTGTTGGATGTATAATTTTTATATGTCTGAGAGGTCAGTCTTGTAAATTGTGTTATTCAGATCTTCTA
TGTCTTGTCTAATAATTTTAACTATTTTCACTTATCATAATTGAAAGAAAGATGTTGAATTTTTTCTTACA
AAAGCAGTTGTATTGATTTTTGCTTATATATTTGTCATCTACTAAGTGCATTATTATATAACCGTTTAT
CTTTTAGGATGATATAATTCATATATGAGGACTTCTCTATCCTTAATGATGTTTCTATGTCTATTTGG

GCTATTATTTATACACCTATAAAATTTTCTCTAAGTGGTTATATTTTCTTATCATTTTACTATCACGAAG
AATTTCTTCGTGATTTAGGAATATCTCTTATAAAAAGCACAGAGGTAAATTTTGAAGAAAAATCCAACT
AAAAATTATCTATCTTTAAAC TAGCAATTTTCTACACTTATGTTTATTGTATCTATTGATATAGTTAGAC
TTGCTTTTACTATCTTACATTATTATGGTGATTTTCCCTTTTAAATGCTCCCTTAAATTTCTTCTTA
TACTTTTGAATGTATATGCCATCTCTCTCATAACAAGACAAACATTCTAGCATGATTCTATGATCTGA
ATGTTTGTTCCTCCCAATTTGTATGTCGAGTCATAATCACCAGGTGATTCTATTAGAAGGTGGAGAC
TTTGGAAAGTGATTAGTTTCATGAAGGTAGAGTCTCATGAACAAAATTAGTGCTCTTATGAAAGAGACCC
AATAGAGCTTCTTGCCTCTTCTAACATGTGAGGTTACAGTGAGAAGATGGTTCTCACCAAATACCAAAT
ATGTTGGTGTCTTGATCTCAGACTTCCCAGGCTCCAGAGCTGCAAAAAGTAAATTTCTATTGTTTATAAA
GTACACAGTTTCTTATATGCTATATTTTGTATATTTTCTTACAGCACCCCAAACAGACTGAGACATAT
GTTACATACTCTTTTATATGCTCTTACCCCTCTATACAATATGATGCTATCTGGATTTTCAATCTAAA
ATTTTAAATCTAGACACTATGACTATTTTACCTCCTTCTCTGTTTTTAGTTTTTTTTTAAAGACATTGAG
AAAATTTATCAAGTATTTTATTCACTTTGCTTTACAAATCTCATGCAACACCTTCAGAATTGGATTCTTC
TTTTATTTAAGCAATCTTCCAAAATTGTTTCCAGTACGTGTTTGGTTGCAGTATTTTGGAGCCTTATA
TGCTTGAGCATATATCTCTTATAGCTGAGAGGCTGTTTATCTCAATGTAAAATTATGGGTTCAATGCTC
TTTTACTTTCAGTACTTAAAAATATATTTCTTTGTCTTTTGTGTACCCACTTTTGTCTGTAGAAAGTGAT
ATACTTTCTTCTGAAAGGCCCTCAATTTTTTTCTTGTCTTTGATATTCATAAAATTTAATATACTTCT
TCCAAATATGTCTGTGTTCTTACTTATCTCTTGTGTTGAGCATTCAATGGGCACCTCTCAACCTGCATTTT
TTGTTTTTTTTAATCTTAGTAAATTTTGAATAATTTTCAATTTATTTCTTTAAATATTTCTCTCTT
CAACTATTTTTTCTCATTTTAAAGGCATTAATAATTAAATTTCTCAATTTTAGTTAAAAATTATGTAT
ATCTTAACCTTTTACCTATATATGCTTTCATGTTTAAATGAAATAACCAATTTTATTTTCCAATTTCTT
TCTTGTTTTAAAGCCATATATTTATTTTATACTATTTTACATCTTGTACTCCATATTTTCTACTTGTCTT
TTTTGTATCTTATTTTGTCTTTTATTTCAATTTGCTAATATTCTTTTCTTATATATTTTGTGTATTTGTA
ATGCTTAAACTCCTGTTAAGTGTTTTGTAAAACAATTACTCCTTATGGTGTCTTCAACCAGTTTACTTT
TTTCTTTCTCTTTTGAATGTTTTCTCAAAGACACTACTATTTTGGCCTGAAGTCACATTACTTAGTTA
TGATAGTTTTCTTTTTTATAGTAATTTGCACAGGGGAAGAGCTAAAGGATAGAACTCTGTCTATTGTGAACCC
TGAAAGCTCAGAAAAAGGGGAGGGAATGAGCCTCAAGGTGATGACCAGTAACCAATAAATCACGTCACT
CTGCCCTTTGACAAACATTTCTTTATCCATGGCTCCCTCAGTCCCTGAATGCGAAATGCTTTGAGGAG
ATTGTTAACTAGTACTGCAGAAATACTGAGGGGATTACCTGTAGAAGGGAATGCTCAAGGCTAGTCAGCC
TTTCTCTCTTTGCTCAGCTGCTCTGATTAGAGCTACTCTGATTTTACTCTGGAGGACACATGCAACCAA
TGTCTGAACAGTCATACTCAATCCCTGCATTGAGGTAGAAAGCACTGATTCTTAGAGGCTGATCTGAATC
ATGCAACTGTATTGAAGGCAACAAAAATAATAAATAGCCATGTATTTAATAGGGAAGTATATAGTA
ATTGAAAAGAAAAACCAAATCAATACAAGTAGTATTGTGACCGAGAGACAAAGGTAAATTTGAAGATAG
GTTTGTGATTTTATAATGGAGACCTTTGAATGCTAGAAGCTACCCCTTCCCTTTGTAAAGAACAACTTA
GGTAAATGATTAAAAAATTATGTCAAAGTCTATGATTTTGAAGCTTACCATATTTGAAAATATTATATT
AAAATAATGATACTAAACAAGAATTTATGACAAATGTTTCATCTTTTAAAGTAAAGAACCTTAAATTTG
TAAGCAGCTAAATCTAATGATATAGGCAACTGCTAGGATATCAGAAAGAAATGGGATTTTAAGATGAAC
TTATACAAATTTGCTGAAATTAATCAATCAGACAGAAATGCACAGATGACAAACACTGTAAGATGTAA
GAGGAATTAATCATAAGAGGTTTATTTGGCTAAAGTGACAATTGTTAAAGATAGAATTGCCCTAACGTTAG
TTAATAACAGAAAAATATCAGAAATTTTAAAAATGCTGTCTTAATCTATTAAAAATTATATAAAGATAA
AGCAAAACAATGTAGGTTTATAACAAGAACCTTTAAAAAGCATAATACGTATGCTTATTACAAATTTA
TATCTTGAGCTGGGGTACATCATCCAATTTACGCATGAGAAAAGTGTTTTATAATTTTCTACTCTGTAAT
TCATATTTTAAAGTTCATCTGAAATGTATTTTACAGAGGTAAAGAACAGCAACTTGGTGCTCAACTCTCTT
CCTGCTCTTCGCCTAGTGCTAAATAATTTGTGTAAATGAAGTGTGAATGAATTTAAGTTTACAGAAATAA
AATTTATATTAATAGAGAGAAAGGAAGGATAAATCAATAGTCTTCCAAATATGATACATGTACAATGCAAT
GATATTCACAAACATCTTCATGAACACACGAACATAATTTCTTTTGAATCTTACCATGACCTTCTAAAAT
AAGTAAGCTAAATATTCTATATTATACTACTATTTATGAGGAACTACATTTCTGTGAATTGTGTAAGTT
TTTCATCTTTTATAAGGTTAGCAAGCAAAACAAACAATAACAAATAAACAACAAAAAACAAAACTTGGC
CCAGATCTGACTTTAAAGTACCTTCACTTTTATGTATCACATACGATCTCAGTCCACAGATGGGTTTCTT
GATTTAGCCAAAGATATAGTAAAGTGAGTGTAAAGTAGAAGAAAAAGGAAGGAAAAATTTAGGTATAGAA
ACCTACATGAAATAAAATGAAATAAAGAGAGCCTACTCTTCTGAAATGCACCAGTAAATGTACTCCTA
TCTTGTGTATTAAAGTTTATAATCATACATTCAATTCAAAATTTAACTAAACTATGGAACTGAGAGCTA
ATAATAAATGATATACACAGCATTTCAACCAGAAAATCTTCTAAGCAATTGTACAATTCAGATAAGAAG
AAATAATTACAAATGTTTCAAGAAATTAAGATTAATTAAGACTGTAAATTTTTTTTTTTTTTTTTTTGAGA
CAGGGTCTCACTCTGTCAACCCAGGCTGGAGTGAGTGGCGCGATCTTGGCTCACTGCAAGCTCTGCCTCC
CAGGTTACGCCATTCTCTGCCCTCAGCCTCCCAAGTAGCTGGGACTACAGGCGCCACCACCACGCCCA
CTAATTTTTTGTATTTTATAGTAGAGACGGGTTTCATCATGTTAGCCAGGATGGTCTCGATCTCCTGACC

TCGTGATCTGCCACCTCGGCCCTCCACAGTGCTGGGATTACAGGCGTGAGCCACCGTGCCCGGCCAAGA
CTGTATAATTTGTTCCCTGAAGGGCAGGGAAAATGTAGTGGTAATTTTCAAGATGAATTGGAAGATAAAG
AAAGAGAGGTCACATTATTTGTGTTATTCAACTGAAATAGTTTTGAATTTCAATAAAACAAGCTAAGAAA
TGCCCTTTGTCATCAAATTGATGTGAAGAGTAAAAAAATTTTAAAAATGAAATTCCTAAGATAATATGT
GAAAATAAGACTATTTAAATTTCAACAAACATTTAACAAGTGTATACCCATCCTATGTTTCGTTTTATCCA
ACTTCTTATCATTTCCCTAAGTATATTAAGTAAAGTAATAGCTATTAATATGTTGACGTCATTAGCAGAAAA
ATAACTTTGCAAATGATTAAGTGATGACAGTTGTATATCCATGTTATTAGATGTTTAAAAATCAAAAAAT
AATTAATTCATAAATTTTGAACAAATCCATAGAATAAAAAACATAGTTTTTCAAATGTATTTTTCAA
AGGTAAAAATTTCTCACATTAGGCTAGGTGCGTGGCTCATGCTGTAATCCCAGCACTTTGGGAGGCCAA
GGCGGGCAGATCACGAGCTCAGGAGTTCAAGATGAGCCTGGCCAACATAGTGAAACCCCATCTCTACTAA
AAATACAAAAATTAGCCAGGTGTGGTGGTGCCTGCCTTTAGTCCCAGCTACTCAGGAGGCTGAGGTGAGA
GAATCGCTTGAACCCAGGAGGCAGAGGTTGCAGTGAGCCAAGACCACGCCATTGCCTCCAGCCTTGGGG
GAAGAGTAAGAGTCTGTCCTAAGAAAAAAAATTTCTCACATTATTGTAAATACTATTACAATAGCTAAC
TAAAGTTCAAGATTATAATTTTCTGATGCTCATACAAATACACATTTTACTGGATCTTGGGTG
TTGTAGTAAAAACAATTTACTAAAAACAAAAAAAAGAAATGTATACCTTAAATACATAGAATTTTATTG
TCAATCATACCTTAATATGAGAAAAAATGTTCTTCTTTTCCAAAGTAAAAAGAAATTAATAGAGCAAAG
CTATATTTTACAACAATGTACATATAATCCATAATTTCTGTCTAATACTTGATATTCTACTAAGTGAATTG
AAGCAGTACTTGCCAACATTTACATATATATGAATAATTGAATTATAAAAGTTATGAGATGCTGATCTGA
ATTACAAAAGTCCCTCTGTGATAGTAAACACATGCATAAATTAATTCTATAAAGTGTATTATGCATTTTCT
CAAATACATTGAAGTTCTGTAGTCAAAGTAATCAATAGAGAGCCAAAACCTGTTTTTGAACAGTTTAGCA
TATTTTCATTATTAAAAACAAAACCTTGCCAATAGATATAAGAAAAAGAGCTGACCAAAATAGAGTTTAAA
TAGCATAAAATAATAATTTTGAAATTCATAAATTTGATTTTAGAAAATCATGACACGTAGAAAAATTAAT
TTAATACAGGTCTCATTGTAATTAGATAAACTTATATTCTATACCTGAATAAAAAGTAATTGAAAATACC
TATGACTTTGCGCAATAAAAAATGGCAAATGATAAAAAATCAAATTTTCTTACATAAAATTTGTGA
AAAGGGGAAACTGAAGAGAGAAAAATATGATAGTTTATTAAAGTGAACATTTACATAGTTTGTGATGAGA
TAAAGTAAATTTGAGAAAATTCCTATTTTGGCATTTATTGCTGTGAGTTTACCAAGATAATGTTTCTCC
ATTTTAAAAACAATGGTCTATGGTCAAAAAGTAAGTCAAACCTATCCCTGTTTGCAGGTGACATGATTCTA
TATCTAGAAAACCCCAAAGCTCCTTCAGCTGATAACAACCTTCAGCAAAGTTACAGGACACAAAATCAA
TGTACAAAATCAGTAGCATTCTTATACACCAACAACAGCCAAACCGAGAGCCAAATCAGGAAGGCAATC
CCATTACAAATTGACACAAAAAGAATAAAATACTTTGAAATATAGCTAACTAGGGAGGTGAAAAATCTCT
ACAATGAGACTTATGAAACACTGCTCAAAGAAATAGAGATGAAACAAACAAAGAGAAAAACATGCTTAT
AGATAGGAAGAATCAATATAATTAATGGTCACTAGCTGCCCCAAAGCAATTTATAGGTTTCAAGTCTATTCC
TATTAACTACCAGCAATATTCTTCACAGAACTAAAAAATTAATTAATTAATTAATTAATTAATTAATTAAT
CAGAACCAAAATGGCCAAATAGCGAAGACAATCTAAGCAAAAAGAATAAAGCTAGAGACATCATGCCGTC
TGATTTCAAATATACTACAGGACTATAGTAACCAAAACAGCATGGTACTAGTAGAAAAACAGACACATA
AACCATTGGAACAAAATAGAGAGCCAGAAATTAGGCCGATGCCTATGAACATTTGATCTTCAACAAAG
CTCAAAAAACAAGCAATGGGGAAAAAAACCTCTGTTCAATAAGTGATTCTGGGATAACTTCTGGTCTAT
ACACAGAAAATTGAAATTGGACCCCTTCTTACACCATAACATAAAAAATTTTAAAAATTTCAAATTTATAAAA
AAGGAAAAAATTAATCAACTCCAGGCAGACTAAAGACTTAAATCTAAACCTCAAACCTACAAAAACCTG
GAAGACAACCTAGGCAATATCATCTGGACATAGGAATGGCAAAGATTTTATGACAAATGACACCGAAAG
CAATCAAAAACAAAAGCAAATATTGACAAATGAGATATAATTAACCTTAAGAGCTTCTGCACAGAAAAAGA
AACTGTCAACAGCATAAACAGACATCCTACAGAATGGGAGAAAAATATTTACAAATATGCATCTAACAAAG
GTCTAATATCCAGCATCTATAAGAACTTAAATTTACAAGAGAAAAACAAACGGCCTCATTAAAAATGTAG
GCAAAGGGTATGAACAGACACTTTTCAAAGAGACATACACATGGCCAACAAGCACTTGAAAAAAGGC
CAATATTACTGATCATTAGAGAAATTCAAATCAAAACCAATGAGACATTATCTCAGCTAGTCAGATT
ATTATTATTAAAAAATAAAAACTAACAGATGCCTGGCAAGGTTGTGGAGAAAAAGTGAACACTTATACAC
TGTTGGTGGGAGTGAAATTAGTTCAACCATGTGCAAGCAGTGTTGGCAATTCCTCAAAGAGCTAAAAAC
AGAATACCATTCAACCCAGCAACCTCATCACTGTGTATATACACCCAGAGGAATATAAATCATTTCTACT
ATAAAGACACAGGCATGTGAATGTTCAATTGCAACATTATTACAAATAGCAAAGAAAGACATGGAATTAAC
CTATATGCCCATCAATGACAGATTGGATAAAGAAAAATGTGGTACATACTATGGAATACTATGCAGCCATA
AAAGAACAAGATCATGTCTTTTGTGGAAACATGGATGGAGCTGGAAGCTATCATCTTTAGCAAACCTAAC
CAGGAAGAGAAAAACCAATACTTCTATGTTCTCACTTATAAGTGGGAGCTAAATGATGAGAACTCATAAAG
ACAAAAAAGGGAATGACAAACACTGGGGTCTAGCTGAGGTTGGAGGGTGGAGGGTGGGAAGAGAGAGAGA
AGCAGAAAGAAATAACTATTGAGTACTAGGCTTAATACCTGAGTGATGAAATAATCTGTACCACAAACCCC
CGTGACACGTGTTTACCTGTACAATAAACCTTCACATGTACCTCTGAACATAAAAGTTAGAAAGAAAAATA
TTAACAACTTTAAATTTAGTAATCATTAATGTCAAATTAATAAAGAAATTTTAGACTCACACTTATAA
TCATAGCACTTTGGGATGCCGAGGTGGGCGAATCACTTGAGGTCGGGGGTTTGAGATCAGCCTGGCCAAC

ATGGTGAAACCCCTGTCTCTACTGAAAAATATAAAAAATTAGCCAGGTGTGATGGCATGTGCCCATAGTCCTA
GCTATTTCAGGAGGCCGAGGCAGGAAAAATCTCTGGAACCTGGGAGGCAGAGGTTGCAGTGAGCCGAGATCA
CAACAGTGCACCTTTAGCCTGGGTGACAAAAGTGAGACTCTGCCTCAAAAAATACATATAAAAAATAAAAAAGA
TTTTAAATAATATTATAAAATAAACATAAAATTTCTAGGAACAATTTTTTAAAAATCAGAAAAATAAGTCATA
TGATAATACAGATACTCTTAAGAAATGCATAAAATATATGAATATACATGTGTACTTTATGTGATGTGCATG
AAGATACACTAATATATCCAACAAGAATAAGCACATCCATTATTTTATAATATTAAAGTAAGCAATAAAAA
GGAACACTTAAAAATATTTTCTTCAATTTAATTGACTATATTTTTTTATTTGGAAAACAATTTTAACACA
TATTTTAAATAGTTTAAATAGAGAAAAATGTAAATAAAGCTGTATTACAAAGATATTCATTGATAAACAC
TTCAAAAAATTTTTCAACTTCCTTATTTTATCAGCTATTTTGCTCTAGAAAAATTTCCATTCCACATGAT
ACATTTGTTGTATAAGAGATACAAAACAAATTCCTACTAGGGGAAATAAAGCTTCAGTAAGGAGGTGGCA
TTAAGCTGGGCTTTAAATTCATGCAGAAATCCCGTTGCTTCAAATGGAGAGAAGCAGCAGTGATACCACA
GATAAATGAAGTGAGACGTAATAAGGGTTTGGCTCAAGATAATAAGGAGATGTATAATACTTTTTTATGT
ATAATACTTTTGTTCCAATTCCTTTATGCTTTACTTCAGTTTTGTTTCTCTAGTTAAATAACTTTGCAT
CTCTAAACTTTATTATCTTATTTGTATAATGAAGAGAGTAACCTATGCCAGGCAAGATTTTACAGACA
CTAGAAAAATATATACAAAATAGTTGGAATAGTTCCTGAAAAATAGTAGGTTCCACATGATAACAAGAT
TTATGCTTGTGCTCTTTCTGTATTATTTGGAAAGAAATATGTGAAGTGCAAGGAAAGTGGTGTGAAGTTAT
TTTTGTGGGATATCTGGTGTAACTTTCTCTTTTATCTATGTTATCAAATATTTTTTCAAAGCTGTATTT
CTCATTAGTGCTTTTTGTGAATAAATTAAGTAGGAAAAATAGAAGAATGGCAACAATATACATCATAGAA
AGGCATAGATTACAAAGAGAGTATATACACAATACCTGTCCAGAAGATGTGGTATAAGCCAATATTTTAA
TTATACTTATTTACTTCAGATATTGCAAAATTTTCTTATTTTATACCTTCTTTCTTTTAAAGACATTTTC
CTATATTTTCATTCACTATGACATTGTTTTCTTTATATCAATACTTATGAAGAGAACTAAGTATTTCTAAC
TAGGGAGTAGTTAGACTAGTTATTTTAAAAATCTTCATTAAAGGACTACAACGTGTGTACCATCTATGAC
TTAGTATTGATTGATTGTCTATCTTTCTATGTTCTTCATAAGTGGGTAATTTTGAACACTGTTATATTATTT
CAAAGGGTGTATTATTGTTTGTTCAGATGTTTTACAAAGTAATTAACCTTTGTTGGCTTGAAATTGCAAACT
CTGTCTTCTTGGTGTCTTAGTCAATTCAGGCTGCTATGACAAAAATACCACAGACTGGGTAGCTTAAACA
ACAAACATTTATTTCTCACAGTTTCAAGTGGGTGGGAGACCAAGATCAGGGTGCCAGTATGGTTAGCTTCT
GGTGACAGTTCTCTTCTTGTCTTTCTGACATGGCTAAAAGAGAGAAAGAGAATGGAAGTGAGTTCTCTTCTT
AAAAGGGTACAAATCTCATTCTGAGGGTTCCACAGCCATTATCTAATCACCCTCCCAAAGCTTCACCTC
CTGATACCATCACATTGGGTTAGGATTTGACATGCGCATTTGAGAGGGACACAAACATTCATTCTATGAC
AGATGGTAATCGAAGCAAAGACAATGAATGGGTTTGGCCAGCAAGAGTATGTAGAGTAAAAAGAGAAGAC
GGTATGAAACAAATCACTGAAAAAATAAATGTAAACAGCCAGAATAACATGATCTAAGGATACCTGGGA
GGAATTATGCAAAAAATAGGATTTGAGTCATGCAGGCAAACTCTTTAAATTTTTTACTGGAAAAGACATGA
GAGACAGAGTTATGGAAAAGAAAGCATTGTTGGTGGAGGCAGATCCATTTTTTCTAATAAAATAAATTAATA
TGGATGAATTGTACAATCATTCCCTAGTAAATTTCAAACCTGCATCCAGGCAAACTCTCTTATGCAACAGG
CCTGCCTTAGTTGTGTCTACTGGGTACTTGTTTATTTTAGGCATGTCAAATTCGACTTGTGAAAAGATG
ATTATATTGTCTTTAATGCTGTCTTCTTTTTCCCAACAAATGACAGTTATTCAAACCAGAACTATAAAA
CAAACATACAGTTATCCGAAC TAGAAAACAAAATCAGAATTTACATTTTCTATTTTCCCACCTGTTT
GGTCTCTCTCTTAAACTTCTCTTGTGTGTCTGTAAAGTGTGTTATACACTTTTCTATCTCTACTCTTTTTT
ATTTTCTGAAGTCAGCTTTCTAACAGATCTCTTTTTCTTAAGTTCTTCTTCTTCTCATGGCTGCCAGAATTA
ACCATCTAAAATTTAATTTTGTATTGTAACATTTTAAAGTGCATATTGACTCCTCAATGTTGAACATATT
TCTATCCTTACACTTCACCTACACAATAATATTCTGTTTTTCAAATAATCCGTGTTATTTCACTTCTT
AGGGGCTTTTCTATGTGCTTCTTATTTTGTTTTAAAGTATTTTGTGTCTTCAATATCTAAGCTTCTATAATC
AACTGAAGACTTAGCCCCAATGTCAACACATCTTTAAGAAGCTTTAAGCTGTAAGGTGAGAAATAGTCCCTT
TTTCTATCTGCACATAACATTACAACTTATGGCAATATAAAACTCAATACATATTATACGTGTCATTA
TTGGTTTATTGCTGCTGAAGATTATAATTTTCAAGTGCATTGATTATGTCTTATTTGTTTTTACTGCCCCCT
GTTCTGTTCTCTGTACCTGCCTCAACTACATAGCTTAGCAGACTAACTGCTATATTACAGTTGCTCAA
TGAATGTTTCTTGAGTAAATCAGTTGAGTTCCAAAGCTAATCCAAGTTGTGCGTTTGACAAATTAGAAGC
TTGGAAGTGTCTTCTGACTTTAAGTTTGAAGCTATGCCCATAATAAATTAATGACCGATCTGCCATGATT
GCAGGCAAGTAGAGACTTTATTTCTTATCTCAATGTCAAGTTGTCTCTTTCTGCCAATGCACATTTTATTT
GATGATTGTGCACATTTATATCTCTGGTTTTTATTTAAATAAATTTAGAACATATAGCTGGAGACGGTAG
CTCAAAGTGAAGATGAAAATAGACATTTATCAAGGTTATTATGTAGCTAGCACTGCATGTACACAGAGGT
ATTTAGGGAGCCACACATATGTCCAAGGCAAGACATATGCTCATAAAACGTCTGAGAAGATTGTATCCTT
TTACCTAATGCTAATCCCCAAGCTTAGAACAAGGCAAGTGAAGGTCAAAGGGATAAAAAAATACAATAA
ACAAAAATAAAATTTACAAGAAGTTGTTATGGACTAAATATTTGTTCCCTCTCCCCAAATTTGTGTATT
GAATTTCAAATCCAATGTGATAGTATTGGGAGTCTTTGGGAGCTAAAGAGATCATGAGAAATTTGCTC
TTATAATGTGAGTAGTGCTTTACAAGAAAATGCTGGAGAGCTCACTAGATTTTTTCTCTCATGTGAGAA
TACAAAGAGAAGTTAGCTGTTTGCAGCCTAGGAGAGGGCCCTCACCAGAAATTGACCATGCTGGCACCCCT

TATCTCAGACTTCTCACCCTTCAGAACTGTGAGAAATAAATGTTTGTGTTTAAAGCCATCCGTTCCATCA
TAATTTGTGATAGCAGTCTGAACCTGACTTAGACAAAAGTTCAACAGCAAATTTGAGCAGTTAGAACACAG
AATCCGCAAACCTTGAAGATAAGACAATTGAAATGATTAGTCTGAGAAGCAGAAAGAAAAAAGCAAG
AAAAATTAACAAAACATACGGAACCTGTGGGACACTATCAGGTGAACCAGCATAACAATTAAGTAGTTCT
AGAAAGAGAAGAGACAGAGAAAAGGGAAGAAATAATATTTGAAAAAAGTGCCGAGAACGTCCCAAAT
TTGATAAAATATATGATCTCAATATCGTAGAAGCATAAGAAAATCCAAATAAACTCAGAGATCCACTTTG
AGGCACATTATGATCAAACCTGTCAAAGGCCAAAAAATAAAAAATAAATTCAGAACTCTTGACAGCAACAAG
AGTAGGAAATAATCATGGGCAAGAGTTCCTTAATAAGATTAACAACCTGATTTCTCATCAGAGACCAGAAG
ACATTGAAATGATATATCCAAATAAAGAACTGATATTCAAAGATGCAAAGAACATCTAAAACCTCAATAA
TTAGAAAAATAACCCAAATGATAAAATGAGGATGATATCTGAACAGATGCCCTCACTGAAGAAGATATAGAG
ACAACAAATGAGCATGTGGAAAAATGCTCCACATCCCGTCATTAGGGAATTTGTAATTAACAATAAGCT
ATGTCACCTGTATACCTTGTAAAAAGGACTAAAATTCAAACACAAAAATATACCAAATACTGGCAAGAATG
TGGAGCGACAAGAACCTTATTTACTGCCAGTGAGAATGCAAAATAGTGCCAGCCACTTTGGAAAAATATTC
TAATAGTTTCTTACAAATTTAAAGATAGGCTTACCATACAATCAAGCATTGTAGTCTTGGTATTTTACT
GAAATAAGTATCAAGTGGGAAAGCATGTCTACACAACAGCCCTACAAAGAGGTGTTTATAGCAGCCTTATTG
ATAATTGCCATAAGTTAGAAGCAACCAAGGTGTCTTCAATATGAGAATAGGTAAAGCGACCTTGGTACA
TTCATGCAATAGAAATAAGAATATTTTATGTGATTAACAAGAAATGAGACATAACCAATGAAAAGACATGA
AACATTAAGTATATTTATAAGTAAAAGAACGCAATATTAATGTTTACCTACTATATGATTCCAACATA
TATGACAAATTTTATTTTATAAATGCTTTACCACAAAAGTTAATTCATAAAATGTTTGCCACCAAAAAAC
AAACAAAAACATGGTAGAGATCATCTTATAGTTTTTTTATAAATCCTCTTGATAAAGATTATATCAT
AAGAAATCTTGACAGTTTACATTCAGGATATGACATTTTATTTACAAATTAATGAAATCTAATAAAATG
TGACAATGAAATTTAGCTGAGTATAAAAAGAACCTAAATTAGTAGACAGTGAGAGAGGAATGGGGGAGGG
GATGTTTACAAGAAGTCTTACATCAGTACAGAACTTCATAAATTAGTGGATAAGAGCATGGTGAAGAGCA
ATTGTAATCAAATGAAATGTTGTGGAACCTCTTATTAGTATCTGCAGCCACTCTGGCACTTTAAACATA
TCCAGTAGGAGAGGTTAATTCCTCAGCAGGAGACCCTCACATTACTTTTTTCTCCCTATAAAATAATG
CATCGTTTTGTCTGCTGCTGTAATAAACACATAACATTAAATGTACCCTTTTCAACCAATTTTTAAGTGTA
AATTAAGAGTGTAAAGTACACTCACATTGATGAACAACAGATCTCTTGAACCTTTTTCATTTTCCATTGC
TGAAACTTTGTATCCACTAACTATCTTCTCCTCAGTTCTAAGTAAGTACCCTTTCCACTTTCTGTTTCTA
ATTTTTTGACTACTTTAAATATTTCTTCTTTTTCTTTCTTTCTTTTTTTTTTTTTTTTAAAGATGGAG
TCTCGCACTGTCAACCAGGTTGGAGTGCAGTGGTGTGATCTCGTCTCACTGCAACCGCCGCTCCTGGGT
TCAAGCGATTCTCCTGCCCTCAGCCTCCCAAGTAGCTGGGATTACAGGTGACTACCACCATGCGCAGGTAA
TTTTTTTTTTTTGTATTTTAGTAGAGATGGGGTTTTCACTATGTTGGCTAGGCTGGTCTCAAACTCCTGAC
CTCGTGATCCGCCACCTTGGCCTCCAAAAGTGCTGGGATTACAAGTGTGAGCCACTATGCTTGGACTAC
TTTAAATATTTTATATGATAGAAATCATACAGTATCTCTCCTTTCGTGACTGGCTTATTTAGCTTAGCATA
ATGTCCTTGAGGTTTATCCATATTTAGTACATGATGTAATTTACTTATTTTTTAAAGTCTGCATAATATT
CCATTGTGTATGATATACACATTTCTTTATTCATTCAGTAGACATTTGGGTTGCTTCTACATCTTG
GCCGTTGTTAATGCTGCATGAATATGCATGTACAAATATCTCTGCTAGATCCGTTGTTTGAATTAATT
TGACTATATACCCAGAAGAATAAATTAATGGCTTGTATGGTGAATCTATGTTTAGTATTTGTGGAACCTC
CAAACCTTTTTTCATGAAAGCTGAACCATTTTATATTTCCATCAACAACATGAAGTTCCCTAACTTCTCT
TACTCGTTATTTTCTATTCTTGAATAGTGGCTTTCTGATGGTTGTGGGGTGATATCTCATGTGGTTT
TAATTTGCATTTCCCTGATAAGTAGAAAGTTGAGCATCTTTAATGTGCTTATTGGCTCTTTGTATATCT
TCTTTGCAGAAATGTCTATGTAAGTCTTGACCCATTTTTAATTTGGGTTGTTCTTTGTTGTGTTTCT
TGGAAAAGTCCATATATTCTAGATATTAACCTCCTCATCACTTATATTATTTGCATTTATCTGTGCCATT
CCATAGGTTATCTTTTACCTGTTGTTTTCTTTTATGTGCAGATGATTTAAGTTTGATATAGTCTGATTT
GTGTATTTTTAATTTTGTGCTGTGCTTTTGTATCACATTTTAAAAATTGCCAAATGAATGTCTCTGA
AGCTTTTCTTTTATTTTTTCTGGAAGTTAAGGTCTTACATTTAGGTATTTAGTTCATTTTGAGTTAAT
TTTTGCATATAGTATAGGTAAGGGCCCAATTTCAATTTAGTATGATGCTGATGCTGATGCTGATGCTG
CATTTGAAGAGGCTGCTCCGCTTCCCTGTACTAAATGAATGGTGTGTTTGTGCTTCTTTTAAAGATCTCTG
TTTGTGTGTAACCTTTTGACAGTTTGAATTAATGCTGCTTGGTATAGAGTTTTTATAGTTTATCTTATTT
GGAATTACTTGAGCTTCTTAAATGTTTAGGTTCTTTATCTCTTAAGATTTAAAAAATGGGGTCCATAA
TTTACAAGTTTTTCAAGCTTTCTCATTTACTTCTCTCTGGTATTCCCATATGATATGTTGCCCTGCT
GGATGGAGTCCCATAAATTTCTTTAGGCTCTTCTTTCTTTTGTCTCTGTGACTCTAATTTTAGAAGTTC
TGTCTTTGATTTTCTGATTTTTTCTTCTGCTAGCCAAGTTACCTGTTGAGTCTTTCTAGTGAATTTTT
CAGTTCAGTTACTTTATAATTAACCTCCAGAAATTTCTGTTTGGTCTTTCATAGTTTATAATCTGTTAATA
TTGCTATTTTGTATTTTGTATGTTCTCTCATTTAATTTGCTGTTTCATATCTCTTTTAAATTCAT
TGCACTACTTGACTAATTTCAAGTTCTATGCTGGCAATTCCTATATCTTCATTTGTTTTTGGTCACTTT
CTGGAGATGTAATTTTTTTTTCTTTTAAATGTGTGAGAATCCTTTCTTTCTTTTTTATACCTTTGTATTAAT

TTGTTGTTGAGATTTTAAACATTTAAAAAATCAGTCAACTCTCCCAGATTTTGTGAGATGATTTTCCATAA
GGAGAACTCTCCTCACTAATTCTGAATAGAGATTCTGTGGCCTACTCATGCTTTTTTCTAGTATGTTTT
CCTTTCTTTCTCCTTTAGGCTTGTGTGTGTGATCTGTTTGAAAAGGTTTGTGGTTTCTATAGAAGACCC
TCCCCTGGGGCTTGAGGTACAGTGGCCTTTCTGGGGCTGCATTAAATTTGTGTACTGGTGTCTCCACCTCG
TGTCTCTGTCTGGAAGTGCAGTTTTTGGGTGTACCTTTGCTTGCAAAGACCGCATTTTTATTAGTACTTGA
ATATAGGCAAGTCAGAAGCCTGTCCCTTGGGCAACCTCCCTAAAAGTCAAAATATTGAACATAGGAGATTT
AAATGTTTCCCTTCCAATTCGATTCACAGGGTGGAGTGAGAAAGACTCTAGTGAGAGAGACTGGAAACAA
TCATGATTTTTCTTGCCAGGTGTTTTCACGATAGCCTGGAGGTACAGAAACCTTGAATTGGTTCTGAA
GTTCTCACAGAGGCATTTAGTACATATGTTGTTAATATTGTGTCTTGTCTGTTGAGGTTCCAGGGCTGTTT
TGCTCTCTTGTGTGATGTCTCTCTCCACATTTCTTAGTCCTTTTTAATAAAATGATTTTTTAATGATT
AGGACCTGAACAAATTTTCATCACTATTCTATGGCACAAGACTGCATACATTTTTACAAGATGTTAGAAT
TGACTATCTTTGAAGAAAATCTTCATAATTTTTGTCTAACTCTGTTGCCCCCTTCTCCTGTTTTATTATT
CCCATCATCAACTTAATACAACTAGTTTTTGATACTCTTCTACATTTTATGCTGTTTTCTTAGATAACTTTT
TACATTTTATTTTTAAACCTTTTAGTTATCTCTATAAGTTGTATCATTTAATAAATCTTTTGAATTCCTTT
TATCTTCATTGTAGCATATATCATTTGATAGTTTCTTATGCAGAAAGGAACACACCCACATTTTGTGCG
CTATCAAAGAGTTTTTGTGGCCTTTTATCTCTGTCCCCCAAACATGGCCTAGGGCCAGACACAGAGTAG
GTTTTGGTTATATAAATGTTCACTCATTATTTCTTAAGCATCTTTGTGACAGACACTGTCTTAATCACTG
GGGACGGAGCAATGAACAAAACAGACAAAACCTATGACTTGATGGGGCTAATATTCTGCTGTGGCAATA
TAAAATAAACTCATAAAGGAATAAATGTATTGTGAGCAGAAAGGGGTGCAATTTTAAAGAGATTGATCAA
GGAAACCTCACTGTGAAAGTTCCACTGAGCAAACTCTTAAGGGTGTGAAGGAATGAATGATAGAAATA
CGACTATGGGGAAGAGCCTTTCATGTCAAGTGAAAAGCAAGAACAAAAGCCTGGAGCAATATAATGAAT
CTGGAATGCTCAATATACAGCAACAAGGTCTAATGTAGCTGGAGAGGAATGACCAAGGACAAGAGTAACA
AAGTATAAGATTAGAAAGATAAAGAGGAATATTTGTGGGGAGGTGGGTGTAAAAAGAGGATAGGTTGTT
TATGGTCTCATAGGTTATTTGGAAAACTTGATATGACTATAAGTTACATAGGAAAACAGAGGGGCAGCAT
GATCTATTTCTGATTTGTAAAGGACTTCTTTAGCTACTTTGTTGAGAAGAGACTGTTAGGCAGATGTGCA
CAGAAGTAGAAACATGGCTCAGGAGGCTCTTGCAATAATTGAAGCTAGGCATGGTGGTGGAAACCACTGG
GAAATATAGGAGGTAAATTAGAAGAGGTCTGTTTAGTCAGTTCAAGGCTGACAGAATAGAATAGACTTTGGTGA
CTTAAACAACAAATATTTGTCTCTCACATTTCCGGAGGCTGAGAATTTCTGATATCAGGGTTCTGGCATAA
TTGAGTTCTGATAAGGGCCCTATTCTGTTTTCCAGAAGGCCATATCCTCATTGTGTGCATCACTTGGGGG
TAGGGGAGAGAGAGAGAGAGAAAGAGAGAAATAGAGGGGAATCCCTAATTTCTTGTCTTATAAGGGCACTGAT
CTTATCAAGAGGGCTCCATTCTCATGACCTAATTTCTCAAAAAGACCCTATCACCACATCAACACAC
TGGAAATTAGAGTTTCAACATATAAATTTGAGGTTAGGGGATATAAAGATGTAATACATAACAGGGTAAAT
ATTAATAGTAGAGAGCCCAAAGAAATTTGTTTATGGATATAAATGTGAGCTGTAATAGAAATGATTAATC
GATACATTTTATTAACATGAAATTGACAAAATAAAACATCTATAACCACATGCATCTTACACTGGATGTGAG
TCACTTGTGTTGGTCTAGAAATTTTCTTTGCTCTGCAAAGTTCTGTTTTCTAGCTGGCTTCTCTGGAAA
TGCTGCCTTTGAGAATGTACTGCCACTCCCCTCCCAGTTAGCCAATGCTATTTCATATGGAAATAAAGAAT
AGCTCACCATGTGCCATCTGAGAACATGATGTAGCTTTCTATAAATCACTTAATGAGATTAATTTAA
AATAACACCTTAACCTGTAGTCTTAATATTTTGAATATTATAACCAAATTAGAAATGATGCTTTATCAG
TGTAAGTATAATAACATTTAAATGGCTGAGTAGTAGTACCTGGTAAAAGGGGAAAACCTAAGTATGGTTTTT
AAGATACAATAATGTTTTTAAAGTAAAGAAGAAAGCTATTATAATCCATGTGCCTATTGACATTATATA
GTCCTTCGATTAAACATTTTCCCCCTTCTCTGATTTTTCTTAGATGTTCTTGGCAGCTCTGTCACTC
AGCTTTATTGCTAAGACACTAGGTGCAATTATTATGAAAAGTTCCATCATTCATATAGAACGGAGATTTG
AGATATCCTCTTCTCTTGTGTTGTTTTATTGACGGAAGCTTTGAAATTGGTAACATTTATTTTCTATTTTA
ATAACCAAACCTTGCAAAGTTAAAAAATATATATGCTTTACACCACCTGGTTATCAACTGGGGTAAATTTAT
CTCTCACAGGCAATTTGGCAATAACTAAAAACATTTGTGGTTGTTCATAACTGCACAGGGGTTGGGGGCAA
TGGAAGTGCTACTGGTATCTAAAGGTAGAGGTGAGGGGTACTGCTAAATATTTCTATAATGCACAAAGAAT
GATGTAAGTGAATGTTGATAGTGAGGATGTTTCAGAAACCTGATTCTACACAAATTCATTTTTTGCAA
ACTAACGCCATGTCTACTTTTACCTCCCCTCTCTCAAGATGAAGAACTTTGGGAGAGGACTGTTATTCT
TAAGGAGAAAGGAATCTTTTTCAGAGCAACCTACGTTAGACCTCTATTGTTTCACTGAGCACACAAAAATC
TTTCTTTGAAATACGAAGATATTTTGTGTCTTCAATTTTATGTTGGATTTCTCCAATAACAGCTCAGG
GAAAACATTTTCTGGTTTCAATTTGTGTTTTTCCCTATTAGTAATTTTTTTCTAGATAATTTATAAGATG
AATATTAAATTTTCTGGGAATTTTCTCTTTAAATTTTTTCTTCTAAATTTCCATTGTTTTTCTTTATG
TTTCATTAATCTTTGATGCCATCATCCATCTTACCATATTAAGTTCTAATTTGTATATTTAATCTGTATT
TTATATTTACAACAGCACTTTTATTATCCCTTATTATTTTTAGGCTGCCAGTTCTGATTTTCATGGATGCA
ATGTGCCCTTGTACCCGTAAAGGTACTAAATTTTTTATAAAGTAAAAAATAATTTACTCATTCAATTTG
GTGCTTTTATTTCAAATTTATTTTATGCTATTTTTTTTTCAGAAAGTGTCTCAGTTATCCTTAACTGCTATTT
GTTTATTGTTATGCCGAGGCTCCAGATGGATTAGAAGTGGTCATGACTTTTTTTTTTTTTTTTTTTGAG

ACGGAGTCTCGCTCTGTCGCCCAGGCTGTAGTGCAGTGGTGCATCTCCCTCACTGCAAGCTCTGCCTT
TCTCCTGCTTCATCCTCCCGAGTAGCTGGGACTACAGGCACCCGCCACTATGCCCGGCTAATTTTTTGT
TTTTTAGTAGAGACGGGATTTCACTGTGTAGCCAAGATGGTCTCGATTTCCTGACCTCGTGATCCACCC
ACCTCAGCCTCCTAAAGTGTCTGGGATTACAGGTGTGAGCCACCATGCCTGGCCTCTGGAAGTCTTAATT
AAGTTCGCTCTTCTGTGGTTTAATAGCACCTCTGTCCATCTATTTTTATCGTTAGTATGAACTTCTTG
AAGACAGATGCCATGGTTTATCTTTTTCAAGTAACTTTCTATTTCTGGCTCTGAGCTTCATGTCAGGT
TCATGTTAGAAATTTAAATAATATTAAAGATAAATAAAGAAACGCATGAAGGAGCACCTTACCTCATCA
GGAAGATTCTATCTCCATTTTTCTTCATTCAGTATAATCCAGTCAACTCCAAATTTTTCAATAAAATTTT
ACTTCACTAATATTGCCAAGTAATCAAGTGCTTTTTTTTTTGTATTTAAACAACCTTTCAATGAGTGGT
CTAATGTAGGTGAATTCACCTTCTCAATTAAATCACATTGTCTTTGAGGGAAGGCACATGTCTTGGA
CTATTTGCATCCATTCGCGGTTTTCAATTTCTAGACGCAAAATTGAACCTAAGCTGTATCAACATAATTTT
GTTCCCTTTCTAGGAAATTTGCTTGTGATTGTATTTGTGAGTTACTTTGGATCCAACTACATAGACCAA
AGTTAATTGGAATCGGTTGTTTCATTATGGGAATTGGAGGTGTTTTGACTGCTTTGCCACATTTCTTCAT
GGGATAGTAAGTGTAAAAAAGGCTCTGTGCCACTATCAGTACCTTTGTAATTAGGAGTAGAA
TTTTATTATTATCCCTTTAAATAGGCAGTTACCTTTTGAGAAGATACCCACTAAGTGTGTACAGAAATGA
AATAGTGTCTATTTGTCTACATAATCATTTTATTTATCGTAGCTTTTCATATACCTTGAAATAACAAAAAG
ACTAACTGTAGAGTTTCAAAATGAAATAAATAGGCTTTTTATGAATTTTTAGTATAACGTATATACTGTA
CGTCTTTGCCATATAAGATTTTGATTATTTTTATAAGACCTCAACACTTACACCTATACCCACTGAAGTA
TAGTTGTTCCCATCATTTCACTGAAGCTGTTATTCTAAGGTCAGTGTGTAGTTATAATTACAGTCAGAT
GCTCCTGAGAGAAAAGTTAAATGGCACATGGGGGAGAACTTATTTTTCACATTACAGTTAATGTAGCC
AGTTCAAGGATGATATGATTCTACCTCTTTCCATCATAGTGTCTATGCCCTGCATGGTCTTGGCTTCATGA
TCCAAATGTGGCAACGTATTTCCAGGCAACAAGATAGAAGAAGAAAGAAATAAGAAGCAACAAACAGTC
CACACAGGCTGAGGCTTAAGAAGCATTTTCAGAAGCAAAATATCTCTACTGACTTTACATTTACCAGATG
TTAGTTACATTTACACATAGATATATAAATGCTGAAAAAATAGACATTATTTCCAAGTTACCAAGTTCC
CGGTAAAAATCCCAAGTATAATTACTGTGGAAGGAAAGAAGAGAGGATATTAGGAGACAATGAGCAGTT
TCTGTTAGAGACACCAATTACTTACTCATTTGCCAAATCCAGCAATGACATCATTTGCTCACCATTATAA
TCCATTACCCACCATTATTTGGCCCTTATAGGAAGTTTCTTCTTAGTGGTACTGCTCTAGCTTGTTTTCA
TCATACTGCACCTCTTTGATTCTATTTCTATCTTTGTGTCTTCTTCATCATGTCCATTTTTTTTCATCTG
CTTTTGGCACCATACCGTCAGAGTCCTCTAATTTCTTTTAACTTTTATTTATGATTCTTCATGAGTTG
TATGGAAAATAAACCTTAAAGGCAAGTATCACAGCTTCATCTTCCATTCTACCTTAAATTAAGGACCAC
AATCTAGATCAGCATTGCTCTAAATATGCCATAATATGTGACACTTTTGCACCTGGTATTTCTACAGCCT
TGAATACCTTTGTTTCTTTGTCTACCTTCTATTCTATCTCCAGATTCTTTTACCCTGTCATTCTCATGT
TGATGTCTTCTCTGATCTATTTCCCGCAACCTCCAAGCAAAGTTGATCATATCCTTTGTCTTTGTGACAAC
TCAGGACCTTATATATTAACTTATAACTTTTATCATCTATGTTTATACTAGTGTGAAATTCCTAAGTA
CAAAAACCTGTGTGTTTTATTTCTAGCTCTTTGAAGCTTAGCATAATGCCCTGGAATACAGTAGGCTGCCTT
TAGAGCTCAGTGGTACCTAATTATTTATGGATATTAAATCTCTGTATTCTTCTATCAAGTTTCTCTCA
TCTAGTTGAATGGATTAGATTTTATTTTACTACATTTTGAAGAGTCATACATTAGACCGTGTGTGTGA
ATATGTGTCATGAAGAAAATCTGACAGACTGATCATCTTTGAAGATAATTCAAAAGGATGAATGGTTA
CACACAATTAATAATTACTTTTTAAAAAGGTGAACTAGGATATTTCATATCTTGACCAAGATATAACCA
CTCCTAGGATAATAGCAAGGTGATAACCCACTTAGCCTGGGGTGTATTGAATTATCTTTCTTGCTGGACA
CTTCCATTTCACTTTTACCCATCACATCTCTTAAACACATGCTGGGAAATTGACAGAAAGTACTCTGGT
AATTTGGGGAAGATAATGGTGCAAAATAAGGGGAATATTTCTCTGTATTTCTAGGAAAAGTGAAATATT
CAGTAGATAAGCAAAATGTTTAAATTCAGTGATGTTCTTACAGTTACAGGTATTTCAAAGAACTAATATC
AATTCATCAGAAAATCAACATCGACCTTATCCACTTGTTTAAATTAATCAAATTTTATCACTCAATAGAG
CATCACCTGAGATAGTGGGAAAAGGTAAGAATTAATATTGACAGTAAAAAGTCTTCTAAAAATGTATACAT
TTTGAATCTTACAGACATAATTATAGTGTAAATATACACAGTTTCGCCCATTAAACACACAGGTTTAACT
ACGCGTTTTCACTTCTATGCAAAATTTGTCCATCTGAACCTGGATGATAAACCTGCCGTAAGAATATCTG
ACATTTTCTATATTTGGATTGAACAGGGCCAACCTGCAGAACTTAAGTGTGCATGAATTTGAGAACACACA
GGCAGCCCTGTAACAAATTCCTTAAATATACCAAGGGATGACTGTATTATATGTAAGGATTTAGAAGTA
GATCAGAAAAGAGAAATATTTTCAATAGGAAATTGACAAAGAATATATGCATTAAAGTAAAAACAGAGGAA
ATGGTATAAATATGTAAATAATAAATTTGCTTTTCAATTGCAAAAGGCAAACTATATATCATTTAAAGA
CTTTTTGCTTATTATAACACAAATTAATAATTATAATTGCAAAATGTACTGCTAAAGATTTTTTTTAACT
ATTAAATAGAAAAGACTAAAAATACATAGAGACGAGGTAGAGGCAAAAAAGGATTTTACATTGTATATA
TTGCTGGAAGTGTATACGTTTGTAAATCTTTCTGGAGATTCAATATCAATATATGTTAAGAACAAAAATA
TACTTACCTACTTAGTCTGAAATCTGCTATTATTGATTAACTTTAAGGAAATAACCAGGAACTGCAAA
AGGACTTATTTACAGTTATAGTCATGATAAACCTAATAGAATAAAACAACAAAAAGAAATTAACATA

AGATACTGAATAAACACATTTGGAACTTATTCAGCACATTACTGTCCAGTCATTAAAGTTTTGATATTA
AAGAAATCTTAACAACATGGAAACAATTGTTATAATATGGTGTAACTGTGTATACCATTTAACAATATGA
ACTAGATTTTTAAATATATAATGGATATAATGAATATAATGTATATGTTTTGTGCAAACTAGAAAGATAT
ATAAAAAAGCTTGAGGTGATCTTCTGTGTGTAATGTGATTACAGATAAATTTTACTTGTGTTGTGCTTTTC
TGTATGATATGGCTTGACTGTGTCCCCACTCAAATATCACCTTGATTGTATAAATCTCCACATGCCAAGA
GTGGGGCCAGGTAGAGATAATTGAATTTTGGGGCGGTTTCCCCATACTGTTCTCGTGGTAATGAAGAA
GTCTCACAAGATCTGATGATTTTATAAATGAGAGTTCCCTGCAAAAGCTCTCTGCTGCCACCATGTA
AGACATGGCTTTGCTCTTCCCTCATCTTCCGCCATGATTGTGAGGCCCCCAGCCATGAGGAACATGAG
TCCATTAGACCTTTTCCCTTTATAAATTACCCAGTCTCAGGTATGTATTTATTAGCAGCATAAGAATGGA
CTAATACACCATATTGTCAAAGTTTGCAAAGTGAATATAAATTACTTGTACTTGTAAATTAATAAAAAAAT
AAGTAGAATAATTAAGAGTTTACAAGTAGTTAAATTTGTAATAGAAATGCTAAAAATTAATGTTTAAATG
AAACACTCTCTTATCTACATAGGTTGTTTAAAGGAATCTGGGTCTACATGTGGATATATGTGTTTCATGG
GTAATATGCTTCGTGGAATAGGGGAGACTCCCATAGTACCATTGGGGCTTTCTTACATTGATGATTTCCG
TTGTCTACTTTTTGAAATAGTAGAGTTACTAAACTTATTATTTTTACCCTATTAGAACATATTGTTGGGTATA
TGTATTGTATCATATTTCTTTTAAAAACATGGTGAATAAGAACCATGCATTCTTGGCATCTAGTAAATTT
GCTTTATAATATTTTCAGGTATATTGAATGCAATAGCAATGATTGGTCCAATCATTTGGCTTTACCTGGG
ATCTCTGTTTTCTAAATGTACGTGGATATTGGATATGTAGATCTAAGTAAGTACAACCAGAACAAGGTA
CCATGATAACGTCTTCTAAGCACACATGCGAAAAACATTTTTTCAATAACTGAATTCACTCTTTCAAT
AGTCCTTTTGCTTAATATAATTAGAAAGTTACAAGTAGGAAATAAATGTATTACTAATCAGAATAAATATA
AAATCCAGCTCCTATTTATACTATCTTTATAACTAAGTGTAAATGAGAGAAATGAAACAAATTTATTTT
CATGAGCTTGGTCCAAATAACCAAATGTAAATGTCTCCCTCCCAAACCTGACTGTCCAGTCAAGTAAAT
TTTATTTTTTCAGTTGATGGTGGCTTGGATGTTGATGTGTACAACCTAAAGTTTGCTTTTGCTAAAGTCTTC
TTGTGGCTGCTGCATTGATTTATGGCTGGAGTCATTTGAGAGACTTCAGTGTGTATTTTATGGTCATTTT
CCCTGGTCTTAGCAGAGGGCTTGGCGTATGGCAATGTTTCAGTAAGTACTTGTGAAACAAAGGAATAAAGC
AGAGGACACATAAATAAAATCTATGATTTTCTTCTTATTCTCAGAGCATACTTCCCTCTTATCTCATA
GATGAAAGAGATGCCATGTTATAAAACTGTCTCAACTTCAGGCCCTTTTCCCTAAAAATATTCTTGCAC
CATATCTATCTTTATCTTCTTTTCTTTTTCAGCTCAGTGGAAATATATACATCTGTATCCAATGTT
GATAGATCTAGCTGGAGCTTAGATTCTCCCTTCCGCTTCTTTATCTCCATCTTCTCTTTTATTTCAGCAA
ACACACCCAAGTATTTCCCATCTTTATATGTAGATACAGTTTTTTTATACCCCAACCAACTTTCCAGCTG
AATCCTTTTTTTTATTCTCTTTAGAACCAAGCACCTAGGAAATATCAGCTAAATTAGCTAAGATATCTC
ACCTTCTCACCTCCCATCCACTTCTAAATCCAGTATAATCTGCTTCTGTTATTAGTGAAACACAATCAAT
TTCTACCTACTTTACTATAGATTTGTAAATGGGTATATTTCTATCATTTTGCCTTAATTGATATTTCCAGT
GCTTCTTCATCCATTTTCCCTCCTTAGATATCTTATTAGTACCTAAAGCACAAATATGTCAAAATCTGATC
TCATCACCTTACCTCCAACCCCACTGTATTCCCTATATTCTCTCTTTTGTATGAATATCCATACCTTATTC
AATTATTGACTGAGTTACTGTGCCCTGTAATCTCACATTTCTCTGCATTTACACTTGGTAAACTTTTCC
CTCTTTTTTGGTTGTGAACCTGCTCTCCCATGCATCCAAAGCACTTGTGTTCCTCAGCTCTGGCCATTTCT
CCACTTTCCATTAGTCTCAAATTAATAGCCAAGAGCATGCCTTTATTGTAACCTTCTCACAATGAGCTA
TTAATATTTGTGTGCTTACTTGCCATCTCTTTACCACATGACAGAATGGCATGTTCTTAGCAAAATAATA
TTAGTTAAGTTTGTGAATAAATAAATATGATTTTCCACCTCATTAGGCCCTTCAATAGATCATTCCAAAGA
GATCAAAGGATTCATTTCCAAGATGGGATAGACATCACAGTGGGCCAGCAACAGCCAAAAACTTGAAAGT
GTTTGCTAATCTAAACTATAAAGAAAATACTTGATAAAATGTTTTACATGTTCAATTTTAGACATATGC
CTTAGAGTAGCTACACATTATGTACATTTATTTCTACTCATTCAACTCCAGTTTCATCACTGCTTTATCAC
GAAGAGTACAGAAATACGTGGTAAATGTCTTAGGTTAATTATTTTATAAGCTCTCTAAATAAGAAATTA
TTACATTATTTGAGAATTCATCACCATACAATTTCTAACATTGAATGTTTCAGATATCATTATATCTTCTC
TTATTTCAGTGATGAGTATGAGCTTCACTTACAAAGTATACTTTGGCAAACCTCAATGCCTAAAGGAGCTG
AAGACATAAAAAATAAATGAGTAAAGAGTGCCAGGAACAGGAATTTAGGGTGTGATGGTTAGAATAGGAGA
ATTCTTTTTGGTTGTGAACCTGCTCTCCCATGCATCCAAAGCACTTGTGTTCCTCAGCTCTGGCCATTTCT
TTTTAATGCACAAATTTAGGCCCTGCATTGGCAAGGACTTCTGATTGGTTTCCAAGAAAATCCAAACACC
AAAATTTTTGTGTAGAATTTTTCAATTTTTAAGACTGTGAGTGAGCCAAGAAAAACTTTTTCTCACGTCC
TATCTAGCGCGATTATGACCTTAGTTACTATGTGTAGAACAGTGAAAGAACAGAAAAAAGTCAATCAA
AATTACATTTGTACAGGTGATGAATAAATACTTTGCATGTAGATGGAGTCACTGATTTAACCAATCATT
TCCTGAAGTCTGAGTTGTTGATTATGACATGGTATGATCATATAAATCAAATTTAAACCCAGATCTGTGC
ATACTTGAAAATAATTATTTCTAGGTAGTTTGTATCAAGTCAATGTTATCTTATATTAGTGAGTTTTCT
TATAGATTAGAGTAATGGCACCATTAAATCGTGCCACAACTTCTGTGGTGTGTGTTTTCTGTATGCATAT
GCTTTTTTATTTCTTATTATTTTCTTTTATTATGGTAAGAACAATTAATTAATGACATCTACCTTCTTAAC
AGGTTTTTGAACATACAGTGGACCCATGAACAATAGGTTTAAATTTATGCTCGTCCACTTATGCACAGACT

TTTTTCAATAAATATATTGAAAAAATTTGGGGAGATTTGTGAAAAATTTGAGAAAAATTTATAGATGAATTG
CATAGTGTAGAAGTAAAGGAAACCCCTAAGAAAAAGGTATATCATGAGTGCATAAAGTATGTTTAGATACT
CCACTATTTTATCATTTTACTACCATAAAAATATACACAAATCTATTATAAGAAATTAACCTTATTAGAGGG
TACAAGATGGCCAACTAGACACACTCAGGAAGCACCCTCCACTGAGGAAGCCCAAAATATTGAATAAA
CTAACATACTTCGAGCATATCTTTTGGAGAGAAAACTGAAAGTCAATAGAGAGGTGACACAGACACTGA
GGCTGAAGAGAGAGAAAGCTGGAAACCCAGTGCAGGGTTGTTGAACACCAGAGATAGTTTCCAGCCCTGA
GTGGCTCCTAGCTAAGGGGTGAGTAAAGTGGCAGTGGGACAGCCTACTCTCACTGTTGACATCTGGGATC
CTACCTACAAGAGAACCCACGACCCCCAGAGACATTGGAACAGGCAGGGGCATCTGCCAGAGAGTAGGC
AGAAATAGAACTACAGCCAGCCTTGAACCCAGGGGGTTTTGCATGTTGGGTAGCTGCAGCAGAACCGCAGC
CATAGGCGCCCAACATCCAAGGCTCTCTTTCTTCCACCAAGTAGCTCTCAACTCACCTGACTTCTGAGCG
AAGAGACAGCGGGGCCAACTTTCTCTGTGAGCTGGGACACATCTGTATTGTAGGCCCTTCTGCCCGCCAGT
CCCTCCCAGTACTCCTGCCCTGGCCACACCTGCAAGAATATGTGCACAGCAGCCCTCCACTGCTCAGCCT
GAGGGTTTTTTCAAGGACCCCACTGAGTACTTCTCAGTATCCTTGGAGCACTTCAGATCCCCCAGTG
TAGCTAGCTTGGGAGTGTGAGCTGAGATTGGTGCCAGCACTCAAGCAGAGGAAGAAATTTGAAATCTCAG
AACACTGAGAGGGGTGAGATGCACGGGTTTCATGGGCCAGTGCAGAATGAGACATGCCCTCATTTTCATAGGC
CCAGTCCAGGAAGGCTGTGTCTGTCTGCCAGCTGCTGCCTCTGCCCTAAGGGAGCTCCATGGCTCAGAAC
AGTTTTCCTAACAAAAGAAATGCAAGTGTGGCACCAGTGACCAGAGCGGGAGATTGGGGGGGTGTCCCTA
TGGCCCCAGGCACAGGCCCTGTAAAGGGGTCTCTCTCTTGGCCGCTGCCACAAGCACTGTTGTAAACACA
CTGAAAAACAAAAGAGTTATGTCCCGAGTAACAGCTTATCTGCCAGCCATTACTCTTAAGCACCATTTA
CTGGATCACAGCTCAATTTAAACATCTGCCATATATATTTGAGACTGTACCTCACTCTGTTTACCCAGGCT
AGAGCGCAGAGAAGCAATCGTAGCTCACTGCAGCCTCAAGCTCCTAGGCTCAAGCCATTCTCCCACCTCA
GCCTTCTGAGTAGCTGGGACTACAGGCACACACCACTACACTTGGCTAATATGTGTTATTTTCTGTAAAG
ACAGGGTTTTCCATGTTGCCCAGGCTGATCTCAAACCTTCTGGCCTCAAGTGATCCTCCACCTTAGCCTG
GCAAAGTGCTGGAATTACAGGCTTGAGCCACTGTGCCTGACTTCAAAAATAGTTTGTCAATATACATTGC
ATATGAAACTGAGAGCAAGAATCTAGCTATAAATAAAAAATATTGTGCAGAGTCTTATCCCAGAAATTA
CCAAGTACCATACTCAACTTATACCACAGTTAAAGGAACACCACTTCTTCAAGATGAAAAAGAAATCAAC
AAGAAATCTGGCAATTCAAAAGTAAGAATGTACCTTAACCTTCAAATGGGTGCATTTGAGCTCTCCAGC
GATGGTTCTTAACCACATTGGAATGACTAAAATGACAGACAGGCAATTCGGAATCTGGATGGCAAGAAAG
CTCATTGAGATTGAGGAAAGTGCTGAAACACAATTTAAGGAATTCAATAATTCCAGTAGAATGATCCAAA
AGCTGAAAGACATAATAGCCATTAAAAAAACACTACTTCTGGAATTAAAAAAATACTACATGGATTGTA
TAATACATCCAGACCTTTAGCAACAGAACATACCAAAGAGAGAAAAGAA'TCTCAGAGCTTAAAAAACAGT
TTTTATAATCCACTCCATCAGACAAAAAGAAAAGAAAAAACAATAAAAAATGAAGAAAACTTCTAG
GAATTTGGTTTCTTCTGTAAAGAAACCAAGCCTATGATTTCATTGGAATTCCTGAGAGAGAAAAAGAGAG
AGTAAACAACCTTGTAAGAAAGTATTTGAGATATAGTCCATGAAAATATCCTCAAACCTTGCTAGAGAGATT
GATATGCAAAATTCCTAAATTACAGAGAACCCCTTTGAGATGCTATAAAGATGACAAATCCCCAAGGCATCT
ACTCATTAGATTTCCCAAGTCCACATGAAAGAAATAAATATTGTAAGATTTTTTTGGGGGCGCAGCATGA
GAGATGGATCAAGTCACTGTCAAGGGGAACCCCATCAATCTTGCAAGAACACCTTTGAGCAAAAAACCATAC
AAGCCAGAAGAGATTGGGGACCTATTTTCAGCACCCCTTAAAGAAAAGAAATTTCAACCAAAAAATTTAATA
TCCCACCAAAATTAATTTTGTAAAGTAAAGAGAACTAAACTCTTCTCATACAAGCAAAACATTGAGGAAAT
TTCTTATCACTAAACCAGCCTTATAACAGGTCTCTAGAAGAGTGCTAAACATGGAAACAAAAGATTAATA
CTTGCCACAACAAATACTCACTTAAATAGGTAGCCAGACACATAAAGCAACTATACAACCAAGTCTATG
AAACAACCAAGCTAACACATGATGCCATGATCAAAATCTCACGTATCAATAATAACCTGAAATGTAAACA
GGCTAAATGCCCAAGTAAAAGACACTGAGTGACAAGCTTCATAAGTAGACAAAACCTTAGCCTTCTGTTG
TCTTTAAAGACACATCTTACATGTACAATACCCACAGGATCAAAGTAAAGGAACGGAAAGAGATCTATC
CATGCAAAACAGAAAAACAAACAGGGCAGTAATCACTATTCTTATATCAGATAAAACAGACATTAAACCAA
AAACCTCAAGAAGGACAAAGAAGGGTATTACATAAGGATAAAGTGTTCCATTAAACGAGAAGACTTAAC
TATTCTAAATATATATATGCAAGTCAAAAGTGGAGGACCCAGATTTACAAAAAGATTCTTAGAGACCTAAGG
AAACTAAAAACAGACAGCCACACCATGATAGTGAAGACTTCAACAACCTCACTGACAGTGTTAGATATCG
AAGCAGAAAAATTAATATGTAATTTTGGACTTAAACTCAACTCTCAACCAACTGGATCCAAAAACATCCT
ACAGAATACTCCACCCAGCACATCAGAATATGCTTCTTCTCATCTGCATATAGATTGTATTCTAAAT
CAATCATATGCTCAGTCATAAAGTCTCAATACATTCAAAAAATTAAGATTTTGAAGTACATTCTTGAAC
AAAAGTGCAATAAAAAATAGAAATCAATACCAAAAAGATTTCTTAAACACCCCAAAAGTATGGTAATTCA
ACAAC'TTTTCTGAATAAT'TCTTGGTTTAAAGAAATGAAAGTAAACCGTTTTTGAACATTAAATAAATAGA
GACACACCTCACTAAATCTTTGGGATCTATCTAAAGCAGTGTTAAGAGGAAGTTTACAATGCTAAAGGC
CTTCATCAAGAAGGCAGAGAGATTTCAAATTAACAATTTAATTTGACCTTACACTAACTAGAAAAAAA
AGGACAACCCCAAGCAAAC'TGAAAAATAAATAACGAAAATCAGAATGAAATTTGTGATGCAAAATGTATAC

AAAAGATAAATAAAACCAAGAGTTTGTATTCAAAGAATACAAAAGATTAAATAGACTGTTAACTAGAT
TAACAAGGAAAAAAGGAGACCCAATTAAGCACAAATCGGAAATGACAAAGATCACATTACAACCTCCATA
GAAATGCATTACAAATGCCCTCTGCACACAAATTAGAAAATCTAGAGGAAGTAGAGTCATTCTTGGA
CAACCTCCAAAGATTAAACCAGAAAAAAGTGAAAACCTGAACAGACCGATAACAAGTTATCAAATTGAA
TTAGTAATAAAAAACCTACTGACCAAAAAAAGCCCTGGACCAGATGGATTCTCAGCCAAATTCTACTA
ATTCTAATTTTATTCTAACATAAAAGTTTCGCTTTTTTAAAGTTAACTTCAAATTTAAGCACAGAAACAC
ATATGTACCTCATATTATCTCATCTACAGTCAAGAGAAGTGAAAACAAATGTGAAGATGTACTATTAAAG
CATAACTTTATACAATTGACTGTAATATATACGTTACTGCTGTAATAATTCATAGCACCTCCTGTAATT
GTAGTAATAAGGTTGTGTTGAAAGCACCTGCTTAAACACCATGTGACACTAATTATCTCCACATGAACA
GTTCTCTCTCCAATAAATTGCGGATTGCAGCAAAATCTGATTGTGATTCTTGTGCGTTTTTATACTGTT
TAGTGCAATACTGTCAACTTTGAATAACACCGTTGGAGCCATATGAATTGCCACTAGTGATGCTGAAACT
GCTCCTAAGAACTGAGAAAAGTCCAGACATTACAAGAAAAGTTGTATTGCTTGATATATAATGCAGAT
TGAGGTCTTCAGCTGCCATTGTTTCAATACAAATGAATCCAGCATAAAGATCATTGTAAAAACAAAA
AAGGGAAAAAAGGAAATTCATGATGGCATTGCTGAGTCTATGCCAGCAGGCACAAAATCTTGCACTT
TTAGTAATATACCGTCTTATCTCATATTGAAAATGAAATTTGTTATATGCGCTGCAACTTTTATAAGAAAG
GCATAACCACAGACTTTAATGTGATTTGAGAAAAAGTGAAGTTATTATATGACCAATTTAAAGCAAAAGGAA
GGTGAGGGATCTAAACTGGAGAACTAATGCAAGCAAAGGATGGTTTGATAATTTAGAAAAATGATTG
GGTTTAAAAATTTTCAAATAACAGAAGCAGCAGCTTCTGCCAAATGAGAGAAAGTGAACAAGTTTTTCAG
ATTCCACTAAGAAAATCATTGAGAAAGCATATCTGCATGAGCAGGTTTTTAAATGCAGATGAAAGTGTCT
ATCCTGGGGAAAAGAAAGCCACGAAGGACGTTTATTAATAAAGAAGAGAAGTGAGCACCAGGATTTAAGG
CAGGAAGGGATGAGGTAAGTCTACTATTCTGTACAAATAAGGTCAGGCTTATTATCAAACTGCTAGTAT
CTACAAAGTTGATAAGTCCCAAACCTTGAAGGCAAAAGATAAAAATCAACTGCTAGTCTTCCAGTCATAC
AAAAGGAAGGTCTGAACAATTAGTACTCTTTTTTCAGAATTGTTTCCATCAATGCCCTTGTCTCCTGAAGACA
GGAAGTAGCTTGACAGTAAGGACTGCCTTTACAGTCTTTTTCATATCAGTCGATGCCCTGGTCACCTA
GAAAGCCCATAAGTTCAACATCAAAGGCATTGTAGTGATCTATTTCTCCACCACAACATCTCTAATTCA
GCTCTAGATCATGGAGTCATAAGAACTTTAAAGGATCATTACAGATGATACCTTAACGAAAGGATTAT
CAGTGCTATCAAGAAAATCCTGTATGGCAGAACATCATAAAGACTAGAAGAAATACACCATTAAAGAT
GCTATTGTTATAGGGAAAAAAGTGAAAAGTCATTAAAGTGCAAAACAATACATTTCTACCAGAGAAAA
TTTTGTTTCAGATGTTGTGCATAAATTCATAGGATTAACAACATGGCCAATCAAGAAAATTATGAAAGAGA
TTATGGATATGGAAGAAAAGTGAGGAGTAAAGAATTTCAAGATATCGGTATTGGAGAAAATCAAGAGCT
AATTCATACCTCATCAGGGAAGTTAACAGAAGATGACCTGATGGAGATGAGTGCTGCGAAGTGTGTCA
GATGATGGGGAAGGAGACATAGAAGCAGCAGTGCCAGAAACAAATTGTTATTAGGCAATCTAGCAGAAGG
ATTCTGATAATTCAGAGCTGTTTTTGGCTTCTTTTATAACAGGGACTCTTGTCTAATGTGGGCACTGAAA
CTAAAGCATGTGTTGGAAGAAGGATTAGTTCCATTTAGAAAAATTTTATAGAGAAATGACAAAACCAAAA
GTCAAATAGAAATTATGGCGTATTTATGAAATAGTTACTGAATGTACTTGCCTCTTTTGCCTTCCCTCTA
CCTCCTCCACCTCTTCCACCTCTTCTACCCTAGTGAAAGCAAGACCAGTGCCCTCCCATTCCTTCTCCTCC
TCAGCTTACTCAATGATGAAGAGATGAGAAAGATCTTATGATGGTCCACTTCAACTTAATAGTAAATATG
TTTATCTTCCCTGTGATTTTCTTTATAACATTTTCTCTAGCTTACTTTATATTAAAGATATATATAT
AATACATATAACATACAAAACATGTGTTAATCAACTGTTTATGTTATTGGTAAGGATTCTGATCAACAGT
AGCTGGTATGATTTGGATCTGTGTTCCCGCCAAAGTCATGTAGAATTGTAATCCCCAATGACGGAGGTGG
GGCCTGGTGGGAGGTGATTGGGTGATAAAGGTAGTTTCTCATGAATAGTTTAAACACCATCCCCCTTGATG
CTGATCTCATGATACTGAGTGAATTCATGAGATTTATTTGCTCAAAAGTGTGTAATACCTCCCCCTC
TCTTCTTCTGTAGAGACTGCAGAACTGCATAACTGAACTTTATACCCATTGACTAACAACCTCCCTGCT
TCCCCCTCCCCCTTAATCACTGGCAATAACCATCTACTCTTTGCTTCTGTGAGTGTACTGTTTTATGTT
CCTCACATGAATGTAATCATGTAGTATATGTCCTTCTGTAACCTGGTTCATTTTGCCTAATGTCTCTCAAAG
TTCATCCAAGTTATCACATATTGCAGAATATCCTTCTTTTTAAAGACTGAATAATATTCATGTATGTC
TATACAATATTTCTTTATCCATTTATCCCTCAGCAGACATGAGGTTGTTTTTACAGCTAGCTATTATGA
ATAGTGCTGCAATGAACGTGCAATGCAATGGTCTCTTCAAGATAATGATTTCAATCTTTTATATATG
TACCCAGAAGTGGGATTGCTGGGTCTATGAGAGTTCTGTATTTAATTTTTGAGGAATCTTTATAATACC
TTTTATACTGGCTGTACCTTTTTGTATTCTACCAGCAGTGTACCGTGTTCAAATATCTCCACATTTCTGC
AAACACTTTCTTTCTTAAATGATAGCCATTCTACAGGTGTAAGGTGTAGGAAAAGAGTGGAGTTGTGCTT
TTGATTTGCATTTCCCTGATATGCAATGTGAAAATCTTTTTATTGACCTGTTGTTTCATTTGTGTGCTT
CTTTGGAGAAATTTCTATTACAGGTATGTAGCCTAATTGTTTTTCAAATTAATTTTTTTTTTTTGAGTCA
CTCTCACTCTGTCAACCCAGGCTGGAGTGCAGTTGTGTGATCTCAGCTCACTGCAATCTCTGCCCTGCCAGG
TTCCAGTGATTATCCAGCCTCAGCCTCCAGAGTATCTGGGATTACAGGTGCCCTCCACCACACCTGGCTAA
TTTTTGTATTTTTAGTAGAGATGGGATTTACCATGTTGGCCTGGCTGGTCTCAAACCTCTGACCTCAGG
TGATCCAATTTGTCTTGGCCTCCCAAAGTGCTGGGATTACAGGTTATCAGCCACTGACTGACATATATAA

AATTGTATTTTTATCATGTACACTCTAATGTTTTGAAATACATATATAAGTGGAAATAGTTAAATTTAGCT
AATTAACAAATGCATTATCTTACATAGTTACTTTTGTAGTGGAAACACTTAACATCTACTCTCTCAGCAT
ATTTCAAAAATACAACATATTGTGGTTAAGAATAGTCACCCCTGCTGCATAATAAATCTCTGCAATTTTTT
CCTCCTAATTGTAAATTATGTATGCTTTGACCAGTATCTCCTCATGTGGGAGATCAGTCAGAGTGGTGGAA
GAAGCTATAGGGAAGGAAGCAGGCCCTTTAGAAAGGTGAGAAGGCCTGCAAAACTTCAGGGGAGACTAAG
CTGAAGATAGCTGTTCTCTTACCCTGAGGCAGAGCACAAGAAATAGGTATTAAGGAAGTATAGGGGAATTT
ATCTAAATAGGCTTGTCTACCCATGTTGTCCAGAACTGACCTTTGACCATCCGTACACGTGACTGTTCC
CAGTAAGGGGGAACAATAATGTTAATTACACACAGATTGTGTTGGCTCCAGCCTTTCGGCATTATGTCTG
TACTAAATAAAAGTGAGCAGCTCCAGCTTGTGGGACTGCTACTCACTCTTTGGCAGTCCCCTAGCCACT
CTTTACCACATACCTGTGTCTGAGTACTCCTTTTCATCTGTTGGTAGGCCAGGGTCTACCAGGATGGACC
AGGCATCCTCAACTCCACTGTTCTCCCAACCACCTGGCTTCTGGTAGCCACCATTCTACTCACTAATAAC
TAATTAATTTTTATTTCAATAGCTTTTGGGGTAGATGTTGTTTTTCGTTACATGGGTGAATTCATATAATG
ATAAATTTTGATATTTTACATACCTGAGTAATGTACATTGTACCCAATATGTAGTTTTTTATCCCTCAG
TCCCCTTCCATCTTTCCCTTCTGAGCCTCCTAAATCCACCACATCAATCTGTATGTCTTTGTATCTTCA
TGGCTTAGCTCCCAATGATAAGTGAGAACATACAGTATTTGGTTTTCCATTCCTGAGTACTTCACTTAG
AATAATGTCTCCAGTTCCATCCAGTTCCTGCAAAATTTTTTCATCGTTATTATTTTTTGTCTATTGAGT
TGTAGGATTTCCCGGTGTGCTTTAGAAATTAACCCCTTTTCATATATAAATGATTTATAATATTTTTATTT
TATTTCTGCATATTTCTTTTTTACCCCATTTATTGTCTCTGTTCTGTTCCATTGGTCTATATTTCTGTCTT
TATGCTGGTACCATATTATTAATTACTATAGCTTTAAATACATTTTGTAAATTAGGAAATATGAGGCA
GCTTTATTCTTTCTCAATGCTTTTTTGGCTATTTGATGTCTCTTCTGGTTCCATATGTATTTAGAATTG
TTTGTATATTTTTTGTAAAAATACTATTTGGGCTTTTGATAGGTATTGTATTGAATCTTTACATATATTTG
GGTAGTATGGACATTTACTATTAATAAGTCCCTCAATTATTAACACAGAATGTCTTTCTAATTTATTTATG
GCTTCTTTATTTCTCAGTGTCTTGAAGTATTTTCATGCACAAGTCTTTCACCTCTTAAATTTATTTTTG
TGTTTTATTCTTTATGATTTTAGTGTAATGGAATTGCTTTCCTAATGTCTTTTCAAATAGTACTTGGTT
AATTCATAGAAATATAAGTAATATCTTATAATTATTTGTATCCTGCAACTTTACAGAATGTGTTTATTC
AATTCATAACAGGTGTGTGTGTGTGTGCATGTGTCTATCTTTAGGGTTTTCTATATACAAAATCATGCCATC
TGCAAGTAGAGGCAATTTTACTTCTTTCTTTCAAGTTTGAATGTCTTTTATTTCTTTTTCTTGGTTAATT
GCTCTGGCATAAAATGGCAGGACTGTGTTGAATAGAAAGTGTAGAGAATGGCCATTCTTCTCTTTGTTCTCTG
AAAGCTTTCTGTTTTTCACTCTTGAATTTAATGCTAGCTGTGAGCTTTTTTAAATATGCACTTCATTTTGT
TGAGGCAATTTTTATCTATTTCTTAGCTTGTGAAAGTTTTTATCACAAACATTGTTGGATTTTATCAAA
TGCTGTTTAAACATCTGCATATTTGATCATGTAGATTTTGTCTTTTTTTTGTAAATGTGTACATTACGCT
TGGTGATATTTGTTAAACTTAGCATTTTCAAGTATAAATCCCCCTTGAATATAGTGTAGTATCCTTTTTAT
ATGCTATTAAATTTGGTTTACTAGTATTGTTTGAAGATTTTTCTCCTCTGTCTTCATCAGATATATTGGTT
TGTAAGTATTTCTCTCTCTCTCTCAATTTTGGCAAGAGATTGGAATGGATTGCCATTAATATTTCTTTA
GCTATTTAGTAACACGCACCAGTAAAGCCATCTGGTCTTAAGTTTTTGTGAGAGTATTTGATATTA
ATTCAATATTTTTTACTGGTTGTAAATCTCTTATATTTTCTATATTTTCTGTGTTTTTATGTTCCAGGAA
TTTTATTTTTTCTTATCTAATTTTTTGATGTATAATTTCTCATAGTAATCTCTTATGATTTGTTTTATT
TTTTTAGCATCAATTAATGTCTCTACTTTTCAAGCTCTTATTTTGTGTTGTTGAGTCTTTTCTCTTTTGTCT
TAGTCTAGTTTAAAGTTTTGTCAATTTTGCCTCTCTTTCAAAAAGATCAACACTTAGTTGTGTGATATTT
TTTTCAATGTTTTTTTTTCCATATTTCTTATGATTTATTTCTTCTCTAATCTTTTTTCTCTCTGCTAA
CTTTGGCCTTAGTTTGTTTTTCTTTTTTATAATTTTGTGAGGTGTAAATAGGTTGTTAGTTTAAAGATAAT
TCTTTACTTTTTTACTAGCATAATTATGTGATATTTATCAGTGTGTACTGAGAGCAAAACATGCCAGATGC
TACTAGTGACCATAAATTAGAGAAATAACCTATGTTTTTGGATATGGAATGAAATTTACCCATACAAAT
GTAGATATTTTTTACTGAACACTTCTCTTACTACTGTTCTTGTCTGCATCTCACATTTTGAATGTTTTG
TTTTTGATTCTCTTCGTATCTAAATATTTCTAATTTCCCTTTTGATTCTTTTGACAAATTAATATTGA
AAAGTTGTTAGTATCCATATTTTTAAATTTTCTACTTTTCTTTTTGATACTAATTTCCAGTTTTTATTC
CATTTGATTTAGAAAAGATAAATGGTATGATTTAATTTTAAATTTATCAAGACCTGTTGCATGATGTAA
CATGTGGTCTATCTTAGAAAATATTTCCATTTCTATTTGAAAAGAATATACATTCTGTTTTTATTGAGTGA
AGTATTCTCTATGTGTCTGTACGTTCAATTTGGTCTATAATGTTGTTGAAGTCCCTGTGTTCTCTCATTGA
TTTTCTCTCTAGTCATTCTATTTATAATTTGAAGTGAGATATTATGAAGTCAGCCTACTATGGAGGGCTA
ACTGTAATACACTATTTTATATAAGAGACTGGAGCATCCTTGGATTTTGGTATCCATAGGGAGTCTCTAGA
ACCATTTGTTTACAGATACCAAGAGATGATTTTATGTATTTCTCTATATTTCTCTTTTTCAGTTCTGTCCA
TGTTTGCTTTATAGCTTTTGGGTCTTTGAGATTGGGTGAATATATTGGGTTGTATATTTCTTGGTGAATTA
ACTTAAAAAATCATTTTTATAATGTCTTTTTTGCACCTTGAGACAGTTTTTTTACTTAACTCTTTTTCTTT
CTTTGACAAATAGTTAGGTTGCAAAATTTCCAACTTGTATGCTCTGCTTCCCTTTAAATATAACTTTC
AACTTTAGGTCATTTCTTTGCTCTCATATCTGAGCATTCATGTTAGAAGCAGCCAACCTATATCTTAA

TGCTTTACTGCTTAGAAATTTCTTCCATCAGATGTTCTAAGTCATTGCTCTTTTTTTTATTTTGGAGAC
AGAGTCTCACCTCTGTGGCCAGGCTGGAGTGAGTGGTGCGATCTCGGCTCACTACAAGCTCCACCTCCC
AGGTTACACTATTCTCCTGTTTCTGCCTCCCAAGTAGCTGGGACTACAGGTGCCACCACCGATGCCTGG
CTAATTTTTTTGTATTTTTTAGTAGAGATGGGGTTTACCGTGTAGCCAGGTTGGTCTCGATCTCCTGAC
CTTGTGATCCACCCACCTTGGCCTCCCAAAGTGCTGGGATTACAGGCGTGAGCCACCGTGCCCCGCCAAG
TCATCACCTTTATTTTACAGACTTCCACAGATCCCTAGGGTATGAACAAAATGCAGCCAAGTACTTTGCC
CGACACCATGCCCGCTTATTTTGTACTTTATTAGTGGAGACGGGGTTTCTCCATGTTGGTCAGGCTGGT
CTCAAACCTCCCGACCTCAGATGATCCACCCGTCTCAGCCTCCCAAAGTGCTGGGATGACAGGCGTGAGCC
ACCGCGCTGGCCTATTTTATTTTCTATAGCCTCATAACAGAGGTGAGACTAGTGATTTTAGAGCCACAC
TTCCTGGCTTCTGTTTTTATTTATTTAATTATTTATTATTATTATTATTATTATTATTATTATTATTATT
TTGTTTTGTTTTGCTAAGGCATAACAAGAGTGACTTTTGCTCTAGCTCCCAATAACTGTCATTTCTATTT
GAGACCTTTTCAGCATGAACCTTCATTGTCCATGTCAGATCTGCATTTTGGTCATAATCATTTATCAGTT
TCCAAGAAGTTTCAAACCTTCCCTTCATTTCTTATCTTCTCTGAGTCCCTCCAAGCTCTTGTAAGCTCTG
CTCATTACCTAGTGTCCAAAGTCAAGTCCACATTTTCAGGTATCCTTATAGCAATGTCCCACTTCTTGGA
ACAATTTCTGTGTAGGCCATTCTGGCATTCTTACACAAGAATGCATGAGACTGGCTAATTTATCAGT
AAAGAGGTTTTAATTGGCTTATGATTTCTCAAGCTGTACAGGCATGGCACTGGCATTATCTCAGATTCTGA
GGAGACCCCAAGGAGCTTTTACTCCTGGCAGAAAGTTAAAGCAGGAGCAGGCACATCAGATGTTGAGAGAA
AGAGCAAGGGGGAGGCAAGGTGCCACACACTTTTTAAGCAATCAGATCTTCTCTGAGAACTCATACACT
ATTGCAAGGACAGCACCAAGCAATGAAGGATCAACCCCATGACCCAAACACCTCCACCAGGCCCTACC
TCCAACATTGGATATTACATTTTACAGCAGGAGATTTGAACAAGACAAATACCCAAACCATATCAGCCTCCA
AGTCTTCATGGACTGGTATTTGTTATAGGAGAAAACCTTTCTTCATTCAACCCAGCAGAGCGTCTGTGGGCC
TCTCAAATTTTGATTCTTTTTTAACTGCTATCTTTTTGTTAGGAACCTTTCAGAATCTAGAGTATGTAGG
GTCTCATGAGCACTTTTAGACAGTGGACAGAGAAGCCCGTCACTTGGTCAACTCCCAAGAAATTTTGAAT
ATTTACATGCTATCCAATTTTTTCTTCCCAAGGAGAATTTGAAAACGTAGGTGTTTTCTTTGTTTTTT
GTTTGTGTTTTGTTTTTCTTTTCTTTTACCTCCTCACTCTGCATAGATCTGGGAGCAGGGAGGAGCT
GTAGCAAGTGCTCATGTGCTAATTTAAGCCACCATTTTTGTGCTCTTTGTAGCCCATTTGGAAGCAAGCAT
ATGCCTAGCCCCAAGATAGGCAAGACAATGACAGCTGCTGGAGTTGGACACAGAAAAGATGAAATGTTA
GGTTTGTGGTCGAAATATTTCCCTCCCCATAGAGAAGCTGGAGTTAAGTTTTTGTGTTCTAATTTTTTTA
ACTTGGTCATTCTGCCCTAAGCTATGGGCCAGGAGCTATGGGAATGCTTACATACTAGTTCAAGCTGCCT
TCTTTATTTTCCGTAGCCTCCAAAGGTCTGGTATATGCTGAGTCTGTCAACACTTCAAGATAGGTGATA
TAGAAGACAGTCGCAAGGGTAGTACCTGAAAAGTTACAGTTTTTGGATGTGCAGTCTCACTCTGTCTCTCC
ACAGGGATAAGCTGGAGATGCAGTTTTCTTACATTCAAGTCTATGTTGAGCCAGGGAATAGAGCTATTGCA
AGTGTTCATAGGCACCTTGCAAATTTCTAGTTCCTCTTGAATGCATGGTATTATAATGAGGAGAGGAACAG
CAAAGAGGTGTCTCCAATTTTCTTAAAGTGTCATGTAGCTAATATTGCACCTCCCTGGGGTACAATGG
CCTGTCAACTAGCTTCTGGATTTTCCACTAATGGAATTGATCGCTGTATAATTGTTGAATAAAATATTGT
TGAAAGAAAAAAGGGTCCAGTCCCTTCTTATAGGCTATCTTGCTGATAACTCATATTGGCTTTTTTTAT
ACTTAGATTGTTTATTTTATACCTGTAAAGAGTGCACTTTACACTTGAGATATAGCATTTACATAATAC
TCTTATTCATGATTTTAAAGAAAAATATGACTGAAATAAAATGGTTAAATTTATCCTTAACTTTTAGAGTCT
AACTCTTCAGGGTTACTTTTTAACTCATATTTTCACTGTATTTTCTTATCCTCTGTGCTGTCAGGAGAGT
TGGAAATGCTTATTTTACGGCATGGTGGGAAGCCCTTTATTGACTCAGTAGATTCTTGCAAACTGCTAA
AATTTCAATTGCTGACCCCTTCTTGATTTTATTAGCTTGTGCCAATAGACATTTTCAGACAACATGAGAC
GTCATAGTTCTTCCACAGGTAGTAATTAACAGTCTGCAAGCTTAAATGTCCAGTGATAGAACTGTCCA
GTCATGTAATCAGAAAAGCCATCAAGTGACACACAAGCTCAGGCAATGACAACAATATCAGACTGATTCC
TAGACAGTATCTGTTGCATTATGTCATCAAATGTTAGACTGATCCTAGTCTCAGAGATGACAAAAAATTA
AAAGAAAAAATCGTGTCTTGGAAATTGAGGAAATGTAGTTTACTTTCTTCATACCATTTATTTCCCTGAAC
CTATTGTATTTCAAATGATTTTGGACTGGCTTCTATAATTATTTATTTCTAGGCATATCAGGATAACTC
CTACTGATTTCTCGATGGGTGGAGCTTGGTGGCTTAATTTCTTGTGCTGAGCTATTCTCCATTATTTCT
TTCCATACCATTTCTTTTCTGCCCCAACTCCAAATAAACCACAAAAGAAAGAAAGCTTCACTGTCT
TTGCATGTGCTGGAAACAAATGATGAAAAGGATCAAAACAGCTAATTTGACCAATCAAGGAAAAAATATTA
CCAAAAATGTGACTGGTAAGTATTTAACATTCATTGTCAATTTGGAGTTGTTAATCTCAATGAAAAGGAA
GAATGAGTATTTCAAATAATAAAGCATACCCAACTCATCTGGAGTTGGCTTTCTTTTGCCTAAATTTA
GATAAATTATTTTCTAAACTCCTATTAAAGTTAACATATATGTCTTGAGCACATAACAAGTGAAGAG
AATTAGGTTTGTACTTTTTTAGCAGGGAGAAACCAACAAAAGTTTACAAACATCCATTTTTTATGAGCCAA
ATAGTAAATATTAATTTTAGTATTATATGGTCTAAACTGGGAGAGTTCAAAGAATTATAATATTTTCAATC
CTTCATTTATTTCAACAAGTAGTACCAGGAACGTACTATGCCCTGGTAATAAAACATTACCTCTATTTTT
CAAGAACCTAGTGGGTGATGCTGAGAAATATATAGACAATAGCAATATAGTGCTTAAGTATTATGGTGA
AATTAACTTAACTATTATCAGGTGTAGAGATGGATTAAGGAGAAGGAAGTCGGGAGAGTTTCTCCCTA

TGTAATTAGAGTAATATTTATTTTGGTAATTATCTATCTATCTATCTTATCTAAATATTCAAAAATAAAGT
GGAAGCAAAGGTGGTAGTTAAGATAATTAGACTAAGTAATGTAAATTAGGATGCATCAGCATTGACAGT
GCCTCCTCTTTTGAATATAAACCTGGGACTAATGGAGAACCATTGAGAGTCAATAAACAAAGAGAATGA
CTTGGCAGTAGCCAGAGCAAGATATGTGAATCAGTGAGGTGTTGACAGCAGTTTTCAGATTTGGGAGAAA
TGGTGAAATAGCCAAAGCAATGCAACACTTAAACCCTCAGCATCTTTTCAAGTTTCTTTAAAGTAAGA
TGACAAATTCTCCAGTGTAGCCTAGGTTCTTCTTTTCATCAGGTCCTTTACTTATTACTTTATTGCTATT
TTCTCCTTTCTATCACACTAACCCAGAGCAGTGGTGTCTGGTACTCTTTATATTGGCTCATAGCAGAG
GACTGTTAAGTTTCAGCTACATTTGGTAGGTTGAAATTGTTTCATGGCAAGAGAATTACCATGATTTATTAC
CATGGAAATTGGGATATACCTACAAGTAGAAGTTTGTCTTCTAAGAATCAGATGTTAAACATTTATGTTT
TTAAATTTAAACATTCACACTAAAAGTACTATACCAATAATTTTCATTTTGTATATGATGTTTCTACTGT
ACCAAATCAAATCTTTAAAAAATAGTAGATTGTCTAAACCTATAAGGAGCGGGGTTGACTGTGATCCAAA
CAGAACAGAGAGGATAATGAAGTTGTAAAAATAGGACAATTGTAGACATAATCTCTATTATGAACAGTTT
TTGTAGGTGTGACCCTAAGAAAGAGGATCTTAAGTATGTATCTATTAGGAATGGATAAAAAAAGAATATA
TAGTCAGAAAAAATATTGAATTTATTCATATGCTCTTGAATAGAACTAAAAGTGAATAGAATGAAAAGA
TGATTTTCAGTTTCATTACAAAAACAGTGTGTAAACAATGAGAACTTTTCAAAAGTGGAGGAAATGCTTCC
TAAGGTACTTAGTTTAATGCCACTTAAGTTGTTTATTGATCCACTTATTAATGATATATAGTAGATCATG
ACTATACAGAAGTTTACACTGGATGACATTGAATTTCTCATCCTCAAAAAATGCAACGCTTGTGTGAATGT
ATATACTCCATTTCTGTGGAAGAAAGGCCACAACCTCACTTATAATACCTACAAATCAGGGATGGTTTTTC
ATGACTGGGGAGACCTGTGGAGAGAAATGTGGCACTTTTGGCCAGAAATTTAAATGTTGTTTATTCCCA
CTATACATTTTCTTATCTCTTCTTTTCTTTTCTTTTCTGTTTCTTTTCTCTAACTCCTTCTACTCCTTATTT
CAAGCAGATGCAACTGTTTCTGTAGCTGACATTAAATGGATGTCCTAGTTCTGACCATATCTAATGAAAAT
CTTTAGAGATTTAATAGAGAAAAATATTTCAAAGTCCGTATCATCCAACCTCTCAGTAACCATATCTTGG
CTCTGTCTTGATGAACCTCTGATACTTCTACTGTTTTTCTAAGTAGTTCCCTTCTACTTTTAAAGTCTTATT
ACAGCTAGTTGACCTGGTGTATCAGATCCAAATGACATAATTTCTACCATGAACAGAGTTAGAAGTTT
GTTACCACAGCTGTTTGTAGGGATAGGTGGTTGTATTATTACTATTATAATACTACTTGGGACACAATAT
TATCCCCTGGCTGCTTCTTCTGTTATCTTAAGACAGAGGGTTAATAATATTGCCAAATTTACTGAGAAAGT
ATGTTATGGTAGAAGAGCTGTATACTAGAGAAACAGGAGGCTCTGAGTCTCATACTAAATTAATCTTTAA
GAATTTTGAACCTCAATGGTCTTATTTCTGTGAGTTTTGAATTATGCTGTCTTTACATTTCCATTTAATA
GTTATATTTTTAATATAATACTTATATCATTAAGTACTAATAAATAAGAAACATCATATGTCTTATTAC
TTTTTGTGTTGTTGTTTTTGGGTTTTTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG
CTCTATTGCCTAGGCTGGAGTGCAGTGTCAACATCTCAGCTCACTGCAACCTTCGCCTCCCTAATTCAG
CAATTCCTGCTGCCCTCAGCCTCCCAAGTAGCTAAGATTACAGGTGTGTGCCATCGTGCTGGCCAATGTTTG
TATTTTTAGTAGAGTTGGGGTTTACCATGTTGGCCAGGCTGGTCTCGAATTCCTGACCCAGGTGATCC
ATCTGCCTCGGCCTCCCAAGTGCTAGGATTACAGGAGTGAGCCACTGTGCCCGGCCTTCACTTTTGT
TTTGAACAATTAGCATATTTGCTGGTACCCAGTTGAAAACCTAACATTTGCTGAATGAATGAATAAGTGA
ATTAATATGTTTGCATAGTATTGTAAAGTACCCAGGATAACCAATATTAAAGTGAAGAAAGCAAGTTAC
AAAACAGCACTTACGTATGACCTATTTGAGGGTAAAAATAAACTAACTAATAAATATTAAATATCGTAT
GGAAAATATTGAAGAATATATTTAAAGCTGTGAACAGCCTGTGGTATTGTCAGGCTATTTCTCACTCTTT
GTGTTATGTGTTTATAGAATTTTAAATCTTACATGACTTACGTTCAACAAATTTTAGATATAAATGTATAT
TTAAGTTGCATTCAAATATTTCTTTATTTTTACAATTTTACAGGTTTTTTCCAGTCTTTTAAAGCATC
CTTACTAATCCCCGTATGTTATGTTGTGCTTTTACAGTTGTTACAAGTAAGCAGCTATATTGGTGCTT
TTACTTATGTCTTCAAATACGTAGAGCAACAGTATGGTCAGCCTTCATCTAAGGCTAACATCTTATTGGG
TAAGACATATTTTTTACTTGTGTGCTTAATAAGTGAAATAATACCTAAATACGTATTTCAAGTGGTATTT
TATTGTGAAAGTGATTTTGTATTTTGTAGTAATACAGGATAAGTATAATTTTCTTGTATTCTTTCTCAAATG
TTATTAAACATATAAACTTTGTGATGTCACTATTGCTCTGCATTTGAAGTTGCATCTTATTTTAGATGAG
TTCCTGAAAAAATGTTGCAATAAATGGACAATTTAGAGGTAGTATCTGTATAATGGATCTTATAATT
TAGTGCTAAGATCTGAGACAAACCCTTTGTAATTATAATCATTATAATCTATAATTTATGGACTTTGA
AATCAAGACTCAGTTACTTACAAAAATATGACACTAATAGTTCCAAAAAGAGTATCGATTTAAATACATC
AAAATATGCATAATTTCAAAACAAATATATTTTACAGAGTATTTTGTGCTACAATATCTATTTTCAATGGC
ACATTTAGATGTGCTTATTAAGGAAAGTTTCTTGTATTATTCTTCCCACTCTAGTATTGTAGACAC
ATTATAGAAATTCATATAAATATATGATGAATTAACAACCTTATCATGTGGTATGTAACAGGTGATAA
GTAAACAAGAAAATGAATGTACTGAAGCAGGAGACCAAGCTTCCAGATAATCTCTTGTGATCTTAAGA
TAAAAGTTTAAATCGAAAAATAATGTTTGTACTCCAGTAACCTAGCCTGAGCTTTTCTAGAGAAGA
CTTCATCTTTGTTAACTCTTTATAGACAAAGATATGGAAAAGTTATAGGAGGGATTAAACATTATTAATC
CTGTATGTAGAGCGATTTGTCTAGTTTCAAGTTCTGTATGTTTTTAAATAAATGACAAAGATATATTAATTT
TTATGTTGTTAAGCTCTGGGCAGATTTAGTGTGAGTTACTGAGGGTTAGAACTCTATCTGAGAGAGGCAA
AAGGCTTTAGATGAAGTTCCATAGGCAGAAAGATGGTGTGTTTGTGTTGTTTATTTCCAGAAAAACAAA

TTGCCTCATAGAAATTATCTGCTCCAACAAATATCCTCAGCCACACTGCCCTTTTGTATTGAGGAAACCA
AACTGTCATCATTGGCAGGAACAAATTACACAGATCCCCTACCACCATACTGCTATATCATTCCTTCTTTT
TAAAAAGTAATAAGATTGGCATTCTACTATAAAGATACATGCACACATATGTTTATTGCAGCACTATTG
CAATAGCAAAGACTTGGGAACCAACCCAAATGACCACCAATCATAGACTGGATAAAGAAAATGTGGCACAT
GTGTACCATGGAATACTATGCAGCCATAAAAAAGAATGAGTTTATGTCCTTTGCAGGGACATGGATGAAG
CTGGAAACCATCATTCTCAGCAAACCTAACACAGGAACAGAAAACCAACACTGCATGTTCCCACTCATAA
GTGGGAGTTGAACAATGAGAACACATGGACACAGGGAGGGGAACATCACACACCGGGGACTGTTGAGGGG
TGGGAAGCAAGGGGAGGAAGAACATTAGGACAAATACCTAATGCATTGAGGGTTAAAACCTAGATGACA
GTTTGATAGGTGCAGCAAACCACTGGCACATGTATATGTATGTAACAAACATGCACATTCTGCACATG
TATCCCAGAACTTAAAGTAAATTTTAAAAAGGAAGCAATAATATTGAATAAATTTGATTGACATACATTG
TGTTTCATCTATAAAGACATATCAGAAAACCTCATATATGATTACAACCTTTTTTTCTTTTTTCTAGGAG
TCATAACCATAACCTATTTTTTGCAAGTGAATGTTTTTAGGAGGATATATCATTAAAAAATTCAACTGAA
CACCGTTGGAATTGCCAAATTCCTCATGTTTACTGCTGTGATGTCATTGTCCCTTTTACCTATTATATTTT
TTCATACTCTGTGAAAACAAATCAGTTGCCGGACTAACCATGACCTATGATGGGTTTGTATATATCACTA
TATCAATTGCATAATATGTTAACCATCAAATTAAGAGTCTCTGTATAAGTAATAAAGGCAGAAAAACAAT
TTTAACTAACTTTCTTTAAGTTAAGAGAAATTTCAATTTTAAATTTTAAAAATATCTGTTTCTTAAGA
CCTCAAACACATTCTTTTATTCCTCCACTAAAGAGAAGCAACATAGGTTGTAATAATAAATACTATTATT
TATGTGGTACTTACAATTAGTAGTGGGTACTTTTATCATTATTTTATGAATGGGAAAAGTAAGGCTTAGA
GAAATACATGGATTACACAGCTAGCATTATTAAGATTCTAACTCAAATTTGAGTTTAAAAAGTCCAAAAC
TCTTAGTCTTAACCACCACCTGTAATCTTGATGGATCATAAGAGTTACATAAATGGCATTAGCCAAAAGT
GACTAAACAACTTTTATCTACAGTTTATATCGATGTTCAACAACCTATCTTAACAAAAGAACACTTTTAAT
GTTGTACTGAATTTCTTTTGTGCAAGCTAATATTGTTTTTTCTGATATTATCTACATTGGAAGTAGCA
TTAAGAAATATTCTATATATAATTGCATATTAGACATTGAAGAATCTTTACTTTTCCATGATTACCATGT
ATAGCAAAGTATTTTTAGTGCACAGTCTCCACCTCAAATCAAGGGCAAGAATCCTATGCAGTTTCTGTA
TAATTTCTGTAATATAGCCAAACATTTAAGCTTAGGAAGGTTACATTCAAGCAACAAGCAGAGATGCTC
AGATCACAATTCAGTAACCATGTTCTTTAGTCTGCTTACTACTGGTGTGAGCTTTCAAAGTCTGGATC
CCATGAGGTGTTGGTTTTAAGTTGTCAAATATTCCACATTTTCTTCTATAAACATTGTGCTATTCTTGG
AGGCTTGCCAAGGTTATCTGAAATGTTTCCCTGCACACTGCTAATCTGAACGTGTTATGTTATCTCCT
ATCCACCATCAACTACTGTAGTAAATTAATAACATTGTCTCTAGAATACTGAATTTTAGAGGTAAAAGAA
CCTTAGAGATGATGCAATCCAACCCCTGTATTATACTTTCTTTTATTATTGAAGAGTCAGAAAAATGTA
ACATGTTGAAGTCACACAATGTCTTTAGACTCTAGACTGATCCTATGTACACCCCTTAGTTCAAAGCCT
TCTTGGTTGTAAGGACAGGCCAGTTTCTTGACAACAAGGTTAGTCACTGTACAAAGTATACAAAAGATGG
CAGCAGAGTTAAACAGAATTTGTTTCATTTAATAAAATTTTATTAAAGCCTTTCTTTAAAGGTAAATATTA
AGGATATTTGTAGGATACATCAGTTCCCTCATGGGACTCATAATCTAATGATAAATAATATAATTAATGG
ATTCAACATTCAATAAATCCTGCGACTGGGATAAGTTTTTTTTTAAGTATGAATTATTGCAGAGGTCTCG
GAATGTATTCTGAATATCTCTAAGGATCCCTGAGACTTTATCAAGGGGTGCACAACCTCAAACATTTT
TATAATGATCTAGACATATTTTGGCTTTTATTTCTCATGCTATCCTGACAGTATAGTATGATTTTCTA
ATGCTCCAAGGTATGTTATTAATTCATTAACTCTGACTGCTAAAATATGTGTGCTTATGTACTTTTGTGTA
TTAAATTTTCTTAGTATTACTTTCTAATATAGTACATGTCAAGAGGTACAACCTAATTTAACAATAATCC
CTTTGGAACAAGCCCTCAATCTTTTATAAGAGTGTGAAGGACTTCTGAGAACCAATTTTTTTTCCAAAAA
AAAAAAAACCCCTGTGAGGTGGCATTATTATCTATGACTTACAAATGGCAAACTGATTTTAGAAAGAA
GTGCCAGAATTAATATAAACACAGATGTGACTGATTGCAATATCTGACTGGGTCAATTGTCTTAGTCCAT
TCAGGCTGCAAAGTTCTAGGTAGCTTATTAAATACACAGAAATTAATTTTTCAAGATTCTAAAGGCTGGAA
CATGTAAGACCAAGGTGATGGCACTTTTGGTGTCTAGGAAGGGCCCATTTCTTAATTTATAGACGGTACC
TTCTCATTTGTGTCCAGGCATGGTGGATGGGGCAGGCAAGGGTCAGTAATTCATTTCATGAGTACTCATC
CTCATGACCTTATCACTTTCTAGAGGCCCTGACTTCATAAAGTCTTCATATACGAGATTAGTTTTCAATCT
ATGAATTTGGGGGCCACAAACATTTGACTATAGTAGTCATAAACCATTCTACTTAACCACCTCAAGTAG
TATTTCCCTCAAGCAGAATATGCTTTTTTAATAAAATTTATTGATAATGTAGTTTCTGAAGTATGAATCTTAG
TTTTTCATTTAAATTATGTGCTCATTCAAAGATAACACATCAATCCTCAATTATTATCAAATTAACATT
TGAAAGAAAATAATTTTTTAATGTTTAAGCAGAAATGAATTATACAAAAATATATTTTATAATTTTAG
CTATGTTATAATCATATTTTATAATTTATAACCATTCATAAAGGAAATCAGTATAAAGTATACATAGT
TTTATTTCAAATAATACTGAGCTTTTCTAGCCTTTTCAACTGATTCTATTCTTGATTTTTTCATTTTGT
AGAGGTTCTGCTTTAAGCATGTCTGTTTTTTCTTACATATTAAATAGAGATTTTTAAATTCACCTAG
TTAAATAGCATTTCGTAGACTCACAAGACTTTACAGTGAGCTGAAAGGAATGTGAGTCTAATGTCTACCC
TTACTGAAGAGAACTCAGTCTCAGAAAAAGATGTAACCTATCTAATGTGAAGTTTCTTCATAGAATTA
TAACAACCTCTTGTCTAAGTCTTAACTCTTTGGTTTATTTTACATTTTGCTTTTCTAGGTCAC
AAGTCATGTATTGGCAAAGATGGAGAGCGTAAATAAATAAGCATTAAAAAACTTTGCCATTTCTGTCA

TCATCAAAGCAAATTTCTTCATATAAAGAAAAATTCTTTATCTACTTTTTTCCCTCTTTCTCTGCTTTC
ACTTTACTTCTTCCCTTCTCCCTCCCTTCTTTGTCTTTTCTTCTCTCTCTCTCTTTTGGATATATGTCTA
TCATATATTTCCAGAAATAATCCAGTGACATCTCATAGAGATGTACCACCTTCTTATTGCAACTCAGACT
GCAATTGTGATGAAAGTCAATGGGAACCACTGTGTGGAAACAATGGAATAACTTACATCTCACCTGTCT
AGCAGGTTGCAAATCTTCAAGTGGCAATAAAGCCTATAGTGAGTATTAGTTTTTACTTTTCTCTCTCTT
ATTCAAAGCACAGATTAGATTGAACAATTTTTTACCAAATATTTCTGTAACTAAGGACTCCATTAAAAA
GATAAAGAGAAAGTTTCCAGTATTATCTGTATTGTGATGGGTGTGATGTATAAACAAAGTTTTATATA
AAAGTCTGCTTAGGGCACAATCAGGTTTTCTGTACTTGAATTCTAATTGGAGATCACCCCACTTTTTT
CCTTTGAGATTGTAAGACTATGACCTTTTGAATTTGAATGCATTTAGAATATCTAAGAAGCACCTCATT
TGACTAAAGCCTATAATTTTCAATTAAGTTGGAATTACTTTATCCCTCAGAAATTCAGGAAAATGAGTTAAC
CCATTGTCAGCACTTCTATCTTACTAAGACAACAGTCAATATGCAATGTTATATACAGATTCTGATCTG
TTTAGCTCTGGGATCACTACCCCTTTTACTTTTTAAGAAATTAATCAAGGCTTCATGCTCACTTGACTGC
CCTATTCTTGATTTTTCTATTTTGATTTTTCCAAAGCTGGCAGCTTCTACCCAGATAATGTAGTATCCTGC
TCACCTAATGTCAATATGTCCCATAGAAATGTCAATTTATCCGTCCGCAAAACCTTCTTTCCATGTGA
ACTACAGTTTTTCTCTAATCTCCTGGGTAGCTACCTGTCACTGGGAATGGGTTATGGTGTTCCTCATACC
TACAATCCACTCAACATCTCACAAAGTTGTGTAATGTTTTCTAGGAACTTTTACTATTACCAACATTAC
TAAACAGTCAACTATAATTATTGCTCTCTGCCACACCCTTCTGTGTTTGATTTTTTAAACATTCTCCATC
TACTCTTGCCCATGGATCTACCTACCAATTAATAAAGGAATGGCATGTAGAATTTTAAAGAATAAAGCA
TCCTGGACTTTTTGAAGAAAGGCCACAACCTTAATAAACTTGCACAAATATGGCCCAAAGACTACTTAAA
AGCCCATATCTTAGTCATGGCAACAATGAATCTTTGTGCAGTTGTTTCTTTTCTTTGCTGTTTATTT
TTATTTTGCTGTTTTTTTTAAAAAATAATTTAACTCTTATTTTAGGTAAAGGGGATACAAATGAATTTGTG
TTAGATGGGTATATTGTGATAAGCTAAAGTTTAGGGTACAATCATTCCCATCCCCAGGTAGTGAGCATA
ATACCCAATAAGTGGCTTTTTTAGTACTTGCTGTTTTTATCTCTCCACTCTAGTAGTCTGTAATATGTAT
TTTTCTGTCTTATATTCTGTGTGGACCCAGTGATTAGCTTCCACTTATAAGTGAGAACATGTGGCATCT
GGTTTTCTGTCTTATGTTAATCTACTTAAGATAATGACCTCCAGCTGCATCCAGGTTGCTGCAAGGGAC
ATTATTTTCATCCTTCTTTTGGCCATGTAGTATTCATTGTCTATATGTACCACATTTCTTTATCTAATTC
ACTGTTGACGGGCACCCAGGTTGAGACCGTGTCTTTGCTATTGTGAATAGAGCTGTGATGACCATAGAAG
TATATAAGTAGATGTGTTTTTGGTAGAAGAATTTATTTTCTTTGGGTATATACCCGGTAGTGGGATTGC
TGAGTTGAATGGTAGTTCTGTTTAAGTTCTTTGGGAAATCTCGAACTACTTTACACAGTGAAGTGA
ATTTACATTCTTACCAACATAGGATAAGCATTCCCTTTCTTCTGCAGCCTTGGCAGCCTGTGTTTTTTA
ATGTTTTGAACAGTCAGCCCTTCTGACTGGTGTGAGATGGTATCTCCTTGGGATTTGATTGCAATTT
TTTGATGATTAGTGATGTTAAACATTTTATGTGTTTGTAGCTGCTTGTATGCTTCTTTTGAGAAGTG
TCTGTTCAATGTCCTTTGTCTACTTTTTAATATTGTTTTTGTTTTTTGTGTTGTTGAATTGTTCAAGTTTCT
TATAGATTCTGGATATTAGTCCGTGTGTAGATGCATGGTTTGCAAAGGTTTTCTCCCAATTCATAGATTG
TCTTTTCACTCTGTTGATTATTTTTGTGTGTCAGAAGCTCATTAGTTTAATTATATCCCACTTGTCCATT
TTTTTTGTGTGCAATGCTTTTGGAGAACTTAGTCACAAATTTTTTGGCAAGGCCAATATCCAGAATCTTTT
CTTGGTTTTCTTCAAGTGTTTTTATAGTTTTTACATTTTCACTCTGTAATACATTTTGAATTAAT
TTTTTATATGAAAAGAGGGGTCCAGTTTCATTTCTCTGCATAGTTAGCCAGTTATTCAGCATTATTA
CTGAATAATGAGTACTTTCCCAATTCGATTCTTTTTGCTAACTTCATTGAAGATCAGATGGTTTTAGGTG
TGTGGCTTTGCTTCTGGGTTCTCTATTCTGTTCCTTTAGTCTAGGTGTCTGTTTTTGAACCACTATG
CTGTTTGGTTACTGTGGCCTTGCAATAGTTTGTATATCAGGTAATGGGATGCCCTCACTTTGTTCTTT
ATGCTTAGGATTGCTTTGACTATTCACTCTCTTTTTTCTATGGAATTTTACAATAGTTTATTCTAATT
CAGTGAAAAATCATGCCGTTGTTTGTATAAGAATACCATTGAATCTGTAGATTGCTTTGGGCAGTATAGA
CAGTTTAATGATAATTTTCTACCAATCCATGAGAGTAGAATGTTTTTCCACTTGTGTGTACCTATA
ATTTCTTTTCATCAGGGTTTGTATTTATCTAGTAGAGATCTTTCACTTCTTGGTTTAAATGTATTCTTA
GGTATTTAATTTATTGTAGTTATTTCTAAATGGAATTGCATTATTGATTGGGTATCAGTTTAACTGTTAT
CGGTGTATAGAAATGCTACTAATTTTTTCCATTGATTTTGTATTCTGAACTTTATTAGAGTATGTTGT
CAGTTCTAGGAGGCTTTTGGCAGAGTATTTAGGGTTTTTTTTTAATTAATTAATTTATTTATTTAATT
ATACTTTAAGTTTTTAGGGTACATGTGCACATGTGTGAGGTTAGTTACATATGTATACATGTGCCATGCTG
GTGCACTGAACCCACTAATCTGTCTCTAGCATTAGGTATATCTCCCAATGCTATCCCTCCCCCTCCTC
CCACCCACAACAGTCCCAAGAGTGTGATATCCCTTCTGTGTCCATGTGATCTCATTGTTCAATTCC
CACCTATGAGTGAGAATATGCGGTGTTTGGTTTTTTGTTCTTGCACAGTTTACTGAGAATGATGTTTTCT
CAGTTTCATCCATGTCCCTACAAAGGACATGAACCTCATCATTTTTTATGGCTGCATAGTATTCATGGTG
TATATGTGCCACATTTTCTTAATCCAGTCTATCACTGTTGGACATTTGGGTGGGTTCCAGTCTTTGCTA
TTGTGAATAATGCCACAATAAACATACGTGTGCATGTGTCTTTATAGCAGCATGATTTACAGTCATTTGG
GTATATACCCAGTAATGGGATGGCTGGGTCAAAATGGTATTTCCAGTTCTAGATCTCTGAGGAATCGCCAC
ACTGACTTCCACAATGGTTAAACTAGTTTACAGTCCCACCAACAGTGTAAAGTGTTCCTATTCTCCAC

ATCCTCTCCAGCACCTGTTGTTTCCCTGACTTTTAAATGATTGCCATTCTAACTGGTGTGAGATGGTATCT
CATTGTGGTTTTGATTTGCATTTCTCTGATGGCCAGTGATGATGAGCATTTTTTCATGTGTTTTTGGCT
GCATAAGTGTCTTCTTTTGAGAAGTGTCTGTTTCATGTCTTCCGCCCACCTTTTGTGATGGGTTTTTGT
TTTTCTTGTAATCTGTTGGAGTTAATTGTAGATTCTGGATATTAGCCCTTTGTCAGATGAGTAGGTTGT
GAAAATTTTCTCCCATTTTGTAGGTTGCCCTGTTCACTCTGATGGTAGTTTTTTTTTGTCTGTGCAGAACTC
TTTAGTTTAAATTAGATCCCATTTGTCAATTTGTCTTTTGTGTCATTTGCTTTTGGTGTTTTAGACATGA
ATTCTTGGCCATGCCTATGTCTGAATGGTAATGCCTAGGTTTTCTCTAGGGTTTTTATGGTTTTAGG
TCTAACGTTTAAAGTCTTTAATCCATCTTGAATTGATTTTTGTATAAGGTGTAAGGAAGGGATCCAGTTTC
AGCTTTCTACATATGGCTAGCCAGTTTTCCAGCACCATTATTAAATAGGGAATCCTTTCCCATTTGCT
TGTTTTCTCAGGTTTTGTCAAAGATCAGATAGTTGTAGATATGCGGCATTATTTCTGAGGGCTCTGTTCT
GTTCCATTGATCTATATCTCTGTTTTGGTACCAGTACCATGCTGTTTTGGTTACTGTAGCCTTGTAGTAT
AGTTTGAAGTCAGGTAGTGTGATGATGCCCTCCAGCTTTGTTCTTTTGGCTTAGGATTGACTTGGCGATGT
GGGCTCTTTTTTGGTTCATATGAACTTTAAAGTATTTTCCAATCTGTGAAGAAAGTCATTGGTAGCTT
GATGGGGATGACATTGAATCTGTAAATTACCTTGGGCAGTATGGCCATTTTACGATATTGATCTTCCCT
ACCCATGAGCATGGAATGTTCTTCCATTTGTTGTATCCTCTTTTATTTCCCTTGAGCAGTGGTTTGTAGT
TCTCCTTGAAGAGGTCCTTACATCGCTTGTAAAGTTGGATTCTAGGTATTTTATTCTCTTTAAAGCAAT
TGTGAATGGGAGTTCACTCATGATTTGGCTCTCTGTTTGTCTGTTGTTGGTGTATAGGAATGCTTGTGAT
TTTTGTACATTGATTTGTATCCTGAGACTTTGCTGAAGTTGCTTATCAGTTTAAAGGAGATTTTGGGCTG
AGACAATGGGGTTTTCTAGATATACAATCATGTCTGCAACAGGGACAATTTGACTTCTCTTTTCC
TAATTGAATACCATTTATTTCCCTTCTCCTGCCATAATTGCCCTGGCCAGAATCTCCAACACTCTGTTGAAT
AGGAGTGGTGAGAGAGGGGCATCCCTGTTTTGTGCCAGTTTTCAAACGGAATGCTTCCAGTTTTTGGCCAT
TCAGTATGATATTGGCTGTGGGTTTTGTCTAGATAGCTCTTATTATTTTGAATACGTCCTCATCAATACC
TAATTTATTGAGAGTTTTTAGCATGAAGTGTGTTGTCATTTTGTCAAAGGCTTTTTCTGCATCFATTGAG
ATAATCATGTGGTTTTTGTCTTTGGCTCTGTTTATATGCTGGATTACATTTATTGATTTGTGTATATTGA
ACCAAGCTTGCATCCAGGGATGAAGCCCACTTGATCATGGTGGATAAGCTTTTGGATGTGCTGCTGGAT
TCATTTTGGCAGTATTTTATTGAGGATTTTGTGATCAATGTTTCATCAAGGATATTGGTCTTAAGATTCTCT
TTTTTTGTTGTGTCTCTGCCCTGGCTTTGGTATCAGAATGATGCTGGCCCTATAAAATGAGTTAGGGAGGA
TTCCCTCTTTTTCTATTGACTGGAATAGTTTCAAGGAATGGTACCAGTTCTCTCTTGTACCTCTGGTA
GAATTCAGCTGTGAATCCATCTGGTCCCTGGACTCTTTTTGGTTGGTAAGCTACTGATTATTGCCACAAT
TCAGATCCTGTTATTGGTCTATTTCAGAGATTCAACATCTTCCCTGATTTAGTCTTCCGAGAGTGATATGT
CAAGGAATTTATCCATTTCTCTAGATTTTCTAGTTTATTTGCGTAGAGGTGTTTGTAGTATCTCTGAT
GGTAGTTTGTATTTCTGTGGGATCGGTGGTGTATCCCTTTATCGTTTTTTATTTGTGTCTATTAGATTC
TTCTCTCTTTTTTTCTTTATTTAGTCTTTGCTAGCGGTCTATCAATTTTGTGATCCTTTCAAAAAACCAGC
TCCTGGATTCACTAATTTTTTGAAGGTTTTTTTTTGTGTCTCTATTTCCTTCAGTTCTGCTCTGATTTA
GTTATTTCTTGCCCTTCTGCTAGCTTTTGAATGTGTTGCTCTTGTCTTTCTAGTTCTTTTAAATTGTGATG
TTAGGGTGTCAATTTTGGATCTTTCTGCTTTCTCTTGGGCAATTTAGTGTCTATAAATTTCCCTCTACA
CACTGCTTTGAATGCGTCCAGAGATTCTGGTATGCTGCTGCTTTGTTCTCGTTGGTTTCAAGAACATC
TTTATTTCTGCCTTCATTTCTGTTATGTACCCAGTAGTCATTTCAGGAGCAGGTTGTTTCACTTTCCATGTAG
TTGAGCGGTTTTGAGTGAGATTCTTAATCCTGAGTTCTAGTTTGTATTGCACTGTGGTCTGAGAGATAGTT
TGTTATAATTTCTGTTCTTTTCCATTTGCTGAGGAGAGCTTTACTTCCAGTATGTGGTCAGTTTGGAA
TAGGTGTGGTGTGGTGTCTGAAAAAATGTATATTCTGTTGATTGGGGTGGAGAGTTCTGTAGATGTCTA
TTAGGTCCGCTTGGTGCAGAGCTGAGTTCAATTTCTGGGTATCCTTGTGACTTTCTGTCTCATTTGATCT
GTCTAATGTTGACAGTGGGGTGTAAAGTCTCCCATTTAATGTGTGGGAGTCTAAGTCTCTTTGTAGG
TCACTCAGGACTTGCTTTATGAATCTTGGTGTCTCTGATTTGGGTGCATATATATTAGGATAGTTAGCT
CTTCTTGTGTAATTGATCCCTTTACCATTATGTAATGGCCTTCTTTGTCTCTTTTGATCTTTGTTGTTTT
AAAGTCTGTTTTATCAGAGACTAGGATTGCAACCCCTAACTTTTTTGTTTTTCCATTTGCTTGGTAGATC
TTCTCCATCTCTTTTATTTGAGCCTATGTGTCTCTGACAGTGAGATGGGTCTCCTGAATACAGCACA
CTGATGGGTCTTGAATCTTTATCCAATTTGCCAGTCTGTGTCTTTTAAATTGGAGCATTTAGTCCATTTAC
ATTTAAAGTTAATATTGTTATGTGTGAATTTGATCCTGTCTTTATGATGTTAGCTGGTTATTTGTCTCTT
TAGTTGACGCAGTTTCTTCTAGTCTTGATGGTCTTTACATTTTGGCATGATTTTGCAGTGGCTGGTACC
AGTTGTTCTTTCCATGTTTAGCGCTTCTTCCAGGAGCTCTTGTAGGGCAGGCCTGGTGGTGACAGAATC
TCTCAGCATTTGCTTGTCTGTAAAGTATTTTATTTCTCTTCTGCTTATGAAGCTTAGTTTGGCTGGATAT
GAAATTTCTGGGTTGAAATTTCTTGTCTTTAAGAAATGTTGAATATTGGCCCCACTCTCTTCTGGCTTATA
GGGTTTTCTGCCGAGAGATCCGCTGTTAGTCTGTATGGGCTTCCCTTTGAGGGTAACCCGACCTTTCTCTCT
GGCTGCCCTTAACATTTTCTCTTCAATTTTGGTGAATCTGACAATTATGTGTCTTGGAGTTGCT
CTTCTCAAGGAGTATCTTTGTGGCATTCTCTGATTTCTGAACTCTGAACGTTGGCCTGCCCTGCTAGAT
TGGGGAAGTTCTCCTGGATAATATCCTGCAGAGTGTTTTCCAACCTGGTTCCATTCTCCCATCACATTTT

AGGTACACCAATCAGACGTAGATTTGGTCTTTTCACATAGTCCCATATTTCTTGGAGGCTTTGCTCGTTT
CTTTTTATTCTTTTTTCTCTAAACTTCCCTTCTCACTTCATTTCATTTCATCTTCCATTTGCTGATA
CCCTTTCTTCCAGTTGATCGCATCGGCTCCTGAGGCTTCTGCATTCTCCACGTAGTTCTCGAGCCTTGGT
TTTCAGCTCCATCAGCTCCTTTAAGCACTTCTCTGTATTGGTTATTCTAGTTATACATTCTTCTAAATTT
TTTTCAAAGTTTTCAACTTCTTTGGCTTTGGTTGAATGTCCTCCTGTAGCTCAGAGTAATTTGATCGTC
TGAAGCCTTCTCTCAGCTCGTCAAAGTCATTCTCCATCCAGCTTTGTTCCATTGCTGGTGAGGAACGCA
TTCCTTTGGAGGAGGAGAGGTGCTCTGCTTTCTATAGTTTCCAGTTTTTCTGTTCTGTTTTTCCCCATC
TTTGTGGTTTTATGTACTTTTGGTCTTTGATGATGGTGATGTACAGATGGGTTTTCGGTGTGGATGTCGT
TTCTGTTTGTAGTTTTTCCCTTAACAGACAGGACCTCAGCTGCAGGTCGTGTTGGAATACCTGCCCCG
TGAGGTGTGAGTGTGCCCTGCTGGGGCGTGCTCCCAAGTTAGGCTGCTCAGGGGTGAGGGGTGAGGGAC
CCACTTGAGGAGGAGTGTGCCCGTCTCAGATCTCCAGCTGCGTGCCGGGAGAACCAGTGTCTCTTCA
AAGCTGTGAGACAGGGACATTTAAGTCTGAGAGGTTACTGCTGTCTTTTTGTTTGTCTGTGCCCTGCCC
CCAGAGGTGGAGCCTACAGAGGCAGGCAGGCTCCTTGAGCTGTGGTGGGCTCCGCCCACTTCGAGCTTC
CAGGCCGCTTTGTTTTTCCCTAATCAAGCTGGGCAATGGCGGGCGCCCCCTCCCCAGCTTCGCTCCGCC
TTGCAGTTTGATCTCAGACTGCTGTGCTAGCAATCAGCGAGACTCCATGGGCGTAGGACCTCCAAGACA
GGTGGGGATGTAATCTCGTGGTGCGCCGTTTTTTAAGCCCTCGGAAAAGCGCAGTATTCGGGTGGGAG
TGACCCGATTTTCCAGGTGCTGTCCGTCAACCTTTCTTTGACTGGGAAAGGGAACCTCCCTGACCCCTTG
CGCTTCCCAAGCCAGGCAATGCCCTCGCCCTGCTTCGGCTCACGCACGGTGCGCGCACCCACTGACCTGCG
CCCACTGTCTGGCACTCCCTAGTGAGATGAACCCGGTACCTCAGATGGAAATGCAGAAATCACCCGTCTT
CTGCGTCTGCTCACGCTGGGAGCTGTAGACCGGAGCTGTTCTATTTCGGCCATCTTGGCTCTCCAACCAG
GGTTTTTGAGATATAGAATCATATCATAGTGCAGAGAGATAATGTGAGTTCATTTCTATTTGTGAGTGT
TTTATTTCTGTCTCTTTCCTGATTGATCTGTCTAGGATTTCCAGTACTATGTTGAATAGGAGTGGTGAGA
GTGGGCATTATGCTTTGCTCCTGTTCTTAAGAAGAATGCTTCCAGCTTTTGCACATTATATATGAAGTT
GGCTGTGGTTTTATCATAGATGGCTCTTATTATTTTGAAGCTATGTTCTTCAATGCCAGTTTGTGAAG
AACTTTATCATAAAAGGATGGTGGATTTTATGAAGCTTTTCTGCATCTGGTGAAATGCTCATATACT
GTTTATCCTAAATTCATTTATGTAGTGAATCAGATTTATTGATTGTGTATACCTGGACCATCTTACATC
TCAAAAATAAAGCCTACTTGGTCATGATGAATTCATTTTGTATGTGCTGCTGGATTTCAGTTTGCTAGTG
TTTTGTTGAGGAATTTTGCACCTATATGCATCTATATTCATCTATATTCACCAGGGATATTTGGCCTGTTG
GTTTGTTTTTGATGTTGTTGTTGTTTTTGTGCTTGTCTATATTTTGGTACCAGGATGATTCTGGCTCAA
AAAAATCAGTTAAGAAAGAGTCCCTCTTCTCAATTTTTCAGAAATAATTTAGTACAGTGGGTACTCACTC
TTTTTTGTATTTCCAGTAGAATTTGGCTATGAATGCATTTGGTCTAGGGCTTTTATTGATAGGCAGGTTT
TTTCAGTACTGATTCAAATTTGGAATCTATATTAGTGTTCAGGGTTTTCAATTACTCTTTGTTCTCTTG
GATGTTGTTGGATGGTTCAATTTGGATGGTTGGATAAGAATGACCCAGTTAATACATGCTCCCTCTTTG
CACACTAGCGAAGGCCCTGAAAGTGATAGAATATTAGAACCCTAAAAAGAATTGTGTCTACCACAAGACAT
AATCTTCATTATACTGGCAATGACTATGCCATTTGGGGACTATTGCAAAGTTTTTATTTATTTATTTATTT
GTGATTTTATTTATTTATTTACTAAATCCTCAATAATGAACCATCACTTCTTAAATAGTGTCTTTGTAC
CAAAGCTTAGTTTTTATTTGACCAATACACTTGTTCATAAAAAAATTCCTCTATATTATTTCTAGTGAAAA
AAATAGTAAGAATGTAAGTTTGGCAGAACTGTAGATGTATAGATTTAAATTTCTTCTACAATTTCTTCCTT
CAATAATTGATCTTTAGCATTAAATAGATTCACGTGAGGTTCCCTTAAACTTTAGCCTAGATTTAGAACA
GAATTTATTAAGCCACCTGTCTATATAAACTGTTCAACTGATTAAAAATCTGAAATCACTTGTCTTCTAC
ATTTTCCACTTCTGTGCTCTAAACACTAGTGGGGCATTCTGTTGTGTTTAACTCTCTGGTAATAATATC
ATCTGTCAATTGTATCCTTGGATTTTGTATGCTGTCTAAATTAATAATTTTAGCATCTCTACCTGTCTCT
ATTTTCCCTGGACTCAGTGCCATTTTCATGGGTGACTCCAGTTAAATTTTGATTACTCCCAACTGCTAA
ATTATCTGAATTTCTTTGGATAATTCCTCCTCAGGGCATGTCTCTGAACTTAGAGATTGTCCAAAAGAGT
ATGTGCTCTGCAGAGGGTAAAAGGGAATGGAAAAATAATTATTAAAGAGAATCTATAGTGATGAGAAAAAT
GTATACAGAGTTCTAGGCACTAATTTCTTTGTTCTTAGTTTTAAATTAAGAATGAATTAATGTCAAT
CATGAATTACATTGTCTTATATAGAAAGAAATCCACAAAACATTTTACCTTTTATCTCTTAAAGCAACTG
TATTTTTAGAACTCTTAAACTGTAAATATATTAGTTTGAACAAGTGAGACTTCACATAATATAATGCA
ATGTATTTGCAGCACTGTTAGGTCTTGCAAAATTTCTTATGTATATTTTATACACAACGCTTAAAGTGTT
TTACAACCTGCAGTTGTTTGAAGTAACGGTCTCCAGAACAGAAATTAATCAGCCCATTTGGGTGAATGC
CCAAGAGATGATGCTTGTACAAGGAAATTTTACTTTTTTGTGCAATACAAGTCTTGAATTTATTTTCT
CTGCACTTGGAGGCACCTCACATGTCTGATGTTGTTAAGTAAGTATGACTTTTAAAAACATTTTCATA
TGCATGAGACTATAAACACACCTAATGATATGCATATTTTACATAATATACTGGGAATTCAAATTCATA
TTTCATCAAATTTTAAATTTCTGAGAAATTCATTTTATTAATAATTAATGAATCTCAAGGCTGTAATTA
ATAATTTTGCCTCTAATTTCTTCCATTTAAAGTCCAGATTCATACGTTTCTTCTTACTAAGAACTGTA
AGACACAGACTGACAATTTCTCTCAGTTGTAAAGAATCGCCCTAGGATCCTAAAGAATTTGTTGAATTT
TGAGTTGCCTTACATCCTAATGAGAGATGCCCTGCATCTCTCAGGGTAAATCTATTGATTTCACTAAAT

AAAGCATTGAAAAC TAGATATAAAATATGCTCCATTGATAACATTCCAAAAC TTTTAATCGACTCACA
GCATGACTTTTATAATACCCTTGTAGAAAAATAAAAAATACACAGGAAGAATTAGTTCCTTTCTTGGCT
CATTAGAAAAGATACAATGCTTGGTGAAATATTACATGGTAAATGAAACCAATAAGATACTTGTGTGTCATA
CAGCTTTCAAATTTACAGGAAAGACTGGTGTGAGATAAATAATCTTAAATCAAAGCACATATTTATAAA
TTGTTCTGAGTCCTCATCAGGAAAAAGATTTCCTTAAAAAGAAAGATTCAAAGGAAAGTTAATTTAGGA
TTGAGGTGGGGGGCTGTGAAGAAGAGGATTTCAGAGTACATCTCAAATAAGTAACATTTATTCTAAAGGT
CTAAAGAAAAAGCCAAATGAAAGGGTTCCAGGAGAGGGTCTTGGTGTGACGCCTTAATACAGGAAAGA
GCTGGTGTGTTTGTAGAAATGAAAAGAGCTGGCAGATTGAAACATACTGAATGAGAGGTTGTGACACATG
ATAAGATTGGAGAGTTAGGAAGGGTGCAGGTAATGCATGCCCTACTGGCCAAGTTGATTCATCACCTAA
AACTTGTAACATGTAATAATTTGCTTTTAGATCTTAAAAATATACATGTGTAAGTATAGTGACCTGGGTT
AACATTCAATTGTACTTTTAAACTTTACATTGTTGATCATAAGTTCACGTGCAGCCACAGCATGACATG
GTAGAGATGAAAAAAAAGCATTTTTAACATTGTTAATATTAGTATCAACCTGTAAATTGAATTTACA
GTTGTTTAAATTTTGACCCTGACTGCAATCTTATCAAATTTATTTATACATAAATGCCACAGATATAGCT
CCATCTTAATATAAAATGTTGTCTACTCAAAGGAGAAGTCTTTTCATATTTGCCAAATTAATTCATTAA
CATATTAATAAATAACCTTAAATTTAAATAAGTCTGCATATCAACAGGTTTTAGCTTTTTATTTTAAAC
TCATGAGTTTGAAAAAACACTGTTCCATCATCGATGATAACAATATCATATCTGTTTCAGAAATTGATTA
AATCAGCATTACAACCTGTCAAATAATTTAACTCTTGCTAGCCTTTGATTTTATTGAAATAAGCATT
GTGAATATGACTACAGAATAAAATATAAATTTGAGTTTGTAAATAGTTTTCTAATGCTTAACACTATGA
AGCTATTTTTTAACTTGATTAAGTAGGCAGAAGGACATCCATTTATTCAATATGTATTCATTTTATTATG
TCAGGCATAGTTGTATGCACGTAGGATGCACTGTGAACAAAAGTGATAGAACTTTATAAGCTTTTAGTA
TGGGTGGGGAATGAAGGAATGAATGTGTGTAGCAGAAAACACAGTAAACAAATAAGTGAGTAAACATCTA
AAATAGAGTAAGTGTGAAGCACTAGAAAGATAAATAAATCACAGTTAAGAAAATAGAAAAAATGAGAAA
ATAGGCAAGAGATACTAGTTTCAGATATGGTGCTTTTGAAGTCCTTTGAGTAAAGACCTGAATGAAGAGAT
AGAAAATAAAGGTACAAGCCATGCTAAATGGAGACATAGGAGGAACAATCCAGGCAAGGTAGAAGAAAGG
TCAGCGTCCTGGTGTGAAGTATAGTTGACATGTACAAGGTCCAAAACGTGTGTAAGGAGGAGAGAGGTG
ACAAGTGCAGCAAGAGAGCTAGCCTAGTTTCAGATCCTATGGGTACAGGAAAGACTTTGAAATATATTCT
AAATGTGTTGAAAGCCCAAGGGGATTTAAGCATTAGTATTTGCAAAGATGCCTTACATAACTAGAAGATC
ACTCTGGCTGTGGGTAGAAAGTGTGTTTTGTGAAAACAATAGTGAAGTCAGGGAACAGAAAGGCTTGAA
TTGTTCTTCTCAAGATGGAAGCTTGATTGAGAATGCTGATAATAGGAAAATATGAAGTAAATGAAATGAG
TAAATGAAACAAATATGAGTCTCAGTTGTTTTGCTTTATTTTATTATTTTATTATTTTATTATTTTATGAG
ACAGTCTTGCTCTGTCAACCCAGGCTGGAGTGCAGTAGCACAACCTTGGATTGCTGCAACCCCTCCGCCCTCC
CAGGTTCAAACGATGCTCCTGCCCTCAACCTCCTAAGTAGCTGGAATTACAGGTGCACGCCACCGTGCTG
ACTAATTTTTGTATTTTTTAGTAGGACCTGGTTTTACCACGTTGGCCAGGCTGGTCTCAAACCTCTGACCT
CAAGTGATCTGCTAGCCTCTGCCCTCFCAAAGTGCTGGGATTACAGGCTGAGCCACAGCACCTGGCCTTT
GTTTTATTTTTTAAATGCAAAGCCAGTAGGGTTTGCTGAGACATTGAATGTGGCATGTGAGAAAGATAAT
TAAGGATAATCCCAAAGTTCTGGCTTGAGTTCTGGAAGGATGGTGGTACTATTGAACAAAATGGGAAAGA
CTAAGAAAGGGTAGATTGGGAAAGTGAAAAGCTAGAGAATTTGTTCTATCTCTATAAAGCTGAGCAGCCTG
TTCAATATCTAGCAATGTCTATATATGCAATCCAACAGGAGAAACCTTGATGCCAGAGCCATAAATTTAG
AGTCAGCAACGTACAGATGGTATTTATTTTATTTTACTTATTTATTTATTTAGAGACAAGGTCTCATTT
TTGTTGTCCAGGCTGAAGTATAATGGCATGATTATAGCTCACTGTAACCTTGAATGCCCTGTATTCAAGCA
ATCCCCCAAGCGGTATTAAATCCATGGAACATAATGAGATCTTCTAGGGACTGAGTACAGATAGAAACA
AGATCCTAGGATCAGTTCTCAATCACCTCTAATTTAAAGATCACTAATAGGAGAAACCAATAAAGAAACT
GAGGAGGTTTTCATGAGAAAAACTAGGAAAGAGCGTTGTCTCAAACATAATAAGCATATGTCAAAGAGAG
CATAAGTAACTGTGTCAAGGGCTGCTGAGAGTTTCACAGGAGTTGAACCTGGGAGGCGGAGGCTGCAGTGA
GCCAAGATCGCTCCACTGCACCTCCAGCCTGGGAGACAGAGCAAGACTGGTCTAAAAAAGAAAGAA
AAGAAAACCAACCAATATCCCTGATGAACATATGAAAAAATTATCAATAAAACACTAGCAAAATCAA
TCCGATGGCACATAAAGAAAAATTTTATAACATGACAGTTGTTTTTATTCTAGGGATGAAGGGTTGGTT
CAACATATATAAATCAATAAATGTGATTTGCCACATAGAATAAACTAAAAACCAAAACCTTTGATAAGA
CAAAATTAATAAACAACCAATATGATCATCTCAATAGATGCAGAAAAATTATTTGATAAAATTTAATCAT
CTTTTCATGACAAAAATCCTCAACAATCTGGGCATCAAAGGAACATACCTCAAATAATAAAGCTATGTA
TGACAAACCCACTGCCAATTCATACTGAAAGGAAAAAGTTGAAAGCATTCTCCTGAGACCTGAAACAA
GACAAGTGTGTCTATTTTCACTACTCTTACTGCACATAGTATGGGAAGTCTTAGCTAGAGCAATCAGGCA
ATAGAAAGAAAGAAAGGTATCCAAATTAGAAAAGAGGAACCTCAAATAAACTCTGTTCACTGATGATATG
CAACAATAACAACAAAAATAGACTAATGGGACTTAACTAAAAATTTCTGACACAGCAATGGAAATAATC
AACAGAGTAAACAGACAACCTACAGGAAGGGAAAAAATTTACAAACAATACATCTGACAAAGGGCTAA
TATCCTTAATCTATAAGAAATACAAAAAATCATCAAGAAAAAATTTATTAATAATAGGGTAAATGATA
CGACCAGCATGTTTTCAAAGACAAACAGTCAACAAACAACAAACATATGACAAAATGCTCAATATCACTA

ATCATCAGAGAAATGAAAATTAAAGCTACAGTGAGATTCCATTTTATACCAGTCAGAACGGCCATTACTA
AAAAGTCAAAAAGCAAGATAC TGGTAAGAATGTTGAGGAAAAGGAATGCTTATATACTGTTGAGAATATA
AATTAGTACAACCTTTATGAAAAACAATGTGGAGATTTTCAAGTATCTGAAAAATAGAAGTACCATTTGA
CCCAGCAATCCAAC TATTGGATATCTACCAAAAGGAAAGTAAATCATT TTTATGAAAAAGACTCATGCTCT
TTCACACTTATTATAACACTGACTAGACCACAAAAAATCAGTATCTTCAGAGGCATAATAAAGTCTGTTC
TAACCACCTTCTCATAGGATTTTCATAAGTACCATATGAGAAAATATTTTAAGCCATCTTGAAATCATGA
TGCATTGAATAAATAAGGGAATAATTATTATTATTGCTCAAGTGTTCGCCTTTAAAAACAATTAAATAT
AATTTTATATAATGGGGCCATTCAACTGTGAGCTTAATTCTATCATGGAGAAAAACAACACAGGAGAAGG
TTTAATGTTGTTTCGTTTGTGATATTTAATGATATTTAATGTTTCTTTGCCTTTGTCTTGTTCAGAATT
GTTCAACCTGAATTGAAATCACTTGCCTGGGTTTCCACTCAATGGTTATACGAGCACTAGGTATGATGA
AAAAAAAAAAAAAAAAAAAAAAAAATATATATATATATATATATATATATATATACACACACACATACAT
ATATTAAATTTAAGTTATAAATATTAAATGTCAAGGATTAAAGACTGTAATGAATCTTTAATTATGATAGT
AAATAAAATTAGTATCCTTTCTATTCTGTGATAAATAAAAAACAATAAGAGACAGAGTAAATTTGAGTGA
TGGACCTAAAGGAGAATTCGATTGTTAATTATACATAAGATGGTCCTCAAATTTTCTTTTTCAGAAAAATAA
TTTGTATTACACTCTTTCAAACACAAAGATAGATGGTCCTCAAATTTTCTTTTTCAGAAAAATAA
GAATATTTCTCCAGTAGGCAGAGTGAAGGGCCTAACTTCTAAACTGTGGCATGATTTAGGCAAGGCCT
AAAGCTAGCTTGGGAAGCGTGGGAATCTGGTCAGAGAATCTGGCCAGGCATGGCCAAATTACAATGAAG
AAATTGTCTAAGAAGCGTATTTGATGATAAAGTCACAAATCCTCAAAGTTAAAAAGAAGAAATATAAAG
GGAATAGAAGAGAGGAAATGAGATGCTATAGTATTCTGTTGGTTTTCTTCCCTCCGTTCCGTTTGTGTG
TCTCTAATCTCCAGACTCTGTACATTCTGGCAGGTTTCTACCTTCAGTTTCAATGGAGATACCTCTCTG
CTAGAACCTGGGTGACAAAAGCTTAAAGTAACATCTGGGTTGTTAGTACTCCTTCTCATATGTAGAAATG
AGACTATGAGAATGGAGTAAATTTTTTTTAGCAATAGAAAATAGGAAAAAAATGAGTTTCAACCATCT
AATTCTGAGTATCCTATTTTCGATGTATCCAATCTGTGGCAGATGGAACCTAAATGCACCTATGAAAAA
ATACACATTTAGTACAAAACCTTTCAATTCATAAACAATTGTCTTGAATACAATAACGTGTAAATTTGTGG
AAGGCCATATATTTACCTGAAAAAGTCATTAGAAAAATAGGTTATGAGTTTAAAAATGTAGTGATTAG
GACAAAGTTTATTACTTTAAAAACAATCCATTACGTTTGTTCAAATCAGTGGCATTTATGTGGGAAAAATAA
CTGTTAGCATATATTTTTCTATTTTCAAAGGGTGGCTGTGATTTTTGAAACCTGAAAAATTTCTCACTCAT
TTCCTCAGTACCGGGTTTTCTCAGATACATTGGCCCTCAGTCCCTTGTCAFTTTAATATTTCTCACTCTCA
AAAAATTGAGACTGAGGAAAAC TAAATGGAATTAGTAAAATTGTGATATATCAATCACTATCATTTTATC
CATGGCAAAATAAATTTCTGAAAATTATTCACCACAATACAAAAAAAACAAAGTAAAGTTATGAACACTT
TAGTTGCACCATCTTAAGGACAGTTCTCTACTGGCGTGTCCCTAAAATTTCTTCATCAAATTACCTTTGCC
TAGAACCAGGAGTGAATCTCAGAGTTCAATAAAAACAGCAGTGGGAAGCAGATGGACACTTATATATAAAC
AACATATCTGTCTGTGAAAAGCCTTGCAATCTGCTAAATCATGAGCTACAAATAAAAAATTAAC TAAGAAA
AAGACCACTGAAAAC TTTATCATTTGTGATCAGAACACTAACACAAACAAATTCAGTACCACAAGCCCTAA
CTTAGCCTAAGCTGCTTCAGGAGGTATTTACAAATGCACAAAATCAATTGTAGAAAATCACTGGACTGTG
AGCTCTAATGACATCAATAAGTGGGAAGTAGATGTCTGAGCCCAGAAAAAAGTACAACCTGCCAAAAGCT
AAGCACTCTCTGAAGCTCAGCCTATACCTTATCTGGGGAGGAGTTCTGATGAAGCACTCACTTTTAAATT
CTCTTAAAAATATGTTAAAAAAGAGTCTGCTTTTACAGCAATTGAGCCAGATCTTTTTCTCTTTC
CCCATAAAATTGTAATTTCTACTCCATTTCAAGGTTTCTTTGCCTAAGAAAAATCCCATATTAACCAACATA
ACTTCCAAGTTTTTACTAACACATTCTCCTTTTTACCATTCAAGGCTTAAGTTAATTGTTATCATAAGAAG
AACAGAGTATATATGCATGTATGTAGGAGGGTACGAGTAGGTAAAAGGTGTCAATGACATTACTACATG
ATTTGGGTCTTTGAGATTTCTAATAATCTTTATTATTGGGTAGATGCAGAACAAAAATAATAACGAATCC
TCCAAATTTTTGAACTTTTATTTAATCAAAATATATCAATGTGGAATATCATGCAGTTACATTTAAAAATA
TGTTCCCTAAACTGACATCTTCTCTTCTCCTATTACAGGAGGAATTTCTAGCTCCAAATATATTTTGGGGCT
CTGATTGATACAACGTGTATAAAGTGGTCCACCAACAACCTGTGGCACACGTGGGTCTATGTAGGACATATA
ATTCACATCATTTTTCGTAAGTTGTCTATAAATATATTTTCAATTATTTTTCTTTGACTATATTAATTCCTA
AAAAATATCATTTTCAATTATATAATAATATTAATAATGATAGCCACCATTAAATGAAAAC TGACTTTGCA
TGCAATGTTGATCAAGCAATCTCGTATCTCATTTTGTAGTACTCATAGAACTATAGGAAATGGATATTTT
CTTCTATTCTGTTATATACGAAGAACTGTGATTCAAGGATAATAACCAACTTGTCAAATAACAGAGATA
ATAGAAAATGGCTAGGATTTGTATGTGAATCTTTTTTGTTCCTCAAACCTCTCCTCATGTCACTATATATA
AGGATAAATATACACATGTAAATATAGACACAGACATATATATATGTCATGTGTGTGTATTTCGATTGCCCTC
TGACTTCTCTAGAAAGAAACAGAAATGACTAGCTGGGGCTCTGGTCATATGTCAATTAAGAAAAAACGGGA
AAATATGTTTCTATATTACTCTATTCTGGGGAGAGATATCCGTAAGTGACATGAAGATAACTGCATGG
GCATCTGGAAAAACAAAAGCTACAATTTACTTTTACCTCTTTAAAAAAAAC TAAATTTCAAATTCATAT
ATTTGACAAATTATACACTTTGAAATGTGAAACTACATGTATTAACCTCATAGTATAATTTCTTTCAATT
ATCTACGAAGCAGAACTAAGTATGACCCAAATGCCCAAAACCATAATAGAAAAAAGACAAAATATTTA
TAAATCTGCATCATTAACCTTTGAAAAGGAAATTTCAAAGTGAAAGTATAAATTAGGAGAATAATTTGC

32/37

TCATGTTTCTTTGATGATATATATGAAGATGTTTGATTCTGTTATATTAACCCCTGGATCCTGTGTCCTGA
AACCTTGCAATAATTGCTTATTAGTTCCAAGTGTGTTTTGTCTGTTATTTTAAACCTTCTACTTAGACA
ATTATGTCATATTGCAACAAAGACAATTTCTTTCTTTCAATCTATATACATTTTCATTTTCTTTCTTT
TTAAAAATTACATTAATTACGACTCCCGATACCATGTTGAAAAACAGTGGTGAGAGGGGACGTTTTTGAC
TTGTTCTGACCTTAGTGGGAAGACTTTGAGTTTCTCACTATTAAGTATGAAGTTAGATGTAGGGTTTTG
GCAGATATTTTGTCAAGTTGAGGAGGTTCTCCCTATTCCAAGTTTAAATGGGAGTTTTTATTATAAAT
GAGTGTGTTGATTTTGCAAATTCACTTTCTAGATCTATTGATGTGATCATGTCATTTTATTATTCTTCTT
TAGCCTGTTAATGTAATGAACGTGAAGAATTCATTTTGAATGTTGAACCAGTCTTGGAACCTGAGGGAA
ATCCCACTTAGTCATGATGTATACATATTTATACATTGTTGGATTCAATCTGATATTTTGTGAGAATTT
TTGCGTCTATGTTTCATGAGAGAAGTTGCTCTGTAGTATTCTTTTTTTTTTTTTTTTTTTTTTTTGGAGACA
TAGTTTTGCTCTTGTACCCAGGCTGGAGGGCAATGGTGCATCATGGCTCACCAGCAACCTCCGCTTCCC
AGGTTCAAGCGATTCTCCTGCCCTCAGCCTCCCGAGTAGCTGGGATTACAGGCATGCACCACCATACCCGG
CTAATTTTGTACTTTTAGTAGAGACAAGGTTCTCCACGTTGGTCAGGCTGGTCTCGAATCCTGACCTC
AGGTGATCCGCCACCCTCGGCCCTCAAAGTGCTGGCATTGTCAGGTGTGAGTCACCATGCCAGCCCTCT
GTAGTATTCTTTTCTGTAATGTCTTTGTCTGATTTTGTATTAGGATAATGCTAGCCTCACAGAATGAA
ATAGGAAGTACTTCTGCTGCTGCTATCATCTGAAGAAGATTGTAATGATTGGTATAATTTCTTACTTAA
GTGTTTGATAGAATTCACCAATGAACCTATCTAATTTGATGCTTTCTTTTTTATTATTATTATTACT
TTAAGTTCTAGGGTACATGTGCACAATGTGCTGGTTGTTACATAGGTATACATGTGCCATGTTGGTGTA
CTGCACCCATTAACCTACTCATTTACATTAGGTATATCTCTCAGTGCTATCCCTCCCCCTCCCCCACC
CACGACAGGCCCCAGTGTGTGATGTTCCCTTCTGTGTCCAAGTGTCTCACTGTTCAATTCACACCTA
TGAGTGAAAACATGTGGCATTGTTGGTTTTTTGTCTTGTGATAGTTTGTGAGAATGATGGTTCCAGCT
TCATCCATGTCCCTACAAAGGACATGAATCATCTTTTTTATGGCTGCATAGTATTCATGGTTTATAT
GTGCTACATTTTCTTAATCCAGTCTATCACTGATGGACATTTGGGTGGTTCCAAGTCTTTGCTATTGTG
AATAGTGCAGCAATAAACAACCTTGGCTTTTGGCTAATATCAAGTATAGTATCTGTTCTTTTCACTTTA
GTTTGTGATGCTTTCTGTTTGTAGAAGGTTATTAATATGGATTCTTTTTTAGAGAGTTCTATCCCTCTTCAA
TGCTTGGGGTTCCATGAGGAAATCAGAGCTTTTCCCAAAAATGGTACCTCTATTTTCCCAAGGACTC
CTCGTCTGTTAGAAATGAACCTAGTTCTTTTCATGTGGTCATCAAGAGGGGCAAAAAGACAGACTGAGGA
AATAATTCACCTCAAGTGAGAAAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAAATAA
AAGCACAAAGGTCTTGTATATAGATATATACACACACAGACACACACATATATATATATATATATAT
TATGTGTGTATATATATATATATATATATATATATATATATATATATATATATATATATATATATAT
ATGTGTGTCTGTAAAGAGAGAGGGAGAGCGAGAGAGAGTATGGGAGAGCACTTGGATATCCATTTTAAAT
TAAGCTGACTTTTAGCTATAGTGCCCTTTTAAAAAAATCCTTTATATCTCTTATTATCTGACTTTAGCAA
GGCCAAACAGCCAGTATTTCTGGCTTTTGAACCTCTTTAGAAATAGTAATCTCCTAGGTGAAATAAATAA
GCCTTAACTGAGGTTGTAACCTTAACCATGAGTGTATGAGGTATTTCAAATAGGTGGTAAGCAGTTTTTA
CAAGATCTAGAATCTTCAAAGGTAACCTCACAGAAACGAAATTCAGAAGGGAAGCCAGAAGTTGGTCA
GGAGGAGCAGAGAATCAACAATGGAAAAAGCCACAAGAATCAAAATCAGAAAGCATTCATTTCCCTGGG
CCAAGAATTGAGTCCAGGCCACCATTTGTGAAAAAGACAAACTCTTAGCTTCTGAGCTATAGCATTTGGATA
GTCTTCATTACCTTTCCAGAAAGGATTCCAGTGCAACCGATTTCAAGCTTGCAAAGGCTTTTAACTGCTC
GAGATAATTTTLAGAGCTAACTATGACATTAACCTACAAAATCTCTGTCTCTAGATGGCAGAGACCAAGA
GTAAGTACTGCCACATAGTTACAAGATCAAGCTCCACGGACATAAAACAAGATGAGAGGGAACCTCAT
CCAGTATAGGTTTCAAGAACACACAGCAAAGTTGTAACCGACAGCCCAAGAGGCTGGCTTAAAAAGTA
GGCTTATAGGAATCCTAAGCCTACTTTCTACATCTTTTCTATGACACCCCTCTCCATTACAGAACACA
CTAAAGACAAATTCCTTAGCACAAAGTACACCAGATTTGCTAAAGCCTAAGACTAGTCTCAAAAATTCAT
TTTTCTATTAATCAGACCACACACACACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG
ACAGAGAAAGACAGAGACAGAGACAGAGAGACAGAGACAGAGACCAGAAGCTTGGCTGGTAACAAATCTTACCCC
TTTTGCCAGCATACCACGTTTCTGGGTTCCTTTCTCTGCAGCTTCCAGAAGAATGAAGTGGCTTTTGAT
GACCTTGCTCATTGCAACCATAGCTTTGGGGGCCAAGCCACTTTACAAAAGAAAATTTATCCTTTTCTGTTT
TATAAAACTATAGGCAAAAGCTTCTCATTTTGTCAAGATGCTGCCCAATGGGCTGCATGAGGAACCAAT
TAACATTTTCCACCCAGCCTAGCAAAATACACATAACAAAACAGACATTTGTACCTCATTCAGCACCC
AATATTGACCTGGCGAGGCTCAAACCTTCTTTTCAATGGTCCCTATCATCTCTGATCCACTCAAGATGTGG
AGGGCTAAACTCCAAGTGAATTCAGGTCTCTGGGCAAGATGAAGAAGTGGACAGTCAACCCGACTCAG
GCCTTTTGTAGCTTCTTTCAGGACTCACTGAATGTGACCAGACAAATAATGAGGGTTTTCTGAGTTAGGT
GTCCTAGACTTCCATCAGTAGTTCTTTAGAGGTCCTTCCACATATACAAATACACACAACAAAGACAA
GACAGACAGAAGGCCTTCCAAACCAGACTTCTAACAAGAATTCAGAGTCTTCTTCCAAACGAACCTT
CTATTCTCCACCTGAGAATCTCTCCCTAAAATCTTCTTGATTGAAGAGAAATCTCTGAACCAAGACTTCC
TACTAATTAGAGCTAACCAACACCTCCAAAGGAGCTGAACCTGAGACCTCAAAAAAAAAACAAACAAACAA
AAAAAAAAAAAAACAAGAGCCCCAAAGGAGCCAAACCAAGGCCCCCTAAAGAAGCCAAATCATGATCCCCAAA

GGAGCCAAACCAACTGGGAGAAGAAAGGAGGAGTTGGCAGTGCCTAGAATACTACCAAATTAGTTTGGAGACAGACATCATTTCCAGGAACATTTCTCCATTGCAATTAAATCCATGCACATTGGGTCAGCAGCACCCTGCCAGTAGAGACAGTGCAGAGTCAGCCCACAGTCCAAGAGAACTAGGCAGCCACTTGGGCTGGCCCTCTGGATCCATCACCAGAGCAGGGCTACTGAACCATGGGCAGGTAGGCACAAAGGCAATCCCAGATGAGACCCCTAGTGTGTAACCACCTAACGGGTTACCTTGCCCACTGCCTAGACAGAGCTTATTTATCAAGAAAGATCTTACTTATCAAAACAGAGAAA'TGCAAT'AAAGAGTAATTCATGCAGAGCCAGCTGTGCAGTACACCAGAGTTTTGTTATTATTCAAATCAGTCTCTCTGAGAATTTGAGGACTGGAGTTTTTAAAGATAATTTGGTGGGTAGGGGGGCCAGTGAGTCAAGAGTTCTGATTGGTCAGGTGAGAGATGAAATCATAGGGAGTTGATACTGTCCTCTCGTGCTGAGTCACTTCC'TGGGAGGGGGCCACAGGATGAGATAGGCCAGTTTATCAATCTGGGTGGTGTGAGCTCATCTGTGAAGTTCAGGATCTGCAAAATATATCAAGTATTGATCTTAGGTTTTACAATAGTGC TGTATCTCTCAGGAGCAATTTGGTTAGAGTCAGAATCTTGTAGCCTCCAGATGCATTACTCCTAAATCAT AATTTCTAATCTTTTGGCTAATTCGTTAGTCTTACAAAGGTAGTCTGTTTCCAGGCAAGAAGCTGGTTT GTTTTGGGAAAGGACTGTTACTGTC'TTGGTTT'AAAAC'TGAAAGCTATAAACTAAATTTCTCCAGAATTA GTTCGGCTTACACCAGAAATCAACAAGAACAGCTTGGAGGATAGAAGCAAGATGGAGTTGGTTAGGTCA GCTCTCTTTTCACTCTCGGTTATAGTTTTCAGTGAATAATTTATAAGCATTTAGTGAATAAACTTTCCA CTTTATGCTGTTGAAGCTATATCTTAGAGGTTTAAAATACTTTGTCTCGATTTTCTATTTGTTTAAAAACA AAAAAATTGTGTTCTGCTCTAATTTTGTATTTACCCAAAAGTAATTCAGGACCAAGTTATACAGATTTCT TGTAAATTGTGTAGTTTCAAGAGTTGCTCTTGATACTGATTTCTATTTTTATTCTGCTGTGGTTCATGAA GATGTTTGTATATACTCTGATTTTTTAAAAAATTTATTGTGACTTATGACTTAGAATGTTGGTTAGTTTGA GAGAATGTTTTATGAACAGATAAAAAATGCAATTTCTCTGATTTTTTGGGTGAAGTATTCTCTAGATATCT ATTAGATCCACTTGGTAAAGAGTCTACTTCAAGTGAATTTTTTTTTTTTTTTTAGCTTTTGGCCCTTG ATGATGTGCCTGCCTAGTGTCTGTCAGTCTGGTGTGCAAGCTTATTACTCATTGTATTACTTTCTATCTCT TTAGCTTAGGTCTGGTAGTATTTATTTTATAAATATGATTGCTTCAGTATTGAGTGTGTATATATTTAGAT TAGTTAAATCTTGTGTAATTAATGCTTTTATCATTAATGTAATGCATTACTTGGTTTTTTTTTAAACTGTT GTTTGTTTAAAGGTCTGTTTTATTTGATACAAAGAGAGGAATTTAGCTTATTTTTGCTTTTCCATTTGAAA GATAGATCTTTCTTCATTC'TTTTACTTTTAAAGTCTATGGGTGTCCTTACATACGAGATGGATTCCCTTAAGG GCAGCAGAAGGTTGCCCTTTTTTTTTTTTAAATCCACTTTGCTACTCTATGTC'TTTTATATGAAGCATTTAGG CAATTTACATTCAAAGTTAATATTGATATGTGAGATTTTGTACCTCTCATACTGTTGTTAGCTAGTTGCT TTATAGTTGCAATTGTGTAGTTACTTAATAGGATCTGTAGGCTTTGTAATTATGGGTGCTTTTATAGTAG CAAGTATTGGTCTGTTTTTCCCTGTTTGAAC'TCC'TTTGAGCATTTTTTCTAAAAC'TGATCTGGTGGTGA CATATTTCTTAGTGTTTACTGGTCTGGGAAATATTTATTTCTACTTTATTCACAAATCTTCATTTGGG AAGTTATGAAGTTCTTGGCTGTCAATATTTATTTTCTTTTGTAAAGTCTAACAATAGGCCCCAGTCTCTT CTAGCTTGTAAATGTATCTGCTGGGAAGTTCACCTTTAGTCTAATGGTATTTCTTTCATAAATAATTTGGC CCTTTTCTCTAGCTGCCGTTAGGATTTGTTTTTTCATGTTGAACCTTAGGCAATCTGATGACTATATTCAT ATAGTATCTGAATGGTTGTTTTGTATAGTATCTCATACTATAGTATGTTTTGTATAGTATCTCATACTACT GTTGCAACCACAACAGTGTACAGTGGAGAGTGGGAAATTACCCTCTATCCAGATTCATTCCTGAGTGT TGGTACTGCCTCCTTCAGTAAT'GGTGTGTCGCCCATGTTCTCTTTGTCCCAGGGGAAGCTATAGTGGGC TACAGTCCCCTCTTTTAGGGGAAGAACACATTTAGGGTTAGATCTCCAGAGGTCC'TGCTGTCTCCCCCA AAGTCCACTGACCCCTGTGCCTACCAAAGTCAGAGCAGTTTGTGGACATGTTTGGCAGGAATTTGGGTGG CATGGTGACTCAAAGATGGAGAATCCTCAGGCAGGGCGGTGGCATAACCATAGATGCACCAACAGTATGGC ACATCTTTCTTTAGATAGAAAGGTGGTGCAGCTGTACCTGTGCAGGCTGGCCACCTAGTTGTCTATCCC TGGGGAGTTCCCAAATTGCCACCAATAGCATTACCCTGCATCAAGAGGGCAGAGGAAATTCCTAACAAAT TGGTGGTCAGCAGATTATCAGAGATGTGAGGGGAGCAGAGAAGCACTTTCAGCTAAATTTTACAGGGTT CTCTGGGGGTTGATTATTACCAGGC'TTTTACCGCTTTTCTTTACTACACCACAGCTGCTTCTTATGGGCA CTATAACAGTTCTTGGCTCTCTTTCTCAGTTTTTATTTGGTACTTCTTTATTCACCAGTAAC'TTGTATC TTCTTTCTGAGGAGAAGTGTAAATTTGATGTCCCTGGTCAGCCATCTTGAAAAGAAGTTGACTTATTTTTT TATCAGTGGCAGCATGATATATCTTCCCTCCATCTAATTACTTTTAACTATACATCTATAAGTAGATCTC TTAGAGACTACATATAGTTTGTTCCTTTTAAATCCTTTAAACAACTCAGTCTTTTAAATTTGGTGGATT TAGATCATTGACATTAAGAGTACTACTGATGTTGTGAGACCAATGTTGATTATAATTTTACTATTGTCT ATTTGTTATACTTGTCTTTGATCCTATTTTGTCTTCTATTCTTTTTTCTTCTGTTGTGTTCTTAACTA AATAGTCTATATGACTCTGATTTTATATGACTATATAATCATAACTTTTTATGTTACCTTTCTTTATGTA TATCAAGTTTCTGACCTATATGAGTCTCTCT'AAAAAGCTTCTCTTAACATTTCTTACAAGGAAGATGTAC TGGAAAAACATTTCTTCAATTGTTGTTGTCGAGAATGTGTTTATTTCTACTTTACTTTTAAAAAGAAAT TCACAGAGTACAGAATTTTAAAGTTGGTGATTTTTTCTCTTAAGACTTTAAATATTTTCACTCCACTCTCT TCTTGTCTTGATGTTTCTGAAGAGAAGTCTATTTTCTCCCTATAGATAAAATTTGTTTTTCTTCTGG TTAGTTTCAGGATAAAGTTTCTTATCTTTGACTTTCTGTAATTTGAAAATAACACACCTACACCTAGT TTTTCTGGTCAATAATAACTTATTTGTATATTTAAAAATAACTTAGGAAGTGTAGTTGAATTTGTTGTAA

CTCAAAGGACAAATCCTTAGCATTTCCTGAGTTTCCTGAATCTGTGATATAGTGTCTGACATTAATTTAA
GAGAAATTCCTTAGTAATTTTTTTTTTTTTTTGAGATGGAGTCTCAGTCTGTTGCCAGGCTGGAGTGCAATG
GCATGATCTTGGCTCAGTGCAACCCCCGCTCCCGAGTTCAAGTGATTCTCCTGCCCTCAGCCTCCTGAGT
AGCTGGGATAACAGGCACCCGCCACCAGCCAGCTAGTTTTTGTATTTTTGGTATAGACGGGGTTTCAC
CATGTTGGTCAGGCTGGTCTCTAACTCCTGACCTCGTGATCTGCCCTGCCCTCAGTCTCCCAAAGTGCTGGG
ATTACAGGCATGATCCACTGCACCTGGCCAGTAATTATTTTTTAAAAATGTTTCTTTTGCCTCTTTCTC
TTTTGTTTTCTTCTAACCTTTCCATTACACCCACTTATATAATTGTCTCAAAATTTTTTATATGATTTCAA
TTGATTTACTTTTTAGTCTTGTCTCTTTGCTTTTCAGTTTTGGAGGTTTTTCATTGATATATCCTCAAA
TTAGAGAGTCTTCATCAGTTGTGTTCTATCTACTAATAAGCCCATCAAAGGCATTCTTTATTTCTGCTAC
AGAATTTTTTATTTTTAGCATTTCCTTGGGTCTTAAAAATTTTTATTTTTTATACTTACATTGTCCATCTG
TTATTGAATCTGTCTACCTTATTTGATTAGAACACTTAACATATTAATCATAGTTGTTTTAAATTCATT
TTGAAAATTTCCACGTCCCGGACATATCTAGGTCTGGTTTAAAGCTTACTTATTCCTTTCAATCTATGTT
TTTTTTTTTCACTTTTGGTATGACTGGCAATTTTTTTTTCATTACAGTTAAGCATAATGCATTAGGTAAAAGG
AACTGCTTTGATAAGCCTTTATTAATATGGTGTAAAGGTGCTGGAGAAGGGGTAGCATTCTACAGGCCTAC
ATTTAGGTTTTATTTATTTTAGTTATAATCCAGTAACCTCTGGATTATAAATTTCAAACATACTTCTCAGT
TTCTCCTCCCAGCTGTAGGTGGGGCAGGATGGCTTAACAGGGCTTGAGTTGTATATTTTTCTCGTTTTAT
GAAGAAGGCCAGAGGCAACTAGAGTATAGTTTCTATGGCTTCATAACCTATTACAATAATAAAATATCT
ATCGTTATGCCCAATAAAAAAGAAATTTATAGAATTATTGTCTTAATATTTTTATTTTATAATTTTTTTCTT
TAGGATCTGGATACTGGAGAAAATGTTTTAAGTTATTACACACAATTTAACTGATTTATTGTTTTATTT
TCTCTATTTCTACAGAAGGGTCTACTTGGGCTTGTCTTCAATGTTAAGAGTCTCATCACTTGTTTTATAT
ATTATATTAATTTATGCCATGAAGAAAAATATCAAGAGAAAGATATCAATGCATCAGAAAATGGAAGTG
TCATGGATGAAGCAAACCTAGAATCCTTAATAAAAAATAAACATTTTGTCCCTTCTGCTGGGGCAGATAG
TGAAACACATTGTTAAGGGGAGAAAAAAGCCACTTCTGCTTCTGTGTTTTCCAAACAGCATTTGCATTGAT
TCAGTAAGATGTTATTTTTTGAGGAGTTCTTGGTCTTTTCACTAAGAATTTCCACATCTTTTATGGTGGAA
GTATAAATAAGCCTATGAACCTTATAATAAAAACAAACCTGTAGGTAGAAAAATGAGAGTACTCATTGTTAC
ATTATAGCTACATATTTGTGGTTAAGGTAGACTATATGATCCATACAAATTAAGTGAGAGACATGGTT
ACTGTGTAATAAAAGAAAAAATACTTGTTCAGGTAATTCTAATTCTTAATAAAACAAATGAGTATCATAC
AGGTAGAGGTTAAAAAGGAGGAGCTAGATTATATCCTAAGTAAAGAGAAATGCCCTAGTGTCTATTTTAT
TAAACAAACAAACACAGAGTTTGAACATAATACTAAGGCCTGAAGTCTAGCTTGGATATATGCTACAAT
AATATCTGTTACTCACATAAAATTTATATATTTTACAGACTTTATCAATGTATAATTAACAATTTATCTTGT
TTAAGTAAATTTAGAATACATTTAAGTATTGTGGAAGAAATAAAGACATTCCAATATTTGCAAGCTGTGA
TTGTCAAACAACATATTACATTATGTGTTAAGTTTCCAGTGGGGCCACGGTAATGTATTAGGAAAAATTG
ACTTTGACTAATGTAGCCACTCTCATACTTATCTTAGCTAGATTTCCCTAGATCATTTGCCCGCTTCTA
CGTCAGCACTTGCTTCTTCACTTTGTACTTAGATAATGAACAGCTTCTTTTTTTTAAACCCCTGTAAC
AAATTTCTACAGCTTTTTTTTCTTTTTGACGCTTTCCCAAGTCTCTTAGTCATCATAGAATGACAGAGAGTTA
TGTCTTGTCTTAGATTAGATTTGGCCTAAGGGAACATTGTGGCTGCTTTGTTCTTCAATCCAGGCTACT
GAAGTTTTCTCCATGTTAGCCATAAGTCTGTTTCACTTTGTTATTATTTGTGTGTTTCACTGAAGTAGGAC
TCTTAATTATCTTCAAGTACTTTATTTTTGCATTCAAACTTGGCTAACTGCTGAATGCAAGATGCTTAG
TTTTGACTTACCTTGGCTCTTGATATGCCCTTCTCACTAAACTTAATCATTTCTAAAATTTGACTTAAAA
TGAGAGATATGTGACTCTTTCTTTTCACTCAACACCTAGAGGTCATTGTAAGGTTATTTATTTGGCTTAAT
TTCTATGTTGTTCTGTCTCAGGACATAGGAAGGCCCAAGGGGATGGAGAGAGATGTAGCAATAGCTGGTT
GGTGGAGCATTACAGAACACACAACTTTATTTGATTAAGTTCCACGTATTATATGGGTATGGATAGTGGC
AAGTCAAATCAATTACAATAGTAACATCAAAGATCACTAACCACAGGTCATATCACAGATACAATAACA
ATGAATAAGTCTGAAATATTGTGAGAATTAGTAAAATGTGACACAGAGACATAAAGTGAGCACATATTTT
TGAAAAAATGATGTCAATAGACTTGTTTGATGCAAGGATTGCCACAACTTCCAATTTGAAAACAAAAAAC
AAACAAAAAAACACCAAATATGTGAAGTGCAATAAAGTGAAGTTCAATAAAATGAAGTATGCCAGGAA
TAAAAACTAGCAGGATCACAGGATCAACCTCTACTTAAAAAGTATTAGAAATATGGAGGTAAATAGAAGAA
ATAGCTAAAAAGAGTTGTAAATGCTTGCCTCTGGAAAGCAGTAATAATAAGCAGAGAAAACTCATTTTC
AATATGAGATTTTTGATATAATCTTATTTTTTACAACCTTTGTGCATAAATGGCTTTGGTAAAAATTA
TCAATCATCAGACTGGTATGTCTCTTATTAATCAACAATAAACAATAATATTGATACCCAGGTACTACAC
TGAGAGCCTTGGGTGAGCCTCCAAGTCTTGCTGGCTTCAGATACCAGAAAGATCACAGGGGTTAATGCAC
TAAGCAGACTCTTGAGGTCCCTGATTCCAGGACTTGACTCTGGGATAGCATTTCGAACCTGCCCTCGGC
CAGAGGGGAGCCCATTTGTTCTGAAGTTTGAATCCCACCTCAGGCAGAAATCAATAGAAGCTGATTAAAGT
GCCCTTGGGCCTTAAGGAAACATTGGCAGTAGTCTAGCAGTACTCCCTGTGGGCCTGAAGTGTGTGGCT
ATGGGTTGAGGCTCCTTTGTATTTGGAAATGCGAGGGAAGAGTGGGAAAGACGGTCTTGTGTTTTGCGTG
CCACCTCAGCCACAATATGATAGAACACCAGGTAGACTTTACGAGTTTTGGCTCTAGTCTCTGACTCCTG
GATGGCATCTCTGGACCCACATGGGACC'TGGGGGACCT'CGCCACCCTGAAAGGAAGGACACAGGCC'TG

TGGCTTTTCTGCCTGCTGATTGTAGAGCCCCATGGCCTTGAGCAAACATTGGCAGTAGTCAGGGAGTAAT
TACAGCAGACCTTGGGCAAGACTCATAAATGTGCTGGCTTCAGGTGTAACCCAATGTAGTCATAGTTCTG
GATGCCACAGAGGTGCTTACGCCACTCCAAACC

Fig. 6 Wildtype SLC01B1 polypeptide sequence (NCBI Accession No. NP_006437.3) (SEQ ID No. 73)

MDQNQHLNKTAEAQPSSENKKTRYCNGLMFLAALSLSFIAKTLGAIIMKSSIIHIERRFEISSSLVGFD
GSFEIGNLLVIVFVSFYGSKLHRPKLIGIGCFIMGIGCVLTALPHFFMGYYRYSKETNINSENSTSTLS
TCLINQILSLNRASPEIVGKGCLKESGSYMWIYVFMGNMLRGIGETPIVPLGLSYIDDFAKEGHSSLYLG
ILNAIAMIGPIIGFTLGSLFSKMYVDIGYVDLSTIRITPTDSRWVGAWWLNFLVSGLFSIISSIPFFFLP
QTPNKPQKERKASLSLHVLETNDEKDQTANLTNQGNITKNVTGFFQSFKSILTNPLYVMFVLLTLLQVS
SYIGAFTYVFKYVEQQYQPSKANILLGVITIPFASGMFLGGYIIKKFKLNTVGIKFSCTAVMSLS
FYLLYFFILCENKSVAGLTMTYDGNNPVTSHRDVPLSYCNSDCNCDESQWEPVCGNNGITYISPCLAGCK
SSSGNKKPIVFYNCSCLEVTGLQNRNYSAGLGECPRDDACTRKFYFFVAIQVLNLFPSALGGTSHVMLIV
KIVQPELKSLALGFHSMVIRALGGILAPIYFGALIDTTCKIWKSTNNCGTRGSCRTYNSTSFVRVYLGLSS
MLRVSSLVLYIILYAMKKKYQERDINASENGSVMDEANLES LNKNKH FVPSAGADSETHC